DANMAP 2016 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark by Bager, Flemming et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
DANMAP 2016 - Use of antimicrobial agents and occurrence of antimicrobial
resistance in bacteria from food animals, food and humans in Denmark
Borck Høg, Birgitte; Korsgaard, Helle Bisgaard; Wolff Sönksen, Ute; Bager, Flemming; Bortolaia, Valeria;
Ellis-Iversen, Johanne; Hendriksen, Rene S.; Borck Høg, Birgitte; Jensen, Lars Bogø; Korsgaard, Helle
Bisgaard; Pedersen, Karl; Dalby, Tine; Træholt Franck, Kristina ; Hammerum, Anette M; Hasman, Henrik;
Hoffmann, Steen; Gaardbo Kuhn, Katrin; Rhod Larsen, Anders; Larsen, Jesper; Møller Nielsen, Eva;
Schytte Olsen, Stefan; Petersen, Andreas; Roer, Louise; Skovgaard, Sissel; Wolff Sönksen, Ute;
Torpdahl, Mia; Vorobieva, Veronika
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Borck Høg, B. (Ed.), Korsgaard, H. B. (Ed.), Wolff Sönksen, U. (Ed.), Bager, F., Bortolaia, V., Ellis-Iversen, J., ...
Vorobieva, V. (2017). DANMAP 2016 - Use of antimicrobial agents and occurrence of antimicrobial resistance in
bacteria from food animals, food and humans in Denmark. Statens Serum Institut, National Veterinary Institute,
Technical University of Denmark National Food Institute, Technical University of Denmark.
DANMAP
 2016
DANMAP 2016 - Use of antimicrobial agents and occurrence 
of antimicrobial resistance in bacteria from food animals, 
food and humans in Denmark
Statens Serum Institut
National Veterinary Institute, Technical University of Denmark
National Food Institute, Technical University of Denmark
This report is issued by DANMAP - The Danish Integrated Antimicrobial Resistance Monitoring and Research 
Programme. It presents the results of monitoring the antimicrobial use and antimicrobial resistance in food animals, 
food and humans in 2016. The report is produced in collaboration between the National Food Institute, Technical 
University of Denmark and Statens Serum Institut. The DANMAP programme is funded jointly by the Ministry of Health, 
the Ministry of Environment and Food and the Ministry of Higher Education and Science.
DANMAP 2016
Editors:
Birgitte Borck Høg (bibo@food.dtu.dk) 
Helle Korsgaard (hkor@food.dtu.dk) 
National Food Institute,
Technical University of Denmark 
Kemitorvet, Building 202, DK-2800 Kgs. Lyngby
Ute Wolff Sönksen (uws@ssi.dk) 
Microbiology and Infection Control, 
Statens Serum Institut
Artillerivej 5, DK-2300 Copenhagen
Authors:
National Food Institute 
Flemming Bager, Valeria Bortolaia, 
Johanne Ellis-Iversen, Rene S. Hendriksen, 
Birgitte Borck Høg, Lars Bogø Jensen, 
Helle Korsgaard
National Veterinary Institute 
Karl Pedersen
Statens Serum Institut
Tine Dalby, Kristina Træholt Franck, 
Anette M. Hammerum, Henrik Hasman, 
Steen Hoffmann, Katrin Gaardbo Kuhn, 
Anders Rhod Larsen, Jesper Larsen,
Eva Møller Nielsen, Stefan Schytte Olsen, 
Andreas Petersen, Louise Roer, 
Sissel Skovgaard, Ute Wolff Sönksen, 
Mia Torpdahl, Veronika Vorobieva
DANMAP Steering Committee: 
National Food Institute 
Flemming Bager
National Veterinary Institute 
Karl Pedersen
Statens Serum Institut
Ute Wolff Sönksen, Anders Rhod Larsen
Layout:
Jens Nørgaard and Charlotte Brunholt Jensen, STEP
Photos: Colourbox and iStock
Printing: STEP
DANMAP 2016 - October 2017 – ISSN 1600-2032
Text and tables may be cited and reprinted only with reference to this report: DANMAP 2016
Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food 
animals, food and humans in Denmark. ISSN 1600-2032
The report is available from www.danmap.org
DANMAP 
 2016
DANMAP 2016 - Use of antimicrobial agents and occurrence 
of antimicrobial resistance in bacteria from food animals, 
food and humans in Denmark
DANMAP 20164
TABLE OF CONTENTS
Table of contents
1. Editorial 7
2. Acknowledgements 8
3.  Introduction to DANMAP 9
3.1 About DANMAP 10
3.2 General information 11
4.  Antimicrobial consumption in animals 15
 Highlights 16
4.1 Introduction  16
4.2 Total antimicrobial consumption 19
4.3 Antimicrobial consumption by animal species 21
Textbox 4.1 New model for the yellow card initiative 27
Textbox 4.2 Use of colistin in animals and humans – a Danish perspective 28
Textbox 4.3 Correlation between quality of mink feed and prescription of
 antimicrobials for mink 30
Textbox 4.4 Stronger focus on preventing illegal import of antimicrobials 31
Textbox 4.5 Antimicrobial use in dogs and cats in Denmark – 2012-2016 32
5.  Antimicrobial consumption in humans 35
 Highlights 36
5.1 Introduction  37
5.2 Total consumption (Primary Health Care and Hospital Care Sectors) 37
5.3 Primary Health Care  38
5.4 Hospital Care 47
Textbox 5.1  Reducing antibiotic consumption among children and elderly through  
knowledge building – interventions joining primary and secondary health care sector 53
Textbox 5.2 Incidence of multi-resistant bacteria and consumption of antimicrobial agents in Greenland 56
Textbox 5.3 Antimicrobial resistance and consumption of antimicrobials in the Faroe Islands 58
6.  Resistance in zoonotic bacteria  61
 Highlights 62
6.1 Introduction 62
6.2 Salmonella 63
6.3 Campylobacter 67
Textbox 6.1 Resistance in bacteria from diagnostic submissions from pigs 71
Textbox 6.2 DANMAP detecting emerging and rare resistances 73
5DANMAP 2016
TABLE OF CONTENTS
7.  Resistance in indicator bacteria 75
 Highlights 76
7.1 Introduction 76
7.2 Enterococci 77
7.3 Indicator Escherichia coli 
7.4 Extended spectrum beta-lactamase (ESBL)/AmpC- and
 carbapenemase-producing Escherichia coli  80
Textbox 7.1 Comparison of ESBL/AmpC-producing Escherichia coli  
  isolates of animal origin ESBL/pAmpC-producing with Escherichia coli  
isolates obtained from human bloodstream infections 84
8.  Resistance in clinical bacteria from humans 85
 Highlights 86
8.1 Escherichia coli 88
8.2 Klebsiella pneumoniae  91
Textbox 8.1 Characterisation of ESBL/pAmpC- and carbapenemase
 producing Escherichia coli from bloodstream infections 94
8.3 Pseudomonas aeruginosa 96
8.4 Acinetobacter spp. 97
Textbox 8.2 Carbapenemase producing bacteria in Denmark 98
8.5 Enterococci 100
Textbox 8.3 Emergence of clinical ST 203-CT859 vanA Enteroccus faecium in Denmark 102
8.6 Streptococci 104
8.7 Staphylococcus aureus 106
Textbox 8.4 LA-MRSA CC398 in animals and humans 110
8.8 Neisseria gonorrhoeae 113
Textbox 8.5 Clostridium difficile surveillance 115
9.  Materials and Methods 117
9.1 General information  118
9.2 Data on antimicrobial consumption  118
9.3 Collection of bacterial isolates 121
9.4 Microbiological methods 123
9.5 Susceptibility testing 123
9.6  Whole genome sequencing   124
9.7 Data handling  124
10.  Terminology 127
10.1 List of abbreviations 128
10.2 Glossary 129
DANMAP 20166
1.
7DANMAP 2016
1.
1. Editorial
For many years Denmark has maintained a strong focus on the 
transmission of antimicrobial resistance from production ani-
mals to humans. It is well documented that a high or irrational 
use of antimicrobials inevitably will lead to development of 
resistance and Denmark has introduced several interventions 
to reduce the antibiotic use in animals to protect public health. 
The control initiatives in animals include: maintaining aware-
ness of the use of antimicrobials in especially food animals; 
surveillance of antimicrobial use at farm level, with penalties 
for farmers who have an unjustifiable high use of antimicrobi-
als; guidelines for use of antimicrobials in pig production and 
in companion animals, and a farming sector led initiative to 
drastically reduce the use of 3rd and 4th generation cephalo-
sporins in pigs and cattle. 
The contribution from the animal reservoir to AMR in humans 
varies across the globe. The Danish preventive initiatives on 
controlling antimicrobial usage in animals continue, and so 
the most immediate AMR hazard to humans today does not 
emerge from the Danish animal reservoir. Carbapenemase 
Producing Organisms (CPO) are resistant to multiple antibiotics 
used to treat humans, and are carried and spread by healthy 
individuals. We suspect that the number of healthy carriers in 
Denmark is increasing, but we do not know for certain. While 
the organisms themselves often only cause disease in vulner-
able patients, the genes can be transferred to other bacteria, 
contributing to an unknown number of combinations of bacte-
rial species and genes that surpasses the traditionally built 
surveillance systems. 
In DANMAP 2016 we report again that non-travel related car-
bapenemase resistance in humans occurs with increasing fre-
quency in Denmark, despite a relatively low national consump-
tion of carbapenems. While the prevalence of CPO remains 
very low in blood isolates from patients with bacteremias - in 
contrast to the situation that some countries in Southern 
Europe and the Middle and the Far East are experiencing - 
several small outbreaks at hospitals have occurred. Carriage 
of CPO by healthy individuals may inadvertently introduce 
CPO into environments with high antimicrobial consumption 
and a high selective pressure. This highlights the importance 
of finding places of introduction and routes of transmission 
at Danish hospitals. A working group under the Danish Health 
Authority is currently working on guidelines defining risk situ-
ations, screening methods and ways of controlling spread at 
hospitals, it is important to remember that some farm animal 
environments also may constitute places of possible risks due 
to locally and periodically high consumptions of antimicrobials. 
DANMAP has to date not found CPO in animals or food of Dan-
ish origin, but the ability of AMR monitoring systems to detect 
rare and emerging AMR genes with a potentially very high 
impact needs to be reviewed.
New transmission routes present new challenges for surveil-
lance and control. A novel approach is to look for genes rather 
than resistant bacterial species as it was done in a recent 
study, where waste from toilets of airplanes arriving in Den-
mark from selected destinations was analysed by metagenom-
ics techniques. This contributed to an understanding of the 
diversity and amount of genes being introduced into a naïve 
environment. Investigations of the transmission of resistance 
genes from the hospital setting to the environment and 
numerous other studies in the use and application of metage-
nomics have contributed to defining the term: resistome. 
Looking for the resistome in the individual and in a population 
as part of the surveillance system is tempting, but raises the 
questions of what, where and when to look. A new approach 
like this also demands new diagnostic tools and rapid tests 
based on gene-analyses. Furthermore, processes for inter-
pretation of results and data capture also need development 
before such data are applicable to surveillance. 
The exact way this information may be used to inform surveil-
lance programmes still needs to be determined, but we look 
forward to overcoming these challenges to remain at the 
forefront of surveillance of antimicrobial consumption and 
resistance with a stable yet dynamic DANMAP. 
DANMAP Steering Committee
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3. Introduction to DANMAP
3.1 About DANMAP
DANMAP was established at the initiative of the Danish 
Ministry of Health and the Danish Ministry of Food, Agriculture 
and Fisheries. The programme participants are the National 
Food Institute and the National Veterinary Institute, both at 
the Technical University of Denmark (DTU), as well as Statens 
Serum Institut (SSI). The DANMAP programme is funded jointly 
by the Ministry of Health, the Ministry of Higher Education and 
Science, and the Ministry of Environment and Food.
The Danish Integrated Antimicrobial Resistance Monitoring 
and Research Programme, DANMAP, has implemented the One 
Health approach, comprising the entire chain from farm to 
fork to sickbed, since 1995. The organisation and collection of 
DANMAP data is presented in Figure 3.1.
The objectives of DANMAP are:
• to monitor the consumption of antimicrobial agents in food 
animals and humans;
• to monitor the occurrence of antimicrobial resistance in bac-
terial isolates from food animals, food of animal origin (e.g. 
meat) and humans;
• to study associations between antimicrobial consumption 
and antimicrobial resistance; and
• to identify routes of transmission and areas for further 
research studies.
The monitoring of antimicrobial resistance is based on three 
categories of bacteria:
Human and animal pathogens that cause infections and are 
thought to reflect resistance caused by the use of antimicro-
bial agents in the respective reservoirs;
Zoonotic bacteria that can develop resistance in the animal 
reservoir, which may subsequently compromise treatment 
outcome when causing infection in humans;
Indicator bacteria (enterococci and E. coli) due to their ubiqui-
tous nature in animals, food and humans, and their ability to 
readily develop or transfer antimicrobial resistance in response 
to selective pressure in both reservoirs.
All pathogens may be considered reservoirs of resistance de-
terminants – genes – that may be disseminated independently 
of the bacterial hosts.
A web annex presenting Minimum inhibitory concentration 
(MIC) distributions, detailed tables of antimicrobial consump-
tion and other additional data are available for download at 
www.danmap.org. Current and previous DANMAP reports are 
also available at the website (PDF versions).
Public health risks
Bacteria become resistant either by spontaneous mutation or by transfer of resistance genes from other bacteria. Resistant 
strains are favoured when use of antimicrobial agents provide a selective pressure. This occurs in humans as well as in animals 
undergoing antimicrobial treatment. Resistant bacteria can spread between humans in the community, at healthcare centres 
and at hospitals. Furthermore, resistant bacteria from animals can be transmitted to humans either through direct contact with 
animals and their environment or through ingestion of contaminated food or other contaminated vehicles.
Antimicrobial treatment failure may occur if the ingested resistant bacteria are a direct cause of disease, or if resistance 
determinants are transferred to pathogenic bacteria causing the disease. Bacteria may be resistant to several – sometimes all – 
antimicrobial agents available for treatment, leading to life-threatening illness.
Currently, there is only a limited number of antimicrobial agents, with novel modes of actions, under development by the phar-
maceutical industry. Therefore, it is vital for public health organisations to ensure the continued effectiveness of compounds 
considered critically important to human treatment by ensuring prudent use for both humans and animals.
Prudent use should include the restriction of critical antimicrobial agents for use in humans only, as well as the elimination of 
overuse, i.e. only humans and animals suffering from an infection responsive to antimicrobial treatment should be exposed to 
antimicrobial agents.
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3.2 General information
The following sections present some general information 
about the human population in Denmark in 2016, as well as 
the production of food animals and the amount of meat avail-
able for human consumption in Denmark over the past decade. 
It also provides an overview of the antimicrobial agents for 
systemic and intramammary therapeutic use in humans and 
animals in 2016.
3.2.1 Populations
Over the past two decades the human population in Denmark 
has increased from approximately 5.2 million inhabitants in 
1995 to 5.7 million in 2016 (www.dst.dk).The distribution of 
the population, which could potentially have received antimi-
crobial treatment in 2016, is shown in Figure 3.2, together 
with the five healthcare regions and the 10 (merged from 11 
during 2016) Departments of Clinical Microbiology (DCM) in 
Denmark.
The production of food animals and the production of meat 
and milk are presented in Table 3.1. In 2016, the number of 
pigs produced was approximately 3% higher than the previous 
year and the number of exported fattening pigs (15–50 kg) 
increased by approximately 9%. Since 2004, the total exports 
of fattening pigs have increased more than six-fold. 
From 2015 to 2016, the number of cattle slaughtered in-
creased by 5%, while the number of dairy cows increased by 
2% and the amount of milk produced remained at the same 
level as in 2015.
The number of broilers produced increased by approximately 
6%, and approximately 19% of the broilers produced in Den-
mark in 2016 were exported for slaughter. The production 
of turkeys has fluctuated considerably over the past decade 
but increased for the first time since 2012. Since 2006, more 
than 99% of the turkeys produced have been exported for 
slaughter, thus the majority of turkey meat available for sale in 
Denmark is listed as imported.
3.2.2 Registered antimicrobial agents
Table 3.2 shows the antimicrobial agents that are registered 
to treat bacterial infections in humans and animals. Some 
of these are considered to be critically important for treat-
Figure 3.1. Organisation of DANMAP DANMAP 2016
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ing bacterial infections in humans. An antimicrobial agent is 
considered critically important if it is the only compound, or 
one of a limited number of compounds, available to treat seri-
ous human disease. Fluoroquinolones, 3rd and 4th generation 
cephalosporins, macrolides and glycopeptides are among such 
agents [AGISAR, 4.revision, WHO 2013]. Critically important 
antimicrobial agents are also used to treat diseases in food 
animals and pets, and bacteria that are resistant to critically 
important agents may be transmitted to humans. Also, bacteria 
that cause human disease may acquire resistance genes from 
bacteria of animal origin.
In Denmark, three antimicrobial classes have been appointed 
as critically important, namely cephalosporins, fluoroquino-
lones and carbapenems. Extra focus has since 2012 been on 
the restricted use of these in both animals and human care.
Growth promoters, which are no longer used for animals in 
Denmark, are shown in parentheses in Table 3.2. Most of these 
had effects on Gram-positive bacteria. Since 1995, the indica-
tor enterococci from animals and meat (and in some years from 
healthy humans) have been used as a measure of resistance to 
growth promoters.
Figure 3.2 The five health care regions and Departments of Clinical Microbiology (DCM) in Denmark DANMAP 2016
North Denmark Region
No. of inhabitants 587,466 
No. of inhabitants/km2 74 
No. of inhabitants/GP 1,914 
Central Denmark Region
No. of inhabitants 1,306,202 
No. of inhabitants/km2 100
No. of inhabitants/GP 1,627 
Capital Region of Denmark
No. of inhabitants 1,811,809 
No. of inhabitants/km2 707 
No. of inhabitants/GP 1,712
Region Zealand:
No. of inhabitants 832,703 
No. of inhabitants/km2 114 
No. of inhabitants/GP 1,731 
Region of Southern Denmark
No. of inhabitants 1,218,010 
No. of inhabitants/km2 100
No. of inhabitants/GP 1,534
Source: Statistics Denmark (www.dst.dk)  
and the Danish Medical Association  
(www.laeger.dk) GP=general practitioner.
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In april 2016 the DCM Midt-Vest (Herning) and the DCM Midt-Vest (Viborg) were merged with DCM Aarhus.
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Year Broilers Turkeys Cattle 
(slaughtered)
Dairy cows Pigs  Farmed fish(a) 
Fresh 
water
Marine
1,000 
heads 
mill. 
kg(b)
1,000 
heads
mill. kg 1,000 
heads
mill. kg 1,000 
heads
mill. kg 
milk
1,000 
heads
Export 
1,000 
heads(c)
mill. kg mill. kg mill. kg
1990 94560 116 571 2,5 789 219 753 4542 16425 - 1260 - -
1992 107188 137 761 5,4 862 236 712 4405 18442 - 1442 35 7
1994 116036 152 1091 8,6 813 210 700 4442 20651 - 1604 35 7
1996 107895 149 961 9,3 789 198 701 4494 20424 - 1592 32 8
1998 126063 168 1124 11,6 732 179 669 4468 22738 - 1770 32 7
2000 133987 181 1042 10,3 691 171 636 4520 22414 - 1748 32 7
2001 136603 192 1086 13,2 653 169 623 4418 23199 - 1836 31 8
2002 136350 190 1073 12,8 668 169 611 4455 24203 - 1892 32 8
2003 129861 197 777 11,2 625 161 596 4540 24434 - 1898 34 8
2004 130674 198 1086 19,6 632 165 569 4434 25141 1712 1967 34 9
2005 122179 183 1237 17,4 549 145 559 4449 25758 2720 1988 31 8
2006 106182 161 785 11,3 509 140 556 4492 25763 3204 1957 29 8
2007 107952 163 1009 14,4 512 141 545 4515 26311 3522 2046 31 10
2008 107595 163 1068 12,3 509 138 559 4585 27078 4943 1985 30 10
2009 108851 165 1175 11,1 507 137 569 4734 27603 6642 1898 29 11
2010 117653 178 1184 14,0 519 142 574 4830 28505 7074 1974 28 10
2011 115454 175 960 9,4 551 145 575 4801 29399 7632 2008 28 11
2012 111080 168 1103 12,4 539 138 580 4928 29047 8794 1902 28 13
2013 117315 177 692 8,3 551 140 574 5025 28996 9318 1896 28 12
2014 115497 174 595 8,8 556 143 563 5113 29926 10517 1924 30 11
2015 114238 172 598 8,8 513 135 561 5270 30874 12133 1954 32 12
2016 120685 182 834 9,9 540 142 571 5276 31660 13280 1943 32 12
Diff.(d) 6% 6% 39% 13% 5% 5% 2% <1% 3% 9% -1% 0 0
Table 3.1. Production of food animals and the production of meat and milk, Denmark DANMAP 2016
Source: Statistics Denmark (www.dst.dk) and The Danish AgriFish Agency. Production data for farmed fish was not available for 2016. Live 
animals exported prior to slaughter are included in number of animals and amount of meat produced. Export data for poultry from Statistics 
Denmark (personal communication) and export of 15-50 kg live pigs from the Danish Agriculture and Food Council 
a) The numbers for 2016 are not final. The production of farmed fish includes fish transferred from one production facility to another
b) Assume a final slaughtered weight of 1.51 kg per broiler produced (Danish Agriculture and Food, 2013)
c) Export of 15-50 kg live pigs. These are included in total number of heads, but antimicrobial use after export until slaughter is not registered as 
it takes place outside of Denmark
d) Difference from 2015 to 2016
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Table 3.2.  Antimicrobial agents registered for systemic and veterinary intramammary  
therapeutic use in animals and humans, Denmark DANMAP 2016
ATC / ATCvet codes (a) Therapeutic group Antimicrobial agents within the therapeutic groups
Animals Humans
J01AA / QJ01AA,QJ51AA Tetracyclines Chlortetracycline, doxycycline, 
oxytetracycline
Doxycycline, lymecycline, 
tetracycline, tigecycline
QJ01BA Amphenicols Florfenicol
J01CA / QJ01CA Penicillins with extended 
spectrum
Ampicillin, amoxicillin Ampicillin, pivampicillin, amoxicillin, 
pivmecillinam, mecillinam
J01CE / QJ01CE Beta-lactamase sensitive 
penicillins
Benzylpenicillin, 
phenoxymethylpenicillin, 
procaine penicillin, 
penethamate hydroiodide
Benzylpenicillin, 
phenoxymethylpenicillin
J01CF / QJ51CF Beta-lactamase resistant 
penicillins
Cloxacillin, nafcillin Dicloxacillin, flucloxacillin
J01CR / QJ01CR Comb. of penicillins and beta-
lactamase inhibitors
Amoxicillin/clavulanate Amoxicillin/clavulanic acid, 
piperacillin/tazobactam
J01DB / QJ01DB,QJ51DB First-generation cephalosporins Cefalexin, cefadroxil, cefapirin Cefalexin, cefazolin
J01DC Second-generation cephalosporins Cefuroxime
J01DD / QJ01DD,QJ51DD Third-generation cephalosporins 
incl. comb. with beta-lactamase 
inhibitors
Cefoperazone, ceftiofur, 
cefovecin
Cefotaxime, ceftazidime, 
ceftriaxone, ceftazidime/avibactam
J01DE / QJ51DE Fourth-generation cephalosporins Cefquinome Cefepime
J01DF Monobactams Aztreonam
J01DH Carbapenems Meropenem, ertapenem
J01DI Fifth-generation cephalosporins 
incl. comb. with beta-lactamase 
inhibitors
Ceftaroline, ceftobiprol, ceftolozan/
tazobactam
J01EA Trimethoprim and derivatives Trimethoprim
J01EB / QJ01EQ Short-acting sulfonamides Sulfadimidine Sulfamethizole
J01EE / QJ01EW Comb.of sulfonamides and 
trimethoprim, incl. derivatives
Sulfadiazine/trimethoprim, 
sulfadoxine/trimethoprim,
sulfamethoxasol/trimethoprim  
Sulfamethoxazole/trimethoprim
J01FA / QJ01FA Macrolides Spiramycin, tylosin, tilmicosin, 
tylvalosintartrat, tulathromycin, 
gamithromycin, tildiprocin
Erythromycine, roxithromycine, 
clarithromycine, azithromycine, 
telithromycine
J01FF / QJ01FF Lincosamides Clindamycin, lincomycin Clindamycin
QJ01XX (b) Streptogramins (Virginiamycin)
J01GB / QJ01RA,QA07AA Aminoglycosides Streptomycin, 
dihydrostreptomycin, 
gentamicin, neomycin, 
apramycin
Tobramycin, gentamicin
J01MA / QJ01MA Fluoroquinolones Enrofloxacin, marbofloxacin, 
difloxacin, ibafloxacin, 
pradofloxacin
Ciprofloxacin, levofloxacin, 
moxifloxacin
QJ01MB Other quinolones Oxolinic acid
QJ01MQ (b) Quinoxalines (Carbadox, olaquindox)
J01XA,A07AA / Not in ATCvet (b,c) Glycopeptides (Avoparcin) Vancomycin, teicoplanin, telavancin, 
dalbavancin, oritavancin
J01XB / QA07AA (b) Polypeptides (incl. polymyxins) Colistin, bacitracin Colistin
J01XC Steroid antibacterials Fusidic acid 
J01XD,P01AB (c) Imidazole derivatives Metronidazole
J01XE Nitrofurane derivatives Nitrofurantoin 
J01XX / QJ01FF Other antibacterials Spectinomycin Methenamine, linezolid, daptomycin, 
tedizolide, fosfomycin
QJ01XQ Pleuromutilins Tiamulin, valnemulin
QP51AG04 Antiprotozoals, sulfonamides Sulfaclozine
Not in ATCvet (b) Oligosaccharides (Avilamycin)
Not in ATCvet (b) Flavofosfolipols (Flavomycin)
a) ATCvet codes start with a Q
b) Animal growth promoters used before 1999 are listed in parentheses
c) Intestinal antiinfectives (A07AA) and imidazole derivatives for protozoal diseases (P01AB) were, for the first time, included in DANMAP 2014, 
since their widespread use in the treatment of Clostridium difficile infections makes them belong to the most used antibiotics in human infections 
in Denmark
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4. Antimicrobial consumption in animals
4.1 Introduction
The use of antimicrobial agents in humans and animals has 
been monitored by the DANMAP programme since 1995. Since 
the early 1990s, there has been both political and public focus 
on the use of antimicrobial agents in the Danish animal produc-
tion. This resulted in discontinued use of several antimicrobial 
agents used for growth promotion from 1994-1999, and more 
recently, in a voluntary ban of use of cephalosporins in the pig 
and dairy cattle production, as well as in regulatory legislation 
regarding therapeutic use [DANMAP 2010].
Figure 4.1 shows the total use of antimicrobials for animals 
and humans since 1994 and 1997, respectively. Changes 
in the antimicrobial consumption patterns for animals can 
partly be explained by an increase in pig production, However, 
national control initiatives to reduce consumption have clearly 
influenced the prescription and  antimicrobial usage patterns  
for animals during the period. For example, the decrease in an-
timicrobial consumption after 1994 was likely the result of 1) 
limitation of veterinary practitioners’ profit from sales of medi-
cine; 2) implementation of preventive veterinary strategies 
with Veterinary Advisory Service contracts (VASCs) and regular 
monthly visits from the veterinarian in order to promote pre-
ventive veterinary strategies and optimize antimicrobial use, 
and 3) enforcement of the so called “cascade rule” [Order (DK) 
142/1993], which limits the use of (cheaper) extemporane-
ously produced medicines. The latter particularly affected the 
use of tetracyclines from 1994. Another important interven-
tion was the restriction on the use of fluoroquinolones in pro-
duction animals through legislation implemented in 2002 and 
    Highlights: The overall use of antimicrobials for animals decreased in 2016, for the third 
consecutive year, by approximately 5% compared with 2015. The decrease was mainly 
driven by the use of antimicrobials for pigs, which was 4% less than the year before. Particu-
larly the use of tetracyclines for pigs has been reduced consistently since 2013. 
  Following on from two years with several serious disease outbreaks, the poultry production 
(excl. turkeys) sharply reduced antimicrobial use in 2016, returning to the same levels as 
before the disease outbreaks. 
  Use of antimicrobials in the aquaculture industry continued to decrease in 2016, where we 
recorded the lowest level of antimicrobial use in a decade. 
  In contrast, the fur animal industry continued to see an increase in antimicrobial use. Two 
studies have found an association between the quality of feed and the amount of antimicro-
bial agents prescribed (Textbox 4.3).The studies raise awareness of its importance in rela-
tion to fur animals’ need for treatments. 
  The use of critically important antimicrobials in food production animals remained low. The 
use of colistin for pigs increased by further 40 kg in 2016. The use of colistin in production 
animals is of concern, since it has becoming increasingly important as a last resort antimicro-
bial in human medicine. The increase in colistin use for pigs has likely been caused by a shift 
from other antimicrobial agents (Textbox 4.2).
  In companion animals, the use of critically important antimicrobials is relatively high com-
pared with other species. Almost all fluoroquinolones and more than half of the cephalospo-
rins used for animals are used for dogs and cats. Despite a small increase in use from 2015 
to 2016, there has been an overall decreasing trend in the use of antimicrobials for dogs 
and cats since 2011.  Furthermore, there has been a shift in the use of antimicrobials with a 
marked reduction in the relative use of cephalosporins and increase in the use of penicillins.
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2003. Furthermore, in July 2010, the pig industry imposed a 
voluntary ban on the use of cephalosporins. This was followed 
by a similar initiative by dairy cattle farmers in July 2014.
From 2010 to 2011, consumption decreased following the 
introduction of threshold values for antimicrobial consump-
tion adopted within the “yellow card initiative”. This enforces 
legal actions on pig farmers with high antimicrobial use per 
pig [DANMAP 2010]. Effects from other parts of the legisla-
tion may be less obvious but are also likely to have affected 
prescription patterns. The “yellow card” principles were revised 
in 2016 and are described in Textbox 4.1
Official guidelines regarding the selection of antimicrobial 
agents for pigs and cattle have been available since 1996. The 
guidelines provide specific recommendations for selection of 
the appropriate antimicrobial treatment of all common indica-
tions in the major production animal species. Initially, guide-
lines were developed by the National Veterinary Laboratory 
(presently, National Veterinary Institute, DTU). Since 2005, the 
guidelines have been updated by the Danish Veterinary and 
Food Administration (DVFA) in collaboration with stakeholders 
and university experts. The latest update was in 2010, when 
new dynamic evidence based treatment guidelines for pigs 
were launched [DANMAP 2010, www.fvst.dk]. In 2012, the 
Danish Veterinary Association published treatment guidelines 
to promote prudent use of antimicrobials in dogs and cats. The 
guidelines were prepared by clinical specialists and expert sci-
entists from the Faculty of Health and Medical Sciences at the 
University of Copenhagen and National Food Institute DTU. 
The treatment guidelines for dogs and cats will be revised in 
2017.
4.1.1 Data sources
Data on antimicrobial use at the product level have been col-
lected in Denmark since 1996, including historical data back to 
1990. In Denmark, all therapeutic antibiotics are available by 
prescription only.
Since 2000, data on all medicine prescribed for use in animals, 
including vaccines, antimicrobial growth promoters (no longer 
permitted) and coccidiostatic agents (non-prescription) have 
been collected in the national database VetStat. The VetStat 
database is hosted and maintained by Danish Veterinary and 
Food Administration (DVFA). Data in VetStat are validated by the 
DVFA.
The data presented in this report were extracted from VetStat 
on 3rd March and  22nd August 2017. Data have been sum-
marized for DANMAP by DTU National Food Institute.
4.1.2 Methods
Metrics of antimicrobial consumption are numerous, each with 
its own advantages and limitations. Therefore, the selection of 
Figure 4.1. Prescribed antimicrobial agents for humans, and for all  animal species, Denmark   DANMAP 2016
Sources: Human therapeutics: The Danish Health Data Authority. Antimicrobials for animals: Until 2001, data are based on reports from the 
pharmaceutical industry of total annual sales from the Federation of Danish pig producers and slaughterhouses (1994-1995) and Danish     
Medicines Agency and Danish Plant Directorate (1996–2000). Data from 2004–2016 are based on data extracted from VetStat (3rd March  
and 22nd August 2017) and includes all antimicrobial agents registered for use in animals.
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metrics used for monitoring must depend on the monitoring objec-
tive and the  information available.
The overall amount of antimicrobial agents is measured in kg 
active compound and is used in Section 4.2 for the purpose of 
an overall crude comparison of antimicrobial use in the veteri-
nary and human sectors and to enable international compari-
sons (Figure 4.1).
In DANMAP 2012, we introduced two new metrics to monitor 
trends in antimicrobial consumption to ensure the robustness of 
the analyses over time and to facilitate comparisons between 
animal species, as well as comparisons between the veterinary 
and human sectors. The new metrics are defined below, and for 
additional information on methodology, please refer to Chapter 
9 and the web annex [www.Danmap.org]. 
DADD (Defined animal daily dose)
DADD is the average maintenance dose per day for the main 
indication of a drug in the appropriate animal species. The 
DADD is not defined at product level but for each antimicrobial 
agent, administration route and animal species; and when 
Table 4.1. Antimicrobial agents sold (kg active compound) by animal species and age group, Denmark DANMAP 2016
Note: Data for 2015 and 2016 were extracted from VetStat 22 August 2017.  Only the ATCvet group contributing mostly to the antimicrobial 
group is mentioned. Combination drugs are divided into active compounds
a)  Penicillins with extended spectrum and combination penicilins, incl. b-lactamase inhibitors 
b)  In DANMAP 2016, new principles have been applied to estimate the antimicrobial use for companion animals, please see section 4.3.4 
c)  Approximately 222 kg of the sulfonamides and trimethoprim registered for pets are products (oral paste) typically used for horses 
d)   This includes data on antimicrobial agents used for sheep and goats (14 kg), data where the animal species has not been defined or where 
the age group does apply to the designated animal species
ATCvet code
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Pigs 371 4163 <1 <1 1875 10113 0 15588 8286 7820 6615 22453 864 81499 78150
Sows and piglets 258 1666 <1 <1 436 528 0 8331 3512 999 4770 1698 102 23366 22300
Weaners 106 2357 <1 0 734 6665 0 1680 3961 2868 1594 13733 752 34985 34449
Finishers 7 140 <1 <1 705 2920 0 5578 813 3953 251 7022 10 23148 21401
Cattle 656 742 66 <1 3 273 0 7719 809 0 1038 1604 10 13150 12920
Intramammaries 0 31 55 0 1 0 0 257 147 0 6 0 <1 503 498
Cows and bulls excl. 
intramammaries
12 240 10 <1 1 114 0 6862 497 0 893 999 <1 10244 9629
Calves <12 months 635 445 1 <1 <1 155 0 467 152 0 128 567 9 2241 2561
Heifers and steers 8 26 <1 0 <1 4 0 133 13 0 10 37 <1 162 232
Poultry 5 60 0 <1 24 153 0 236 218 <1 111 748 6 2440 1560
All poultry excl. turkeys <1 36 0 <1 18 103 0 168 97 <1 106 414 0 1931 942
Turkeys 4 24 0 0 6 50 0 67 121 0 5 334 6 509 619
Other production 
animal species
315 325 <1 <1 160 789 893 1 2054 0 2284 795 <1 8146 7617
Aquaculture 314 0 0 <1 0 0 893 0 11 0 1071 <1 0 2969 2289
Fur animals 2 325 0 0 160 789 0 1 2043 0 1213 794 0 5177 5327
Companion animals(b) 1 15 137 14 69 3 0 29 717 <1 1393 45 31 2312 2458
Pets (estimated)(c) <1 14 137 14 69 3 0 20 717 <1 276 40 31 1245 1326
Horses (estimated) <1 <1 <1 <1 0 <1 0 8 <1 0 1117 5 <1 1067 1131
Other(d) 5 175 3 3 7 22 <1 766 245 11 283 130 1 2194 1647
Total 1353 5480 206 17 2139 11353 892 24339 12329 7832 11724 25775 913 109741 104352
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appropriate, also age group. The DADDs have been specifically 
defined for use in DANMAP based on current knowledge and 
may vary from the prescribed daily dose or the recommended 
dosage in the Summaries of Product Characteristics (SPC) or in 
the VetStat database.
DAPD - proportion of population in treatment per day 
Trends in antimicrobial usage for animals, both within and 
across species, are presented in DAPD, because this measure 
allows for comparison between sectors. DAPD=DADD per 
1000 animals per day, where ‘animals’ are represented by 
their live biomass and adjusted for life-span. The estimated 
live biomass is expressed as the number of standard animals 
with an estimated average weight on a given day. This may 
also be referred to as the ‘standard-animals-at-risk’, and allows 
comparison between species with large differences in body-
mass and life-span.
DAPD, or estimated treatment proportion, is a statistical 
measure that provides a rough estimate of the proportion of 
animals treated daily with a particular antimicrobial agent. For 
example, 10 DAPDs indicate that an estimated 1% of the pig 
population, on average, receives a certain treatment on a given 
day (Section 4.3 and Chapter 9, Materials and Methods). DAPD 
also allows comparisons with the antimicrobial consumption in 
the human sector, which is measured in defined daily dose per 
1,000 inhabitants per day (DID), see Chapter 10, Terminology, 
for a description of DID.
4.2 Total antimicrobial consumption in animals
Measured in kg active compound, the total use of antimicrobial 
agents used for all animals, amounted to 104.4 tonnes active 
compound, representing an overall 5% decrease compared with 
2015, Figure 4.1 and Table 4.1.
In 2016, the antimicrobial use for pigs, cattle, fur animals 
and poultry comprised approximately 75%, and 12%, 5% 
and 2% of the total antimicrobial consumption for animals, 
respectively (Figure 4.2). The decrease in antimicrobial use 
for animals was mainly attributed to a 3% decrease in the 
amount used in the pig industry, which is the main driver of 
antimicrobial consumption in animals in Denmark, due to the 
size of the industry. Cattle and pigs are the two major pro-
duction species in Denmark and they comprise almost equal 
proportions of live biomass. However, the vast proportion of 
cattle biomass consists of dairy cows, which have very low 
consumption of antimicrobial agents compared with growing 
animals.
Historically, the overall consumption, measured as kg active 
compound, was 49% lower in 2016 compared with 1994 
(Figure 4.1). In contrast, the total meat production increased 
by 15% during this period (Table 3.1). A major part of the 
decrease in consumption can be explained by the discontinued 
use of growth promoters from 1994 to 1999.
Between 2000, when antimicrobial consumption was first 
registered in VetStat, and 2009, when it was at its highest, 
the amount of kg active compound increased by 62% (Figure 
4.1). This increase was driven mainly by consumption in pigs, 
and during this period the number of pigs produced went up by 
23% (Table 3.1). At the same time, the proportion of exported 
live pigs (approx. 30 kg) increased and thus resulted in a 
decrease in the overall biomass of the pig population. Since 
then, the antimicrobial consumption for animals has gradually 
decreased and in 2016 it was 20% lower than in 2009.
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Figure 4.2. Live biomass (mill. kg) and antimicrobial consumption (kg) in main animal species, Denmark DANMAP 2016
Note: The live biomass is estimated from census data (pigs, cattle and pet animals) and production data (poultry, fur animals and aquaculture). For 
poultry: the figures comprise only the biomass for the main production types (turkeys and broilers). The live biomass estimates for cattle, poultry, 
aquaculture, fur and pet animals are based on 2012 data. The estimation procedures are described in Chapter 9, Materials and Methods
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Figure 4.3. Change in antimicrobial use (kg active compound) in pigs, cattle, fur animals and pets (dogs and cats) 2012 – 2016, Denmark
Note: The figure includes the antimicrobial agents registered for use in the particular animal species. Note also the different scale on the x-axis 
Poultry has not been included in the figure, since several serious disease outbreaks in 2014 and 2015 have caused considerable fluctuations in  
the antimicrobial consumption for poultry over the past three years, see Table 4.1 and section 4.3.3  
a)  Penicillins with extended spectrum and combination penicilins, incl. b-lactamase inhibitors
b)  The use of antimicrobial agents for pets (dogs and cats) has been estimated as described in section 4.3.4 
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Figure 4.3 illustrates the changes in usage in pigs, cattle, 
fur animals and pets over the past five years. With the 
exception of fur animals, the changes in the antimicrobial 
use within the different animal species have been clearly 
affected by the different campaigns to reduce the total use 
and to reduce the use of particular antimicrobial classes. 
In particular, the use of tetracyclines for pigs has been re-
duced significantly, the usage patterns in cattle has shifted 
towards more penicillins and less sulfonamides and trim-
ethoprim, amphenicols and cephalosporins and in dogs and 
cats the use has shifted away from the cephalosporins. 
4.3 Antimicrobial consumption by animal species
For this issue of DANMAP, updated data from 2004-2016 were 
extracted from VetStat1 and all measures for the antimicrobial 
usage in pigs were calculated for all years, using the updated 
dataset.
4.3.1 Antimicrobial consumption in pigs
In 2016, the total antimicrobial consumption in pigs (sows and 
piglets, weaners, finishers) was 78.2 tonnes active compound 
(Table 4.1), a decrease of 3.3 tonnes (4%) compared with 2015. 
The treatment proportions (DAPD) in the pig population overall 
and by age group are presented in Figure 4.4 and Figure 4.5 and 
the DADD’s are shown in the web annex (Table A4.1 and in the 
DADD description). 
The treatment proportion (DAPD) of the total population 
reflects the trends in selection pressure within the popula-
tion. However, the DAPD is much higher in the weaning pigs 
than in finishers and sows (Figure 4.4). Furthermore, the 
biomass of the weaning pigs is also very small (7.5- 30 kg, 4 
weeks), compared with the finishers (31-107 kg, 12 weeks) 
and the sows. The large differences in DAPDs between age 
groups affects the DAPD of the total population and trends are 
influenced by changes in population structure. Thus, signifi-
cant changes in export or productivity need to be accounted 
for, before interpreting the antimicrobial consumption patterns 
and selection pressure in the pig production. As an example, 
increased export of live pigs right after weaning could lead to 
an increase in DAPD for the remaining population, since the 
exported pigs were only in the country, while the treatment 
proportion was highest.
Historically, the treatment proportion (DAPD) increased from 
2004 to 2009, followed by a decrease in 2010 and 2011, 
which is considered a result of the “yellow card initiative” (See 
DANMAP 2010). 
In 2016, the antimicrobial consumption in pigs, measured in 
DAPD, decreased by 5% to approximately 25 DAPD (Figure 
4.4) when adjusted for changes in export. Overall the number 
of pigs produced in 2016 increased by 3%, and the number of 
1 Data extracted from VetStat 3rd March and 22nd August 2017
pigs exported increased by 9% (Table 3.1). Within the different 
age groups, the treatment proportions decreased in weaners 
and finishers, but remained at the same level for sows and 
piglets (Figure 4.4). Thus, on average, on a given day in 2016, 
approximately 2% of sows and piglets, 1-2% of finisher pigs 
and 10% of weaner pigs were under treatment with antimicro-
bial agents.
Also measured in DAPD, the antimicrobial use in pigs was 27% 
lower in 2016 than in 2009, when adjusted for changes in 
export (Figure 4.4).Overall, the decrease was primarily seen 
for tetracyclines, pleuromutilins and beta-lactamase sensitive 
penicillins (Figure 4.5). Tetracycline has been one of the most 
commonly used antimicrobials in the Danish pig production 
for more than a decade. It is almost exclusively administered 
orally, and is especially used for treatment of gastrointestinal 
disease in weaning pigs and finishers. The overall use of tetra-
cyclines in the pig production fluctuated from 2009 to 2013, 
but has since then decreased and 2016 saw the lowest DAPD 
levels since 2005. Measured in DAPD, the use of tetracyclines, 
for all age groups was reduced by 8% from 2015 to 2016 and 
has decreased 35% since 2009. The proportion of weaner pigs 
under treatment with tetracycline, on average, on a given day 
has decreased from approximately 5% in 2009, to approxi-
mately 3% in 2016
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Note:  The” all age groups adjusted” is adjusted for the increasing 
export of pigs at 30 kg (see text). “Sows” includes treatment in boars 
and piglets pre-weaning    
a) The DAPD is calculated as the number of standard doses for one kg 
animal divided by the estimated live biomass in the age group of the 
total population (in tonnes) 
Figure 4.4. Antimicrobial consumption (a) in the pig production, 
and the distribution on age groups, Denmark  
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Figure 4.5. Antimicrobial consumption(a) in the total pig production(b), and in finishers, weaners, sows and piglets, Denmark  
DANMAP 2016
Note: The figure includes all antimicrobial agents registered for use in pig and in specific age-groups. Amphenicols, colistin, 
fluoroquinolones, intramammaries, gynecologicals and topical drugs are not included in the figure
a)  The DAPD is calculated as the number of standard doses for one kg animal divided by the estimated live biomass in the age group or 
the total population (in tonnes)
b)  The total is adjusted for the increasing export of pigs at 30 kg (see text). “Sows” includes treatment in boars and piglets pre-weaning
c)  Lincosamide/spectinomycin combinations comprise 65% of this group
d)  Beta-lactamase sensitive penicillins
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While the overall consumption of antimicrobial agents for pigs 
has decreased almost consistently since 2009, the use of 
colistin for pigs has increased more than two-fold from 407 
kg in 2009 to 864 kg in 2016, of which 752 kg were used for 
weaners. Although the use of colistin constitutes a very small 
fraction of the overall antimicrobial consumption in pigs (ap-
proximately 1% in 2016), the increase has potential implica-
tions on human health, since polymyxins, to which colistin be-
longs, have found a new role for treatment of carbapenemase 
resistant infections in human medicine, see also Textbox 4.2 
concerning colistin. 
Of the critically important antimicrobial agents, the use of fluo-
roquinolones and cephalosporins was close to zero in 2016.
Consumption of zinc oxide and zinc in the pig production 
Zinc is relevant in the context of DANMAP, because its use may 
select for antimicrobial resistance in some bacteria, including 
MRSA. Medicinal zinc, in the form of zinc oxide, is fed to piglets 
after weaning to prevent or treat diarrhoea. Figure 4.6 shows 
the use of medicinal zinc in Danish pig production. The most 
commonly used product is zinc oxide (ZnO) which contains 
80% zinc and which is largely insoluble in water.
For more than a decade the consumption of zinc has increased 
steadily, reaching a peak in 2015. However, in 2016 we ob-
served a 4% decrease, equivalent to approximately 23 tonnes 
of zinc oxide or 18 tonnes of zinc, compared with 2015. Since 
DANMAP 2015, a number of errors were identified in VetStat 
data on zinc consumption. This has been adjusted and Figure 
4.6 shows the updated data on consumption of medicinal 
zinc in pigs and reflects the situation better than figure 4.6 in 
DANMAP 2015.
4.3.2 Antimicrobial consumption in cattle
In 2016, the overall consumption of antimicrobials in cattle 
decreased by approximately 3% (363 kg) compared with 2015. 
The production of veal and beef remained more or less at the 
same level from year to year, while milk production continued 
to increase (Table 3.1).
The use of fluoroquinolones in cattle has been low for the last 
decade and no use of fluoroquinolones was reported for cattle 
in 2016.
Approximately 11 kg of cephalosporins (all generations) were 
used systemically, which represents a 61% reduction since 
2014, when the dairy association decided to phase out its use, 
HUSK Neo Sans 8pt. Ændre til 100% sort - rammer 50% sort
0
5
10
15
20
25
30
35
0
100
200
300
400
500
600
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
P
ig
s 
pr
od
uc
ed
 (
m
ill
. 
he
ad
s)
Z
in
k 
co
ns
um
pt
io
n 
(t
on
ne
s)
 
ZnO Zn Pigs produced
Figure 4.6
Figure 4.6 Consumption (tonnes) of zinc oxide (ZnO) and zinc (Zn) in the pig production, Denmark  DANMAP 2016
Figure 4.7. Consumption of 3rd and 4th generation 
cephalosporins in pigs and cattle, Denmark 
DANMAP 2016
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and an 83% reduction compared with 2008, when cephalosporin 
consumption was at its peak. The use of 3rd and 4th generation 
cephalosporins is low in cattle and mostly used for systemic 
treatment (Figure 4.7).
The majority of antimicrobials administered parenterally for 
cattle are used for dairy cows (Table 4.1), and mainly pre-
scribed for mastitis. From 2005 to 2013 there was a slight 
reduction in the overall level of intramammary treatment. 
Following an increase in 2014 the use of intramammary treat-
ment has decreased again in 2015 and 2016 (Table 4.2). 
Since 2014, the Danish dairy industry (the Danish Agriculture 
and Food Council) has had a strategy for reducing the amount 
of antimicrobials used for treatment of mastitis by 20% com-
pared to the 2012 level. From 2015 to 2016, the overall use 
of antimicrobials for cattle decreased by approximately 2% 
(corresponding to 230 kg). 
Order (DK) 785/2010 provides legal regulations of use of 
antimicrobial agents for mastitis in cattle and the industry 
has emphasized that farmers should use narrow spectrum 
penicillins to treat mastitis caused by Gram-positive bacteria, 
unless sensitivity testing reveals resistance towards these 
antimicrobials. The overall use of intramammary treatment, 
measured in DADDs, decreased from 2010 to 2011, but has 
increased again after 2013 (Table 4.2). However, it is notable 
that the use of 3rd and 4th generations cephalosporins has 
been reduced significantly and the relative proportion of dry-
ing-off treatment versus therapeutic treatment has shifted 
markedly from 22% versus 78% in 2010 to 55% versus 45% 
in 2016 (Table 4.3).
Table 4.2. Use of antimicrobial agents for intramammary application in cattle in DADD’s (1000s), Denmark  
DANMAP 2016
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Doses per antimicrobial class DADDs (1000’s)
Penicillins(a) 201 211 211 236 282 314 318 324 311 317 275 262
Aminoglycoside-benzylpenicillin 
combinations(b)
130 104 101 101 110 93 48 47 58 90 143 177
Cephalosporins, 
1st generation
103 98 89 85 89 89 99 105 111 113 96 89
Cephalosporins, 
3rd and 4th generation
110 124 127 112 76 51 34 30 24 21 10 9
Others(c) 21 20 16 15 14 12 9 8 0 0 11 10
Total 566 558 544 549 570 559 508 514 504 541 535 547
Total DADD per cow per year 1,0 1,0 1,0 1,0 1,0 1,0 0,9 0,9 0,9 1,0 1,0 1,0
Note: For intramammary treatment, 1 DADD is defined as the dose to treat two teats for 24 hours  
a) Includes benzylpenicillin, cloxacillin, and cloxacillin-ampicillin combinations (QJ51CE, QJ51CF, QJ51RC)
b) Mainly dihydrostreptomycin-benzyl benicillin combinations; includes also combinations of penicillin/aminoglycoside with bacitracin or nafcillin 
(QJ51RC)     
c) Lincosamides, neomycin-lincomycin combinations and trimethoprim-sulfonamide combinations
Table 4.3. Number of treatments with antimicrobial agents for intramammary application in cattle, Denmark 
DANMAP 2016
Note: Includes data for Intramammaries registered for use in cattle.  For intramammary therapeutic treatment, 1 DADD is defined as the dose to 
treat two teats for 24 hours. For drying off treatment, 1 DADD is defined as the dose to treat 4 teats. 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Total doses per indication (a) DADDs (1000's)
Drying off treatment  (4 teats) 73 75 71 76 82 99 97 117 125 140 154 174
Therapeutic treatment (2 teats) 420 408 388 377 378 350 307 279 253 259 227 199
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4.3.3 Antimicrobial consumption in poultry
In Denmark, poultry production comprises mainly broiler pro-
duction, followed by egg layers and turkey production. In addi-
tion there is a small production of ducks, geese and game birds.
Danish broiler farms have a very high level of biosecurity and 
the antimicrobial consumption in broiler production is generally 
low compared with other species. Accordingly, a few disease 
outbreaks in some farms can markedly affect and cause 
considerable fluctuations in the national statistics on antimi-
crobial usage. This was the case in late 2014 and throughout 
2015, where the broiler industry experienced several large 
disease outbreaks, and the use of antimicrobials in the popula-
tion increased significantly during this period. However, the 
problems were resolved during 2015 (personal communication: 
J. Dahl and M. Nielsen Blom, Danish Agriculture and Food Council) 
and in 2016 use of antimicrobials for poultry (excl. turkeys) 
decreased sharply to 1,560 active compound, a decrease of 
36% compared with 2015. For broilers, amoxicillin has been 
the most commonly used antimicrobial agent for more than a 
decade. However, in 2016 tetracycline was the most com-
monly used antimicrobial (Table 4.1).
Currently, VetStat does not allow differentiation of the use of 
antimicrobials between different sectors of the poultry produc-
tion. However, the consumption for turkeys was identified by 
combining information from the Central Husbandry Register 
with information provided by poultry veterinarians and the 
industry (personal communication: S. Astrup, PoultryVet, and 
M. Nielsen Blom, Danish Agriculture and Food Council) and the 
information in VetStat.
Over the past few years, the turkey industry has introduced a 
new hybrid of birds, less prone to arthritis, and improved the 
vaccination strategy against Turkey Rhino Tracheitis virus 
(personal communication: S. Astrup, PoultryVet). This may have 
explained the decrease in antimicrobial use in 2015. However, 
in 2016 the turkey production increased (Table 3.1) and the 
use of antimicrobial agent increased by 110 kg. 
4.3.4 Antimicrobial consumption in aquaculture, fur 
animals and companion animals
The antimicrobial consumption in aquaculture decreased by 
23% to 2,289 kg in 2016 compared with 2015 (Table 4.1). 
This is the lowest amount registered for more than a decade. 
The distribution of the different compounds was sulphon-
amide/trimethoprim comprised 47%, quinolones (oxolinic 
acid) 39% and amphenicols 14%, when measured in kg active 
compound.
Antimicrobial consumption in aquaculture is mostly influenced 
by the summer temperatures, because diseases are more likely 
to occur in warmer waters. In recent years, the aquaculture 
industry has developed new and better vaccines and improved 
vaccination strategies to reduce the risk of diseases that 
may require antibiotic treatment. A combination of favourable 
weather conditions (lower temperatures during summer) and 
a positive effect of the revised vaccination strategies may 
explain the reduced consumption seen over the last few years 
[personal communication: N. H. Henriksen, Danish Aquacul-
ture].
With the exception of 2013 and 2014, the use of antimicro-
bial agents in mink production has increased every year for 
more than a decade, from less than two tonnes in 2004 to 
more than 5 tonnes in 2016. The production of mink has also 
increased significantly during this period and peaked at 17.8 
million in 2015. In 2016, 17.1 million mink were produced in 
Denmark (Source: Kopenhagen Fur). In recent years, the indus-
try has introduced interventions to reduce the antimicrobial 
consumption, by increasing the quality of feed and improving 
animal welfare (personal communication: T. Struve, Kopenha-
gen Fur). In 2013 and 2014, this appeared to have resulted 
in a decrease in antimicrobial consumption of 11% and 14%, 
respectively. However, in 2015 the use of antimicrobial agents 
increased by 23% to 5,177 kg and in 2016 by further 3% to 
5,327 kg active compound; mainly penicillins, sulphonamide/
trimethoprim, tetracyclines and macrolides (Table 4.1). There 
is no apparent diagnostic explanation for this increase in 
antimicrobial use (personal communication: National Veterinary 
Institute, DTU). Recent studies have identified risk factors for 
antimicrobial use in mink, including feed quality, see Textbox 
4.3.
Use of fluoroquinolones and cephalosporins in fur animal pro-
duction has been close to zero for more than a decade. 
It is noteworthy, that the use of prescribed medical zinc (zinc-
oxide) in mink production has increased markedly in recent 
years, from approximately 200 kg in 2012 to 1,045 kg in 
2016. In the mink production, medical zinc is applied topically 
on pre-weaning mink kits in the nesting boxes to keep them 
dry ( personal communication:  M. Chriel, National Veterinary 
Institute, DTU).
The information available on antimicrobial consumption in 
companion animals is not as complete as for production ani-
mals, and a substantial amount of the antimicrobials used for 
companion animals are entered into VetsStat without defining 
animal species. For DANMAP 2016, the principles for estimat-
ing the amount of antimicrobial agents used for companion 
animals (pets and horses) were adjusted to improve the 
estimates. In the Tables 4.4 and 4.5, the following principles 
have been applied: 1) all antimicrobial agents registered, by 
the either the pharmacy or veterinarians for use in dogs, cats 
and horses have been included, 2) antimicrobial agents, where 
no animal species is given, were allocated to pets or horses 
based on relevant type of preparation or registration. However, 
the estimates may underestimate the actual use for compan-
ion animals, since the antimicrobials administered parenterally 
- with no information on animal species - are not included (see 
table 4.1) 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Doses per antimicrobial class DADDs (1000’s)
Penicillins(a) 201 211 211 236 282 314 318 324 311 317 275 262
Aminoglycoside-benzylpenicillin 
combinations(b)
130 104 101 101 110 93 48 47 58 90 143 177
Cephalosporins, 
1st generation
103 98 89 85 89 89 99 105 111 113 96 89
Cephalosporins, 
3rd and 4th generation
110 124 127 112 76 51 34 30 24 21 10 9
Others(c) 21 20 16 15 14 12 9 8 0 0 11 10
Total 566 558 544 549 570 559 508 514 504 541 535 547
Total DADD per cow per year 1,0 1,0 1,0 1,0 1,0 1,0 0,9 0,9 0,9 1,0 1,0 1,0
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Measured in kg active compound, the overall antimicrobial 
consumption for horses, specifically the use of sulphonamide/
trimethoprim, has increased steadily over the past five years 
(Table 4.4). For pets (dogs and cats), the use decreased from 
2012 to 2015, but increased in 2016 (Table 4.5). Antimicrobial 
use in dogs and cats from 2012 to 2016 has been described in 
further detail in Textbox 4.5.
A large proportion of antimicrobials used for companion 
animals are prescribed for treatment of chronic or recurrent 
disease, mainly dermatitis. Due to the close contact between 
owners and their pets, the repeated use of critically important 
antimicrobials may pose a risk to the owners.
In 2016, the use of fluoroquinolones for use in pets was 14 
kg, compared with 13 kg in 2015. Almost all fluoroquinolones 
used in animals in 2016, were prescribed for pets. Similarly, 
the pets accounted for a significant proportion (137 kg or 
66%) of the use of cephalosporins used in animals.
However, over the past three years, since the treatment guide-
lines by Danish Veterinary Association (November 2012) were 
first published, the use of cephalosporins has been reduced by 
36%. Thus, there appears to be a shift away from the use of 
cephalosporins, sulphonamides and trimethoprim and towards 
penicillins (Figure 4.3) This may be an effect of treatment 
guidelines, recommending that use of critically important anti-
microbials should be reduced as much as possible. 
Birgitte Borck Høg and Helle Korsgaard 
Table 4.4. Estimated use of antimicrobial agents for horses measured in kg active compound, Denmark 
DANMAP 2016
Table 4.5. Estimated use of antimicrobial agents for dogs and cats measured in kg active compound, Denmark 
DANMAP 2016
A
m
in
og
ly
co
si
de
s 
A
m
ph
en
ic
ol
s
Ce
ph
al
os
po
rin
s
Fl
uo
ro
qu
in
ol
on
es
Li
nc
os
am
id
es
M
ac
ro
lid
es
O
th
er
 A
B
O
th
er
 q
ui
no
lo
ne
s
Pe
ni
ci
lli
n'
s,
  
b-
la
ct
am
as
e 
se
ns
it
iv
e
Pe
ni
ci
lli
n'
s,
  o
th
er
s(
a)
Pl
eu
ro
m
ut
ili
ns
Su
lf
on
am
id
es
 a
nd
 
tr
im
et
ho
pr
im
Te
tr
ac
yc
lin
es
To
ta
l
2012 <1 <1 <1 <1 0 <1 <1 0 14 <1 0 1000 3 1018
2013 1 <1 <1 <1 0 <1 <1 0 13 <1 0 893 5 914
2014 1 <1 <1 <1 0 <1 <1 0 15 <1 0 1024 6 1047
2015 3 <1 <1 <1 <1 <1 <1 0 10 <1 0 1049 4 1067
2016 <1 <1 <1 <1 0 <1 <1 0 8 <1 0 1117 5 1131
Note: Data extracted from VetStat on 3rd March and 22nd August 2017. The estimates include all antimicrobial agents registered, by the either 
the pharmacy or veterinarians for use in horses. Furthermore, antimicrobial agents, where no animal species is given, were allocated to horses 
based on relevant type of preparation (eg. oral paste) or registration. Antimicrobials administered parenterally - with no information on animal 
species - are not included
a) Penicillins with extended spectrum and combination penicilins, incl. b-lactamase inhibitors
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Textbox 4.1
New model for the yellow card initiative 
The Yellow Card Initiative was introduced in 2010 to reduce the use of antimicrobials in pig production in Denmark. Use of 
antimicrobial agents on each holding is monitored and if it exceeds a pre-specified threshold of animal daily doses (ADD) per 
pig per day, a warning in form of a ‘yellow card’ is issued. A yellow card restricts antimicrobial usage further and requires more 
frequent veterinary consultations (DANMAP 2010). If the farmer does not reduce the consumption of antimicrobials to a level 
below the threshold, the Danish Veterinary and Food Administration (DVFA) requires a second opinion on the health issues 
on the farm by an independent private veterinarian. The Yellow Card Initiative works as an incentive to all pig producers to 
contribute to the goal of reducing the overall use of antimicrobials in the pig production (see DANMAP 2010).
On the 30th of June 2016, the DVFA further developed the Yellow Card Initiative by weighting the use of each antimicrobial 
agent according to the importance of the specific antimicrobial class in development of antimicrobial resistance. The weights 
are shown in table 1. The weight for a specific antimicrobial is multiplied by amount used to generate a “weighted ADD” to 
motivate the veterinarian and owner to restrain from using antimicrobial agents with higher weights. The weights are deter-
mined according to the importance of the antimicrobial agent for treating human illness and the importance in contributing 
to the development of antimicrobial resistance (AMR). In addition to the new weighted approach, the threshold for receiving 
a yellow card was lowered by 5 percent. The period for calculating the average antimicrobial consumption in a pig holding is 
nine months and if a yellow card is issued, the farmer is expected to reduce the antimicrobial consumption on the pig holding 
to a level below the threshold levels within nine months of the issuance of the injunction. 
The allocation of yellow cards based on the new weighted approach, took place for the first time in May 2017. The designati-
on was based on the antimicrobial consumption in the pig herds from July 2016 to March 2017. The weights were fully imple-
mented by March 31st 2017, when an average of the past nine months could be calculated. The applied weights are shown in 
Table1.The new approach is not appropriate for monitoring of antimicrobial consumption in the population, but is valuable in 
targeting specific resistance problems.
On the 31st of December 2016, the DVFA adjusted the weight for tetracyclines from 1.2 to 1.5. The adjustment was made to 
motivate further reduction in the consumption of tetracyclines in the pig production (Table 1).The first allocation of yellow 
cards including the new weight for tetracyclines will take place in November 2017 and will be based on the antimicrobial 
consumption in the holding from January to September 2017.
For further information: Anette Grønkjær Thomsen (agxt@fvst.dk)
Class of antimicrobial Factor applied  31. March –29. September 2017
Factor applied from  
30-September 2017
Fluoroquinolones, 3rd and 4th generation 
cephalosporins(a) 
10.0 10.0
Tetracyclines(b) 1.2 1.5
Simple penicillins, sulfonamides,  
trimethoprim and pleuromutilins(c)
0.95 0.95
Other antimicrobials 1.0 1.0
Table 1: The weights that are used for calculating antimicrobial consumption in the pig production  
for the yellow card initiative in 2017 
DANMAP 2016
a) ATC-codes: QJ01MA, QJ01DD, QJ01DE
b) ATC-codes: QJ01AA
c) ATC-codes: QJ01EQ, QJ01EW, QA07AB, QJ01CE, QJ01XQ
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2012 22 <1 272 13 67 7 49 0 42 651 <1 306 51 1483
2013 19 <1 231 12 63 5 42 0 31 642 <1 292 45 1383
2014 21 <1 213 12 69 6 34 1 31 653 <1 300 35 1376
2015 18 <1 157 13 68 4 32 0 25 655 1 235 39 1249
2016(b) 14 <1 137 14 69 3 31 0 20 717 <1 276 40 1323
Note: Data extracted from VetStat on 3rd March and 22nd August 2017. Data include all antimicrobial agents registered, by the either the 
pharmacy or veterinarians for use in pets. Furthermore, antimicrobial agents, where no animal species is given, were allocated to pets based 
on relevant type of preparation (eg. tablets, eye- or eardrops) or registration. Antimicrobials administered parenterally - with no information on 
animal species - are not included
a) Penicillins with extended spectrum and combination penicilins, incl. b-lactamase inhibitors 
b) In 2016, approximately 222 kg of the sulfonamides and trimethoprim registered for pets are products (oral paste) typically used for horses
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Textbox 4.2
Use of colistin in animals and humans – a Danish Perspective
 
Background: Traditionally, colistin was considered an inferior antibiotic to control and treat Gram negative infections in hu-
mans. Its toxicity profile combined with the availability of more efficient and less toxic alternatives such as beta-lactams and 
fluoroquinolones meant that it had low priority as a treatment option in humans. Since it played only a minor role as a human 
drug, it was recommended for veterinary medicine, especially to treat diarrhea in pigs. In addition to the fairly low risk profile 
of using colistin for animals, acquired resistance towards colistin was until recently only associated with chromosomal (non-
transferrable) mechanisms, leading to no horizontal spread between resistant veterinary and human pathogenic isolates. 
However, plasmid-mediated (transferrable) colistin resistance conferred by the mcr-1 gene was detected in late 2015 in E. 
coli isolates from animals, foods and patients in China [1] and was soon also found in imported poultry meat (five isolates) 
and in one bacterial isolate from a patient with bloodstream infection in Denmark [2] and many other countries world-wide 
[3]. Recently new variants of the mcr-gene have been described and two newly published studies from Denmark found the 
mcr-3 gene in one blood isolate from a Danish patient dating back to 2014 [4] and nine Salmonella isolates from human 
infections have also been found to carry either the mcr1 or mcr3 gene [5]. Simultaneously, an increasing need for colistin in 
human medicine is emerging due to increasing prevalence of infections caused by multi-resistant bacteria. The combination 
of these two new situations has forced both national and international risk managers to revise the risk profile of colistin in 
veterinary medicine.
Use of colistin in humans
In Denmark, colistin has primarily been used for inhalation treatment of lung patients suffering from chronic infections with 
Pseudomonas aeruginosa and occasionally for treatment of patients suffering from chronic urinary tract infections or other 
infections with ESBL-positive and multi-resistant Gram negatives. The consumption of colistin for human treatment used to 
be less than one Defined Daily Dosis (DDD) per 100 admitted patients at hospitals and without any measurable consumption 
in the primary health sector. In 2016, the use of colistin for intravenous treatments of severely ill patients suffering from 
bacteremia with carbapenemase-producing E.coli or K. pneumoniae was very rare, but it is becoming one of the few treat-
ment options in this patient group. It is therefore of utmost importance that the drug is effective and no additional resistance 
mechanisms are introduced into these already multi-resistant bacteria. 
Use of colistin in production animals
In Denmark, almost all the colistin prescribed for animals (881 kg in 2016) is used in the pig production for treating 
gastrointestinal infections in weaners. Only smaller amounts (less than 20 kg in 2016) are used for cattle and poultry, 
respectively. An overview of colistin consumption in production animals 2004-2016 is shown in Figure 1. Except for 2011 
and 2013, the use of colistin has increased all years since 2006, but the increase was particularly steep in 2014 and 2015. 
In 2010, colistin was introduced as one of the “first choice” antimicrobial agents for the treatment of gastroenteritis in 
the treatment guidelines for pigs. In 2014, the Danish pig producers committed themselves to reduce the consumption of 
tetracyclines by 50% and the increase in colistin use in 2014 and 2015 may be a response to this. However, in 2016 the 
increase levelled off, probably due to an increased focus on colistin use in animals and humans, because of the emergence 
of new colistin resistance. 
One Health perspective
Immediately following the detection of the mcr-1 gene in Denmark, the Danish Veterinary and Food Administration took 
initiative to convene experts from the health sector and DTU to assess the gravity of the situation. In autumn 2016, the DFVA 
recommended to restrict the use of colistin in pig production. In spring 2017, pharmaceutical products containing colistin were 
assigned a weight of 10 in the calculations of individual herd consumption of antibiotics against the farm threshold according 
to the differentiated yellow card scheme. This change was implemented in April 2017, and is expected to significantly reduce 
the use of colistin in pigs.
29DANMAP 2016
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The Danish Health Authority is currently leading a working group of experts developing guidelines on the management of 
carbapenemase-producing organisms, including carbapenem-resistant Enterobacteriaceae. The introduction of screening 
methods of risk patients upon admission to hospitals is expected to reduce the spread in the hospital environment and protect 
vulnerable patients, thus being able to keep colistin as a very last line drug for the clinical cases demanding treatment. 
As part of the increased awareness of colistin resistant bacteria in humans the reference laboratory at Statens Serum Institut 
offers phenotypic resistance testing to clinical microbiological departments suspecting these resistance mechanisms in clinical 
strains, thereby broadening the surveillance of multi-resistant bacteria. 
Ute Wollf Sönksen, Henrik Hasman and Birgitte Borck Høg 
For further information: Birgitte Borck Høg (bibo@food.dtu.dk)
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Textbox 4.3
Correlation between quality of mink feed and prescription of 
antimicrobials for mink  
 
Background: Due to the increasing prescription of antimicrobials in the commercial mink (Neovison vison) production in Den-
mark (from 2,420 kg in 2007 to 5,558 kg in 2012), two register based studies were carried out to identify potential causal 
factors for antimicrobial use. Both studies included data from all active Danish mink productions, with data on farm size and 
the relation between farm and feed producer obtained from the registers at Kopenhagen Fur. Information on prescribed an-
timicrobials was obtained from the national database VetStat, October 2014 (Study 1) and October 2015 (Study 2). Data on 
microbiological feed quality was obtained from the Voluntary Feed Control under the Mink producers Organization.
Methods and Results: In the first study, the objective was to identify risk factors for antimicrobial use at farm level in the 
period 2007–2012. We found a clear significant effect of season on antimicrobial use (measured in DAPD), with a peak around 
the time of whelping in May and a high level in the following months. In autumn, a minor peak in the use of antimicrobials 
occurred throughout the study period. From 2007 to 2011, we observed a 102% increase in annual antimicrobial use. At farm 
level, the annual number of months with antimicrobial prescriptions was significantly (p<0.01) affected by feed producer, vet-
erinarian, disease (laboratory diagnosis of specific pathogens), farm size and year, with an interaction between feed producer 
and year. Furthermore, in months with antimicrobial use, the treatment proportion at farm level was significantly (p<0.001) 
affected by year, month (season), feed producer, feed quality score, veterinarian, farm size and laboratory confirmed diagno-
sis of specific infections. We also found statistically significant interactions between year*feed producer and the actual farm 
size*month were noted. Moreover, the prescription patterns varied significantly between veterinarians. Some veterinarians 
prescribe not only more frequently, but also larger amounts of antimicrobials than others. Farm outbreaks of Pseudomonas 
aeruginosa, astrovirus, or influenza virus, were associated with an increase in antimicrobial use. Salmonella spp. and mink en-
teritis virus were also found to significantly influence the prescription of antimicrobial agents, but the number of diagnosed 
outbreaks was low (Figure 1), [1]. 
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Outbreaks - Significant effects
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Farm size Season 
(month)
Time trend
(year)
Feed 
producer
Faecal cocci 
in feed
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Figure 1.  Risk factors for antimicrobial use in the Danish mink production  
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The second study focused on the potential effect of specific feed parameters on oral use of antimicrobial agents at farm 
level. Mink are fed moist feed, based on perishable ingredients. All feed batches controlled during 2012–2014 were included 
in this study; Prescription of oral antimicrobials at farm level, within time slots of 3, 5 or 7days after receiving an included 
feed batch, was applied as outcome variable. A multi-variable variance analysis was carried out analysing the effect of the 
feed parameters (total volatile nitrogen, dry matter, crude protein and fat; total bacterial count (21°C), and counts of sulphite 
producing bacteria (21°C), Clostridium spp., faecal cocci (44°C), fungi, and mould; presence of Salmonella spp. and Clostridium 
perfringens). Two binomial models were applied, adjusting for significant effects (Pseudomonas aeruginosa outbreak, farm 
size, season and year). Prescription of antimicrobials was significantly associated with counts of faecal cocci in all three time 
slots and in both models [Jensen et al, Prev Vet Med, 2017] 
Conclusion: Both studies identified important risks factors for prescription of antimicrobial agents for mink and there is a 
clear association between the quality of the feed and the amount of antimicrobial agents prescribed. Thus, the quality of the 
daily produced feed is a very important factor for the health of the mink. However, it is difficult to implement quality assur-
ance systems for the large amounts of perishable products included in the feed because the feed has been eaten before the 
results are available.
Mariann Chriél and Vibeke Frøkjær Jensen 
For further information: Mariann Chriél (march@vet.dtu.dk)
 
Textbox 4.4
Stronger focus on preventing illegal import of antimicrobials   
In May 2016, the Danish Veterinary and Food Administration published the report “Strengthening the efforts regarding illegal 
import of antibiotics for production animals”. As a part of the Second Veterinary Action Plan running from 2013 to 2016, a 
comprehensive study investigated whether illegal import of antimicrobials were used in farm animals to avoid the restric-
tions on antimicrobial consumption. The study also suggested ways to strengthen authority efforts to prevent illegal import 
of antimicrobials. The study investigated, evaluated and concluded on: Cases of illegal import of antimicrobials, the Danish 
enforcement and monitoring system, the temporal patterns in consumption of antimicrobials, the development of the Danish 
consumption of antimicrobials and the development of regulation on veterinary medicines.
The study found no evidence of systematic illegal import of antimicrobials for food producing animals, even though a few 
cases of illegal import were identified. The threat to the high level of food safety in Denmark was considered negligible at 
this point in time. It is acknowledged that a change in the risk may have a great impact on the Danish approach to control us-
age of antimicrobial agents and development of antimicrobial resistance. The work has led to a strengthened effort to restrict 
illegal import of antimicrobial agents by dissemination of information to farmers describing the risks associated with illegal 
import, and by raising awareness in the enforcement system.
The full report can be found here:  
https://www.foedevarestyrelsen.dk/Leksikon/Sider/Import-af-lægemidler.aspx
For further information: Mette Kirkeskov Sie (meksi@fvst.dk)
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Textbox 4.5
Antimicrobial use in dogs and cats in Denmark – 2012-2016 
 
Background: In November 2012 the first Danish National Antimicrobial Treatment Guidelines for companion animals were 
published by the Danish Small Animal Veterinary Association. This textbox describes the development of antimicrobial use in 
companion animals from 2012 to 2016.
The data on antimicrobial use in companion animals in Denmark derive from the national database VetStat. In previous Danmap 
reports from 2013-2015, consumption in companion animals was estimated from prescriptions for companion animals plus a 
proportion of veterinary antimicrobials not recorded for production animals. However, in an attempt to assess the effect of the 
treatment guidelines, we applied the principles described below to provide a more precise estimate of the actual antimicrobial 
use for dogs and cats over the past five years.
Methods: Data on prescription of antimicrobial products for companion animals were extracted from VetStat on April 18th 
2017. The antimicrobial consumption was estimated according to the principles described below:
• All antimicrobials (including human products) for oral use dispensed directly to companion animal owners via pharmacies;
• Antimicrobial preparations licensed solely for use in companion animals dispensed directly via pharmacies or by the veterinarian. 
This group comprises exclusively products for oral use with the exception of the injectable 3rd generation cephalosporin cefovecin;
• Oral formulations registered for use only in horses or production animals, but recorded in VetStat as prescribed for companion 
animal use are assumed to be registration errors and are thus not included.
• For fluoroquinolones, only parental use of preparations with a low concentration of drug per ml, suitable for use in dogs and 
cats (50 mg/l or less) is included. Fluoroquinolone preparations with a high concentration of drug per ml are assumed to be 
used for horses and are not included
• Other antimicrobials for parental use formulated for use in multiple species, including companion animals and horses, are not 
included, as target species cannot be assumed with certainty.
The resulting estimates on antimicrobial consumption may underestimate the total consumption in companion animals by ap-
proximately 20%, as most parenteral use is not included [DANMAP 2011].
The calculations of DAPD (Defined Animal Daily Doses per 1000 animal per day) are based on estimated population numbers for 
dogs and cats of 546.000 and 646.000 individuals in the year 2000 [Statistics Denmark], and an average body mass of 10 kg. 
Thus, changes in population size and differences in treatment frequency between dogs and cats are not taken into account.
Results: The relative use of the different antimicrobial groups in 2007-2016 is illustrated in Figure 1. From 2007 to 2012, 
the use of antimicrobial agents for dogs and cats was estimated at levels of approximately 12-13 DAPD (Figure 1). From 2012 
to 2015, the estimated antimicrobial usage in companion animals decreased by 14%, from 12.4 DAPD in 2012 to 10.7 DAPD 
in 2015. In 2016 the consumption increased to 11.2 DAPD, however, this still represents a 10% reduction in the consumption 
compared to 2012. 
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Figure 1. Antimicrobial consumption(a) in dogs and cats, Denmark 
DANMAP 2016
Note: Includes antimicrobials (including human products, except for small amounts of metronidazole and nitrofurantoin) for oral use, 
dispensed directly to the companion animal owner, and antimicrobial preparations licensed solely for use in companion animals.
a) Measured in DAPD, estimating the percentage of animals treated on a given day (10 DAPD ≈1 % under treatment on average).The DAPD is 
calculated as the number of standard doses for cats and dogs assuming an average weight of 10 kg. For all years, the assumed population is 
1.192.000 dogs and cats [Statistics Denmark 2000]
In 2016, the most commonly used antimicrobial was amoxicillin/clavulanic acid, which accounted for 53% of the antimicrobial 
consumption in companion animals. Other commonly used antimicrobials were lincosamides (clindamycin), 1st generation 
cephalosporins, and aminopenicillins (amoxicillin). The use of 1st generation cephalosporins has markedly decreased from 
16% of the total consumption in 2012 to 9% in 2016, whereas the use of lincosamides has increased in the same period from 
11% to 13% of the total consumption, and thus constituted the second most common antimicrobial class used for companion 
animals in 2016.
From 2014 to 2015, the use of potentiated sulfonamides decreased substantially, by 91%. It should be noted that oral formu-
lations of potentiated sulfonamides licensed for use in dogs and cats have been unavailable on the Danish market since March 
2015. The total antimicrobial consumption for companion animals in 2016 (excluding most parenteral preparations) accounted 
for approximately 1% of the total veterinary antimicrobial consumption.
The consumption of the third generation cephalosporin cefovecin has decreased since 2010. Between 2012 and 2016, the 
consumption of cefovecin decreased by 41% (Figure 2). The consumption of fluoroquinolones for oral use has remained rela-
tively stable, at 0.66 DAPD in 2012 and 2016, with a minor transitory decrease in 2013 (Figure 2). Similarly, the estimated 
consumption of fluoroquinolones for parental use has been stable at 0.1 DAPD during this period. In 2016, the consumption of 
fluoroquinolones for companion animals accounted for 82% of the total veterinary fluoroquinolone consumption.
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Figure 2. Antimicrobial consumption(a) of 3rd/4rd generation cephalosporins and flouroquinolones  
in companion animals, Denmark  
DANMAP 2016
Note: Includes only parenteral use of 3rd generation cephalosporin cefovecin and fluoroquinolones for oral use 
a) The DAPD is calculated as the number of standard doses for cats and dogs assuming an average weight of 10 kg. For all years, the 
assumed population is 1.192.000 dogs and cats [Statistics Denmark 2000]
Concluding remarks: Using the described method for estimating antimicrobial consumption in dogs and cats, we observed 
a 10% decrease from 2012 to 2016. The consumption of fluoroquinolones has been stable throughout the period, and 
compared to other animals in Denmark, companion animals are by far more frequently treated with this antimicrobial class. In 
contrast, the use of the third generation cephalosporin, cefovecin, has substantially decreased since 2012. 
Lisbeth Rem Jessen, Peter Panduro Damborg and Vibeke Frøkjær Jensen 
For further information Lisbeth Rem Jessen (lrmj@sund.ku.dk)
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5. Antimicrobial consumption in humans
    Highlights: In 2016, the total consumption of antimicrobials in humans, when calculated 
in defined daily doses per 1000 inhabitants per day (DID), remained with 18.47 DID very 
close to the consumption in 2015 (18.50 DID) and to the consumption a decade ago in 2007 
(18.37 DID). In general, the consumption of antimicrobials increased from registrations in the 
first DANMAP report in 1996 (13.60 DID) until 2011 (19.31 DID) and has since levelled off. 
Penicillins remained the most frequently used antimicrobial agents in both primary health  
care (65%) and in hospital care (54%), but the changes in consumption observed within this 
drug group in the last decade continued. Thus in 2007, beta-lactamase sensitive penicillins 
constituted 55% of all penicillins consumed in primary health care, while in 2016 this had 
decreased to 39% (from 5.67 DID to 4.16 DID,  a decrease of almost 30%). Simultaneously, 
consumption of combination penicillins increased in both sectors, from 0.19 DID to 1.42 DID 
in primary health care and from 2.95 defined daily doses per 100 occupied bed days (DBD) 
to 18.04 DBD in hospital care. In 2016, combination penicillins constituted 9% of the anti-
microbial consumption in primary health care and 18% of the consumption in hospital care, 
making them, together with penicillins with extended spectrum, the largest antimicrobial 
drug group consumed at hospitals. 
In 2016, Fluoroquinolones constituted 3% and 8% of the consumption in primary and hos-
pital care, respectively. In Denmark, fluoroquinolones, cephalosporins and carbapenems are 
defined as critically important antimicrobials, cephalosporins and carbapenems being used 
solely at hospitals. In 2016, the consumption of the three drug classes constituted alto-
gether 22% of the consumption at hospitals, a  decrease from 24% observed the year before 
and from 32% in 2007. The consumption of cephalosporins and fluoroquinolones has shown 
slow but continuous decreases since 2011. The consumption of carbapenems has shown 
more fluctuations but decreased notably from 2015 to 2016. In 2016 fluorquinolones ac-
counted for a consumption of 8.11 DBD, cephalosporins for 10.24 DBD and carbapenems for 
3.93 DBD. 
In 2016, the total antimicrobial consumption at hospitals was measured at 99.98 DBD and 
310.53 defined daily doses per 100 admissions (DAD), respectively, a slight decline from 
103.02 DBD and 313.38 DAD the previous year. From 2007 to 2016 the total consumption 
at hospitals increased with 36% and 1.2%, respectively, when measured in DBD or DAD.   
Since 1999, the number of DDD´s per prescription and per package have increased notably, 
resulting in an increase of DDD´s per treated patient from 15.2 DDD in 1999 to 21.5 DDD in 
2016. In contrast the number of patients treated has decreased markedly, in 2016 it was on 
average 270 treated patients or 522 prescriptions per 1000 inhabitants. This corresponds to 
reductions of 17% for both the number of treated patients and the number of prescriptions 
per 1000 inhabitants for the last decade. Decreases are noted for all age groups but are 
biggest in the youngest children (0-4 years old), where the number of treated patients de-
creased with 33% from 472 to 318 treated patients per 1000 inhabitants per year in 2007 
and 2016, respectively. 
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5.1 Introduction
In Denmark, all consumption of human medicine including 
antimicrobials is recorded through the Register of Medicinal 
Product Statistics at the Danish Health Data Authority. The 
primary sector has reported on antimicrobial sales data since 
1994, whereas the hospital sector has submitted data since 
1997.
Recording of the consumption in the primary sector covers 
all antimicrobials on prescriptions from general practitioners, 
medical specialists and dentists as well as prescriptions given 
to hospital patients upon discharge. No over-the-counter 
sale takes place, all sale is through pharmacies and based on 
prescription only, which gives a close to total of all systemic 
antimicrobials used in Denmark. For the hospital sector, only 
data from public somatic hospitals are included – data from 
psychiatric hospitals, private hospitals, hospices and rehabili-
tation centers were omitted since they contribute with a low 
consumption of antimicrobials (2.3% in 2016), but in many 
ways differ from the patient population at public somatic 
hospitals.
In the primary sector, sales are reported through the pharma-
cies and include information on the generic and the brand 
name of the product, formulation, active drug, size and number 
of packages, as well as age, gender and regional residence of 
the patient. For 2016, clinical information on the indication for 
prescribing the drug was available for 86% of prescriptions. 
Yet some indication codes suffer from being unspecific, like the 
term “infection”. Specific indications account for 70%. Better 
and more precise indication codes will, in the future, give the 
opportunity to register and evaluate on a more prudent use 
of antimicrobials. For the hospital sector, data are available 
through the hospital pharmacies and include information on 
the amount and formulations of antimicrobials delivered to 
the different departments; these also include multi-packages 
and marginal products. In addition, work is going on to include 
details on the patient level thus improving the possibilities of 
monitoring actions on more prudent use. 
In this chapter, the term `antimicrobial agents´ covers all sys-
temic antibacterial agents for human use listed in the Anatom-
ical Therapeutic Chemical (ATC) Classification under the code 
J01. The only other antimicrobials included are metronidazole 
(ATC code P01AB01) and vancomycin (A07AA09), since these 
constitute important systemic antibacterial treatment as well. 
Their consumption has been included since DANMAP 2014, 
tables and figures were updated ten years back. Tuberculo-
statica, antiviral and antifungal drugs are not included. 
5.2 Total consumption (Primary Health Care and 
Hospital Care Sectors)
In 2015, the total consumption of antimicrobials in Denmark 
was 18.47 defined daily doses per 1000 inhabitants per day 
(DID), which is similar to the consumption in 2015 (18.50 DID) 
and to the consumption a decade ago in 2007 (18.37 DID), 
(Figure 5.1). The total consumption in 2016 corresponds to 
49,605kg active compound consumed (Table A5.1 in web an-
nex). 
The primary sector accounts for approximately 90% of the to-
tal consumption and thus has significant impact on the overall 
consumption patterns. Overall, the consumption of antimicro-
bials showed no significant trends for the first five years of 
regular registration from 1996 (13.40 DID) until 2000 (13.63 
DID), but increased steadily onward until 2011 (19.31 DID) and 
has since levelled off (Figure 5.1). HUSK Neo Sans 8pt. Ændre til 100% sort - rammer 50% sort
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Figure 5.1 Total consumption of systemic antimicrobial agents in humans in primary health care vs hospital care. Denmark 
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At the European level, Denmark reports a comparatively low 
consumption of antimicrobial agents and is specifically charac-
terized by the proportionally high consumption of penicillins, 
which contributes to the total consumption with significant 
amounts (ECDC.ESAC-Net 2015). This is because penicillins 
in general and especially penicillins with extended spectrum 
contribute with high DIDs per treatment and thus account for a 
significant part of the measurable consumption.
Among the Scandinavian countries the proportional consump-
tion of small-spectrum penicillins is generally high and all coun-
tries are characterized through a general awareness on the 
rational use of antibiotics in the population as well as among 
health professionals. Still, the trends in consumption over time 
have been quite different. While Denmark had the lowest con-
sumption of antimicrobials in the late nineties and Sweden the 
highest, overall increasing trends in consumption in Denmark 
and simultaneously decreasing trends in Sweden, resulted 
in Denmark having the highest consumption of the three 
countries in 2015 and Sweden the lowest (https://ecdc.europa.
eu/en/antimicrobial-consumption/database/trend-country). For 
Norway and Denmark consumptions in the primary sector have 
shown comparable trends for the last decade, both stabilizing 
or slightly decreasing for the last four years. The Norwegian 
national action plan from 2015, aiming for a 30% reduction in 
the total consumption (with 2012 as the reference point), did 
not show marked changes for 2016 but is expected to result in 
a lower consumption in the coming years. 
5.3 Primary Health Care 
5.3.1 Total consumption in Primary Health Care
In 2016, the total consumption of antimicrobials in primary 
health care remained with 16.45 DID close to the 16.46 DID 
in 2015, thus continuing the trend of a stabilized or slightly 
declining consumption that has been observed since the peak 
of 17.34 DID in 2011 (Figure 5.1, Table 5.1). Since 1997, the 
consumption increased with 34% from 12.24 DID.
In 2016, beta-lactamase sensitive penicillins continued to be 
the biggest group consumed with 4.16 DID (accounting for 
25% of the total consumption in primary care), followed closely 
by penicillins with extended spectrum with a consumption of 
3.63 DID (corresponding to 22% of the total consumption). The 
third biggest group consumed were the macrolides with 1.82 
DID (accounting for 11% of the total consumption).  
The group of penicillins accounted for altogether 10.7 DID and 
thus continued to constitute the majority of antimicrobials 
consumed in primary health care; a decade ago, in 2007, they 
accounted for 10.2 DID.
In Denmark, penicillins are the only beta-lactams used in primary 
care, other beta-lactams such as cephalosporins, monobactams 
and carbapenems are solely used in hospital care and primarily 
in somatic hospital with surgical or acute care functions. A dis-
tribution of the different antimicrobial classes between primary 
care and hospital care is shown in Figure A 5.1 in web annex.
ATC group(a) Therapeutic group
Year
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
J01AA                        Tetracyclines               1.48 1.54 1.61 1.69 1.64 1.76 1.96 1.66 1.61 1.62
J01CA               Penicillins with extended spectrum 3.25 3.26 3.29 3.47 3.41 3.40 3.48 3.53 3.61 3.63
J01CE                        Beta-lactamase sensitive penicillins     5.67 5.30 5.12 5.25 5.31 4.68 4.65 4.38 4.33 4.16
J01CF                        Beta-lactamase resistant penicillins     1.09 1.12 1.13 1.17 1.14 1.21 1.30 1.36 1.38 1.48
J01CR                        
Combinations of penicillins, including beta-
lactamase inhibitors   
0.19 0.27 0.45 0.68 0.89 1.05 1.22 1.30 1.42 1.42
J01D                        Cephalosporins and other β-lactam antibiotics  0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
J01EA                        Trimethoprim and derivatives   0.49 0.49 0.48 0.51 0.50 0.52 0.53 0.55 0.56 0.56
J01EB                        Short-acting sulfonamides       0.31 0.28 0.27 0.26 0.24 0.22 0.22 0.21 0.18 0.16
J01EE                        
Combinations of sulfonamides and 
trimethoprim, including derivatives
0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.00 0.00 0.00
J01FA                        Macrolides                  2.42 2.28 2.21 2.44 2.47 2.19 1.93 1.79 1.77 1.82
J01FF                        Lincosamides                0.02 0.03 0.03 0.04 0.04 0.04 0.05 0.05 0.05 0.06
J01GB Aminoglycosides 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01
J01MA                        Fluoroquinolones            0.44 0.51 0.52 0.57 0.57 0.55 0.52 0.50 0.49 0.48
J01XC                        Steroid antibacterials (kombination fusidic acid)   0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
J01XE Nitrofuran derivatives (nitrofurantoin) 0.47 0.47 0.49 0.51 0.50 0.49 0.49 0.48 0.45 0.43
J01XX                       Other antibacterials (methenamine >99%)                0.26 0.27 0.26 0.27 0.26 0.25 0.24 0.24 0.25 0.27
J01XD and P01AB* Nitroimidazole derivatives (metronidazole) 0.23 0.24 0.27 0.28 0.28 0.28 0.28 0.28 0.28 0.28
J01+P01AB Antibacterial agents for systemic use (total) 16.45 16.15 16.22 17.21 17.34 16.75 16.95 16.40 16.46 16.45
Table 5.1. Consumption of antimicrobial agents for systemic use in primary health care (DDD/1000 inhabitant-days), Denmark 
 DANMAP 2016
a) From the 2016 edition of the Anatomical Therapeutic Chemical (ATC) classification system 
*) all metronidazole preparations, formerly only listed as J01XD, 10 years retrospective data included in the DANMAP report since 2014
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5.3.2 Trends in consumption of the leading 
antimicrobials
Even though the total consumption of penicillins has only 
changed slightly over the years, within the group of penicillins 
marked changes have been observed during the last decade. 
Since 2007 the consumption of beta-lactamase sensitive peni-
cillins decreased almost continuously with 27%, paralleled by a 
decrease of macrolides with 25% (from 5.67 DID and 2.42 DID, 
respectively), (Figure 5.2a and 5.2b). For both drug classes this 
may be the result of a more restrictive use of antimicrobials 
observed in primary care in general, since an overall declin-
ing number of treated patients and of redeemed antimicrobial 
prescriptions parallels the decrease in DID (Table 5.2 and 5.3).  
Both antimicrobial classes are the main drugs in the treatment 
of upper airway infections, being the most common type of 
infections seen at general practitioners and the focus of the 
National antibiotic campaigns from 2013 to 2015. Recom-
mendations on a more prudent use of antibiotics through the 
Danish College of General Practitioners may also have had an 
impact on the prescribing of beta-lactamase sensitive peni-
cillins and macrolides.  For the three other penicillin groups’ 
continuous increases in consumption occurred in the same 
periode - penicillins with extended spectrum increased with 
12%, the beta-lactamase resistant penicillins with 36% and 
the combination penicillins including beta-lactamase inhibitors 
with more than 600% (Figure 5.2b).
Thus, while in 2007 the beta-lactamase sensitive penicillins 
constituted 56% within the group of penicillins consumed, 
in 2016 they constituted 39%. If the shifting trends in the 
consumption of the different penicillins are to continue, the 
leading antimicrobial will probably become the penicillins with 
extended spectrum within the next few years. Within the total 
consumption of different antimicrobials the group of penicillins 
accounted for altogether 65% (Figure 5.3) 
Tetracyclines are the fourth biggest group of antimicrobials 
consumed in Denmark. In 2016 they accounted for 1.62 DID, 
corresponding to 10% of the total consumption in primary care. 
During the last decade the consumption has increased with 
10% from 1.48 DID in 2007. In 2013, the consumption peaked 
unexpectedly with 1.96 DID but has since shown continu-
ing decreases. Tetracyclines are consumed by all age groups 
above 12 years and by both genders. The treatment of acne in 
adolescents is the main driver of consumption and contributes 
considerably to the total consumption with both DIDs as well 
as the number of redeemed prescriptions and patients treated.  
While the number of DIDs consumed increased in women 
(primarily girls from 15 to 24 years) from 1.58 DID in 2007 to 
1.88 DID in 2016, it simultaneously decreased slightly in men 
(primarily boys from 15 to 19 years) in the same period, from 
1.35 DID in 2007 to 1.33 DID in 2016 (Figure 5.7a.).
Fluoroquinolones are the smallest drug class among the 
leading antimicrobials, in 2016 accounting for 0.48 DID, cor-
responding to 3% of the total consumption in primary care. 
The consumption of fluoroquinolones followed the general 
increasing trends in the total consumption from 2007 (0.44 
DID) until 2010 and 2011 (peaking with 0.57 DID) and has 
since been decreasing, giving an overall increase of 8.5% from 
2007 to 2016. In Denmark, fluoroquinolones are designated as 
“antimicrobials of special, critical interest” through the National 
Health Authority and are mentioned in the National recom-
mendations on the use of antibiotics issued in 2012. According 
to these fluoroquinolones are to be solely used for treatment 
of very few specific infections, where they are considered 
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Figure 5.2a Consumption of leading antimicrobial groups for systemic use in primary health care, Denmark DANMAP 2016
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Figure 5.2b. Changes in the consumption (% DID) by leading groups of antimicrobial agents (J01) in the primary sector, Denmark 
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the drug of choice (fx exacerbation in a patient with chronic 
obstructive lung disease and penicillin allergy). They are also 
recommended in the case of infection with multidrug resistant 
bacteria, where microbiological results point towards a fluoro-
quinolone to be the only or best choice. 
5.3.3 Penicillins 
While beta-lactamase sensitive penicicllins decreased almost 
continuously since 2007, the combination penicillins including 
beta-lactamase inhibitors (represented solely by amoxicillin 
with clavulanic acid) increased markedly in the same period 
from 0.19 DID in 2007 to 1.42 DID in 2016 (Figure 5.4). For 
the first time in this decade, no increases were observed from 
2015 to 2016. The increases are probably due to a combina-
tion of changed recommendations in the treatment of exacer-
bation of chronic lung disease and demographic changes with a 
growing elderly population, but may well be a sign of the drug 
becoming more popular in the treatment of upper respiratory 
infections as well. This is to be investigated in the future when 
a sufficient number of the specific indication on each medical 
prescription will give the opportunity to look more thoroughly 
into the prescription habits regarding this drug class.  
The increases described for the penicillins with extended spec-
trum from 1.09 DID in 2007 to 3.48 DID in 2016 are primarily 
due to increases in the consumption of pivmecillinam, account-
ing for about two thirds of this drug class. While pivmecillinam 
increased with 3.9% from 2015 to 2016 and with 88% since 
2007, pivampicillin and amoxicillin decreased with 7% and 5%, 
respectively, from 2015 to 2016 and with 62% and 33% since 
2007. In 2016, pivmecillinam accounted for 2.47 DID, amoxicil-
lin for 0.92 DID and pivampicillin with 0.20 DID. In Denmark 
pivmecillinam is the recommended first choice in the treatment 
of uncomplicated urinary tract infections (UTI). Its´ increases 
are paralleled by decreases in the other drugs used for the 
treatment of UTI, primarily sulfamethizol and nitrofurantoin 
(Figure 5.2b and Table 5.1 and 5.2). Amoxicillin is primarily 
used in the treatment of upper respiratory infections in small 
children (age 0 to 4 years). The decreases observed in the 
consumption of amoxicillin when measured in DID are mirrored 
in a reduced number of children treated with the drug (Figure 
5.6a and 5.6b).
Increases were also observed for the beta-lactamase resis-
tant penicillins. These comprise dicloxacillin and flucloxacillin. 
Flucloxacillin was introduced to the Danish market due to a 
shortage of dicloxacillin in 2010. Beta-lactamase resistant 
penicillins are used in all age groups and both genders. Their 
increased consumption needs yet to be investigated but is 
paralleled by an increased occurrence of staphylococcal skin 
infections observed in recent years.  
5.3.4. Measures at treated patient level
In 2016, the number of prescriptions was 522 per 1000 inhab-
itants, a 1.6% reduction from the 531 prescriptions per 1000 
inhabitants in 2015 and a 17% reduction compared to the 630 
prescriptions per 1000 inhabitants in 2007 (Table 5.2). The 
average number of prescriptions per patient is 1.9. This has 
not changed significantly during the last decade, thus in 2016 
the number of treated patients was 270 per 1000 inhabitants, 
showing a similar decrease of 17% since the 323 patients per 
1000 inhabitants in 2007 (Table 5.3 and A5.2 in web annex). 
Trends in the number of prescriptions and treated patients for 
the different antimicrobial classes followed mainly the trends 
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already described for the consumed DIDs. Most pronounced 
for the ten year period were the decreases in the number of 
treated patients with beta-lactamase sensitive penicillins (- 
29%), sulphonamides (- 48%) and macrolides (- 25%). Also for 
penicillins with extended spectrum and for tetracyclines a de-
crease was observed, (- 10% and – 12%, respectively). Similar 
decreases were noted when measured in the number of pre-
scriptions per 1000 inhabitants for beta-lactamase sensitive 
penicillins (- 33%), sulphonamides (- 51%), macrolides (- 30%), 
tetracyclines (- 17%) and penicillins with extended spectrum 
(- 7%). Fluorquinolones decreased with 5.4% and 5.7% in the 
number of treated patients and the number of prescriptions 
per 1000 inhabitants, respectively. A comparison of the dif-
ferent indicators of consumption is shown in Figure 5.5.
In 2016, each patient received an average of 21.5 DDD, a 
slight decline from 21.8 DDD the year before and a 9.7% 
increase compared to 2007 (19.6 DDD). The number of DDD/
package increased similarly from 9.3 in 2007 to 10.5 in 2016 
(13%). The number of packages has remained unchanged 
during all ten years with 2.1 packages per patient in average, 
(Table A5.3 in web annex).
5.3.5 National initiatives on continued  
reductions of the antimicrobial consumption
The National Action plan on the reduction of antibiotics 
Table 5.2. Number of prescriptions per 1000 inhabitants for leading antimicrobial  
agents in primary health care, Denmark  DANMAP 2016
ATC group(a) Therapeutic group
Year
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
J01AA                        Tetracyclines               20.78 20.92 21.62 22.49 22.70 22.55 22.89 20.00 17.90 17.18
J01CA               Penicillins with extended spectrum 121.86 120.31 119.28 127.23 125.17 115.89 114.28 113.83 113.54 113.17
J01CE                        Beta-lactamase sensitive penicillins     234.86 216.09 205.85 212.19 213.32 186.88 180.51 170.70 163.10 157.14
J01CF                        Beta-lactamase resistant penicillins     41.83 42.22 42.10 42.32 42.75 40.41 41.24 41.04 40.82 41.87
J01CR                        
Combinations of penicillins, including 
beta-lactamase inhibitors   
5.14 7.05 11.15 16.53 21.11 24.71 28.01 29.02 30.73 31.13
J01E                       Sulphonamides and trimethoprim 53.03 48.89 47.17 47.35 45.05 43.85 43.53 41.51 38.39 36.42
J01FA                        Macrolides                  97.74 91.47 87.24 97.34 104.22 85.87 74.50 68.01 68.00 68.85
J01MA                        Fluoroquinolones            19.87 22.07 21.71 23.69 23.15 22.14 20.64 19.67 19.51 18.74
J01X                       Other antibacterials (methenamine >99%) 16.42 17.34 17.93 17.49 18.23 18.03 17.41 16.73 16.28 15.82
P01AB Nitroimidazole derivatives (metronidazole) 16.91 15.32 19.02 19.67 19.69 19.67 19.26 19.06 19.16 18.63
J01  
(incl. P01)
Antibacterial agents for systemic use (total) 630.08 606.26 595.28 628.78 638.08 582.69 565.16 542.53 530.62 522.23
a) From the 2016 edition of the Anatomical Therapeutic Chemical (ATC) classification system
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in humans issued in July 2017 uses two measurable goals 
directed at the consumption trends in the primary care. The 
first goal aims at a continued general reduction in the number 
of prescriptions issued in Denmark (from 462 prescriptions 
per 1000 inhabitants among general practitioners, medical 
specialists and dentists in 2016 to 350 prescriptions per 1000 
inhabitants in 2020). The second goal focuses on the more 
prudent choice of antimicrobials emphasizing the importance 
of continued use of beta-lactamase sensitive penicillins as the 
drug of first choice in many common infections, especially in 
respiratory infections. 
The National Action plan is supported through the National 
antibiotic campaigns aiming at a continued education of the 
public on general issues regarding prudent use including also 
hand hygiene as an important measure to reduce the spread of 
all kind of infections. 
The National Action plan is issued from the Danish Health 
Ministry and supported by the National antibiotic council repre-
senting all relevant health institutions, organisations and spe-
cialties, working with the prevention, control and treatment of 
infections in Denmark.  Together with the National Action Plan 
a One Health Strategy was issued, building on the National 
Action Plan on controlling the development of antimicrobial 
resistance from 2010. Both are available at the Danish Ministry 
of Health’s homepage at www.SUM.dk. 
5.3.6 Consumption of antimicrobials in children
The total consumption in children of all age groups continued 
the decreases observed for the last decade, regardless of the 
indicator used (Figures 5.6a and 5.6b). In 2016, altogether 7.9 
DID were consumed in children and young from 0 to 19 years, 
corresponding to 218 treated patients per 1000 inhabitants 
(children) and 355 prescriptions issued per 1000 inhabitants. 
It is important to note that measuring the consumption in 
children in Defined Daily Doses is problematic since the system 
of Defined Dailys Doses was developed based on the “mainte-
nance dose per day for its main indication in adults” (https://
www.whocc.no/ddd/definition_and_general_considera/). For 
children, different pharmacodynamics and –kinetics apply and 
especially dosing in the younger classes is based on doses per 
bodyweight in kg. Still, assuming that dosage regimens did not 
vary considerably over the last decade, the decreases shown 
for the consumption of DIDs in the different age groups show 
a clear tendency to reductions for especially penicillins and 
macrolids (Figure 5.6a). 
From 2007 to 2016, the total DIDs consumed in 0 to 4 year 
olds decreased with 35 %, in 5 to 9 year olds with 20%, in 10 
to 14 year olds with 13% and in the young adults with 8%. 
The corresponding number of prescriptions redeemed for all 
young age groups (0 to 19 year olds) decreased from 542 to 
355 prescriptions per 1000 inhabitants (- 33%) and from 305 
to 218 treated patients per 1000 inhabitants (- 28%) for the 
decade, respectively. Differences in reduction varied from a 
decrease of 43% in the number of prescriptions for the young-
est (0 - 4 years old) to - 22% for the oldest, (15 to 19 year 
olds). When measured in the number of treated patients, the 
decreases varied from - 33% in the youngest to -19% in the 
adolescents.
In the youngest age group of 0 to 4 year olds, the boys receive 
on average 10% more prescriptions than the girls, a trend that 
has been quite stable. Thus in 2007, they received 488 versus 
453 prescriptions per 1000 inhabitants (children) and in 2016 
331 versus 304 prescriptions per 1000 inhabitants, respec-
tively (not shown). For the 5 to 19 year olds the trends are 
opposite, girls receiving on average 10% more prescriptions.
Table 5.3. Number of treated patients per 1000 inhabitants for leading antimicrobial  
agents in primary health care, Denmark   DANMAP 2016
ATC group(a) Therapeutic group
Year
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
J01AA                        Tetracyclines               12.52 12.73 13.02 13.44 13.66 13.53 13.85 12.20 11.32 11.04
J01CA               Penicillins with extended spectrum 82.03 81.27 81.07 85.04 84.19 77.29 76.09 75.32 74.88 74.05
J01CE                        Beta-lactamase sensitive penicillins     177.07 164.38 158.72 162.81 164.34 145.50 142.16 134.79 130.07 125.70
J01CF                        Beta-lactamase resistant penicillins     29.67 29.89 29.87 30.02 30.34 28.50 29.07 29.24 28.85 29.70
J01CR                        
Combinations of penicillins, including 
beta-lactamase inhibitors   
3.57 4.95 8.02 11.70 14.95 17.34 19.71 20.52 22.03 22.17
J01E                       Sulphonamides and trimethoprim 33.62 30.49 29.51 29.31 27.63 26.47 26.15 24.65 22.45 21.20
J01FA                        Macrolides                  71.38 66.84 64.44 72.67 78.75 64.72 56.15 51.38 51.75 53.21
J01MA                        Fluoroquinolones            15.19 17.05 16.87 18.45 18.10 17.24 16.04 15.30 15.04 14.37
J01XX                       Other antibacterials (methenamine >99%) 7.17 7.43 7.67 7.53 7.74 7.54 7.48 7.16 7.35 7.47
J01XD and 
P01AB
Nitroimidazole derivatives (metronidazole) 14.44 15.32 16.28 16.73 16.90 16.86 16.51 16.31 16.47 16.04
J01  
(incl. P01)
Number of treated patients in total 323.49 311.37 306.41 318.69 324.91 296.32 289.47 278.62 273.49 269.73
a) From the 2016 edition of the Anatomical Therapeutic Chemical (ATC) classification system
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Since children contribute with a high proportion to the total an-
timicrobial consumption, continued focus on these age groups 
and their consumption habits is important for the success of 
the overall reduction plans for the consumption of antimicrobi-
als in humans. Thus, continued focus will be paid to this group 
and their parents in the National Antibiotic campaigns and in 
the continuing education of general practitioners and medical 
specialists on continued prudent use of antimicrobials. Children 
suffer more often than any other age group from upper airway 
infections caused by different virus and thus will be a core 
focus in the overall reduction of antimicrobials prescribed 
in Denmark as mentioned in the National action plan on the 
reduction of antibiotics from 2017. 
Macrolides are the drug of choice for respiratory tract infec-
tions with Mycoplasma pneumoniae and in patients with 
known or suspected allergy to penicillins. In the young age 
groups the 15 to 19 year olds account for the biggest con-
sumption of macrolides (78 prescriptions per 1000 inhabitants 
per year compared to 34 for the 0 to 14 year olds for 2016, 
not shown). Since Mycoplasma pneumoniae primarily affects 
young school children and tends to occur every four to six 
years, the consumption of macrolides is expected to mirror 
these epidemics. In the winter of 2015 to 2016, a long-lasting 
but less fulminant epidemic with Mycoplasma pneumoniae oc-
curred, spanning two seasons as had been observed with the 
last epidemic in 2010 to 2012 (Epi-News No 41_2016, avail-
able at www.ssi.dk). After an overall decrease of the number of 
prescriptions on macrolides issued from 2007 (69.3 prescrip-
tions per 1000 inhabitants) to 2015 (40.7 prescriptions per 
1000 inhabitants), the consumption increased slightly in 2016 
to 44.8 prescriptions per 1000 inhabitants redeemed on aver-
age for all young age groups. Increases were noted for all, but 
were most obvious in the 5 to 9 year olds (from 23 to 29 pre-
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Figure 5.6a. Consumption of leading antimicrobials in children/adolescents aged 0 - 19, Denmark DANMAP 2016
Figure 5.6b. Number of prescriptions and treated  
patients per 1000 inhabitants aged 0-19 in 2007  
and 2016, Denmark DANMAP 2016
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Figure 5.7a. Consumption of leading antimicrobials (DDD/1000 inhabitants/day) in males and females, Denmark
 DANMAP 2016
Figur 5.7b. Number of treated men/women and of prescriptions per gender per 1000 inhabitants, 2007-2016
 DANMAP 2016
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scriptions per 1000 inhabitants, corresponding to an increase 
of 30%).
Tetracyclines account for a considerable part in the consump-
tion of antimicrobials among adolescents due to the treat-
ment of acne. Treatments are long-lasting (up to six months) 
and in addition may be repeated in a situation of relapse in a 
patient, who may be suffering from the condition for years. 
Both genders are affected, but there exist clear differences in 
prescription habits between boys and girls. Thus, among girls 
the treatment periods are longer and extend into the young 
adults of 20 to 24 years, while boys primarily are treated in 
shorter periods at the age of 15 to 19 years. In 2007, 15 to 19 
year old boys received, on average, 70 versus girls receiving 
52 prescriptions per 1000 inhabitants per year, correspond-
ing to 32 versus 28 patients treated per 1000 inhabitants.  In 
2016, the number of  15-19 year old boys receiving treat-
ment had declined to 28 treated patients (corresponding to 49 
prescriptions) per 1000 inhabitants, while the number of 15 to 
19 year old girls had increased to 32 treated patients (corre-
sponding to 54 prescriptions redeemed) per 1000 inhabitants. 
Still, in 2016 girls, on average, received fewer prescriptions 
per patient than in 2007, pointing towards shorter treatment 
courses and an increased awareness on a more prudent use. 
Danish treatment recommendations issued in October 2014 
through the former “Institute for Rational Pharmacotherapy” 
(now the “Initiatives on Rational Pharmacotherapy” under the 
Danish Health Authority) underline the importance of reducing 
the  use of tetracyclines in the young. They focus on topical 
(immunomodulation) treatment in mild to moderate cases and 
on shortening and frequently evaluating the treatment course 
once treatment with systemic tetracyclines is begun. 
5.3.7 Consumption of antimicrobials in men and women 
Differences between the genders regarding consumption of 
antimicrobials is well known, (Figure 5.7a and 5.7b). Women 
receive in general more treatments, a trend driven by a much 
higher consumption of antimicrobials used for the treatment 
of urinary tract infections. Thus, the consumption of sul-
phonamides, trimethoprim and nitrofurantoin is three times 
higher than in the male population and the consumption of 
pivmecillinam in women doubles the consumption in men. For 
beta-lactamase sensitive penicillins and tetracyclines there are 
less marked differences in gender and for the consumption of 
fluoroquinolones no differences have been observed through 
the years. 
From 2007 to 2016 the number of treated women per 1000 
inhabitants decreased from 373 to 317 (- 15%) and the number 
of treated men from 273 to 222 (- 19%). In the same period, 
the amount of DDD/prescription increased for women from 8.9 
to 10.8 and for men from 9.6 to 11.5, resulting in an overall 
decrease of DIDs consumed in women from 1.99 to 1.90 DID (- 
5%), and a decrease in men  from 1.40 to 1.26 DID (- 10%). 
As urinary tract infections (UTI) are a common condition in 
many women and contribute significantly to the number of 
antimicrobial treatments in these, several Danish studies have 
investigated in better diagnostic tests helping to differenti-
ate between bacterial conditions demanding antimicrobial 
treatment and more unspecific irritative signs from the urinary 
mucosa better left untreated with antibiotics.  Especially in 
elderly women, it becomes difficult to clearly differentiate 
between inflammation and infection, not least due to transient 
asymptomatic bacteriuria. In 2016, the National antibiotic 
campaign thus focused on reducing the amount of antimicrobi-
als consumed for the treatment of UTIs through two different 
initiatives, one using an educating movie on the social media 
targeted at young women, the other directed at health person-
nel at nursing homes dealing with often confused or dement 
elderly women with unspecific signs of UTI. Hopefully, the 
initiatives will show a measurable effect in decreased amounts 
of antimicrobials used for women in the future.
Table 5.4. Consumption of antimicrobial agents for systemic use in primary health care at regional level, Denmark DANMAP 2016
Region Indicator
Year
2011 2012 2013 2014 2015 2016
Capital Region DDD/1000 inhabitants/day  17.9  16.9  16.9  16.3  16.4  16.0 
Prescriptions/1000 inhabitants  657.6  599.2  576.7  549.4  533.6  519.6 
Region Zealand DDD/1000 inhabitants/day  17.8  16.7  16.9  16.5  16.9  17.2 
Prescriptions/1000 inhabitants  677.4  618.6  601.4  579.5  575.4  574.8 
Region of Southern Denmark DDD/1000 inhabitants/day  17.3  16.2  16.5  15.8  15.8  15.8 
Prescriptions/1000 inhabitants  658.0  598.4  588.9  556.5  540.3  530.7 
Central Denmark Region DDD/1000 inhabitants/day  16.0  15.3  15.5  15.1  15.2  15.1 
Prescriptions/1000 inhabitants  573.8  531.9  512.8  500.5  494.5  487.4 
North Denmark Region DDD/1000 inhabitants/day  16.4  15.2  15.4  15.1  15.2  15.4 
Prescriptions/1000 inhabitants  620.1  557.6  541.2  525.6  510.6  509.4 
Denmark (total) DDD/1000 inhabitants/day 17.3 16.8 17.0 16.4 16.5 16.2
Prescriptions/1000 inhabitants 637.4 581.1 564.2 542.2 530.9 522.2
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5.3.8 Prescribing activity in primary care
Although Denmark has a very homogenous population with 
relatively small geographic and socioeconomic variations, 
there are still considerable differences in the prescription 
habits among medical doctors. In 2016, the Central Region of 
Denmark had the lowest prescription activity with 15.1 DID 
and 487.4 prescriptions per 1000 inhabitants, (Table 5.4). The 
Region of Zealand had the highest prescription activity with 
17.2 DID and 574.8 prescriptions per 1000 inhabitants. All 
regions have seen marked decreases in the DIDs and number 
of prescriptions issued for the five years shown, decreasing on 
average 6.4% in DID and 17% in the number of prescriptions 
per 1000 inhabitants (Table 5.4).
There may be several reasons for the differences in prescrib-
ing habits, e.g. the density of the population and number 
of general practitioners as well as the proportion of elderly 
or chronically ill in a given geographic area. The number of 
patients assigned to each clinic, driving distances to the 
nearest hospital or the nearest medical specialist as well as 
organizational differences could also play a role. Finally, the 
number of general practitioners in a clinical practice probably 
will influence the prescribing habits – in clinics with more per-
sonnel it is easier to participate in educational courses and 
academic meetings. A Clinic with more staff also gives the 
advantage to discuss individual patients with the colleagues 
and supervise each other on a daily basis. General practitio-
ners can follow their own prescription habits through the 
website www.ordiprax.dk, a closed IT system that collects all 
prescribed data and enables comparison with other practices 
on a regional level. 
Support of the general practitioners regarding their prescribing 
habits in general is provided through regional medicine con-
sultants, who also have access to Ordiprax on each clinic level, 
thus being able to monitor consumption and give individual 
advice.  In the Central Region of Denmark, these consultants 
have worked specifically with focus on a prudent use of anti-
microbials. 
In Figure 5.8 the number of prescriptions on municipality level 
is shown, spanning from 434 to 728 prescriptions per 1000 in-
habitants. In 2016, most municipalities were within the range 
of 475 to 575 prescriptions per 1000 inhabitants. From the 98 
municipalities in Denmark, four were excluded from the Figure 
due to very small populations (typically islands).  
The part of prescriptions issued through hospital doctors 
has been increasing through the last decade; in 2016, they 
accounted for 13% of the antimicrobials sold at pharmacies, 
in 2007 it was 6% (not shown). The prescribing activity of hos-
pital doctors has presumably increased due to the mentioned 
changes in hospital activity with the shortening of bed-days. 
These changes rely on patients completing a treatment at 
home and on a primary sector who takes care of and follows 
up on these patients. In this regard, it is important to note that 
the goals in the National Action Plan on antibiotics in Human 
Healthcare from 2017 directed at the consumption in primary 
care include prescriptions issued from General Practitioners, 
medical specialists and dentists but exclude the prescribing 
activity from hospital doctors upon discharge of the patient. 
This will be taken into account when defining the different 
initiatives on prudent use of antibiotics and most of all the 
monitoring of these. 
5.4 Hospital Care
5.4.1 Introduction
Antimicrobial consumption at hospitals is reported to DANMAP 
once a year through the Register of Medicinal Product Statis-
tics at the Danish Health Data Authority. Reporting is based 
on deliverances from the hospital pharmacies to the different 
clinical departments and includes all generic products that 
are supplied through general trade agreements between the 
hospital and different medical suppliers. In the case of produc-
tion failures and shortages in deliverance of specific products, 
the hospitals have to apply for special deliverances through 
the Danish Medicines Agency. These special deliverances are 
reported separately to DANMAP. In general it is assumed that 
the amount of sold antimicrobials is comparable to the overall 
consumption at the different departments. Still, informa-
tion is lacking on consumption at the individual patient level. 
Although all hospitals have been connected to the centralized 
“shared medicine card”, collecting information on all medicine 
prescribed on an individual level for all Danish citizens, the sys-
Figure 5.8 Number of primary health care prescriptions/1000 
inhabitants in Danish municipalities, 2016 DANMAP 2016
(National average=522 prescriptions/1000 inhabitants)
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tem does not yet include more detailed information regarding 
the hospital stay such as indication for the actual treatment 
or dosages given, length of treatment etc. This information is 
expected to be available through the future National “Hospital 
Medicine Register”, which is currently being developed.
DANMAP 2016 covers the total sales on systemic antimi-
crobials (all ATC code J01 as well as ATC code P01AB01 and 
A07AA09) reported from all Danish hospitals. Consumption at 
private hospitals and psychiatric departments was excluded, in 
2016 accounting for approximately 2.2% of the total hospital 
consumption.
The consumption of antimicrobial agents in hospital care is 
presented as DDD per 100 occupied bed-days (DBD) and as 
DDD per 100 admissions (DAD) to account for hospital activity. 
Data are also presented as DID to enable comparison with 
primary health care. During the past decade, the hospitaliza-
tion pattern in Denmark changed notably: more people are 
admitted to somatic hospitals, while the average length of 
stay is shortened considerably. Since selection pressure for the 
emergence of antimicrobial resistance increases with increas-
ing hospital activity, the selection pressure has increased 
considerably from 2007 to 2016.
5.4.2 Somatic hospitals – DDD per 100 occupied bed days 
(DBD)
In 2016, the consumption of antimicrobial agents in somatic 
hospitals was 99.98 DBD, 3% lower than the 103.06 DBD in 
2015 and 4.2% lower than the highest consumption measured 
in 2014 (104.34 DBD). Since 2007, the consumption increased 
with 35% (from 74.33 DBD), (Table 5.5). This reflects the 
changing workflows at hospitals with an increased number 
of admissions and decreased number of bed-days. In 2016, 
Table 5.5. Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 occupied bed-days), Denmark
ATC 
group(a)
Therapeutic group 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
J01AA            Tetracyclines               0.63 0.78 1.04 1.09 1.18 1.58 1.52 1.73 1.85 2.06
J01CA                        Penicillins with extended spectrum 13.42 13.96 15.37 14.61 14.41 14.90 15.06 16.40 17.01 16.75
J01CE                        Beta-lactamase sensitive penicillins     10.79 9.98 9.90 9.49 9.32 10.13 10.13 10.31 10.03 9.77
J01CF                        Beta-lactamase resistant penicillins     6.70 6.81 7.40 7.71 7.30 8.37 9.07 9.57 9.80 8.80
J01CR                        
Combinations of penicillins. 
incl. beta-lactamase inhibitors   
2.95 4.00 5.65 7.13 8.51 12.00 13.64 16.04 17.80 18.04
J01DB                  First-generation cephalosporins 0.13 0.18 0.13 0.13 0.13 0.12 0.11 0.06 0.04 0.04
J01DC Second-generation cephalosporins 12.31 13.32 15.76 16.21 16.14 14.15 12.32 11.68 10.37 9.16
J01DD Third-generation cephalosporins 1.03 1.25 1.42 1.26 1.39 1.07 1.08 1.02 1.06 1.04
J01DF Monobactams 0.04 0.07 0.06 0.09 0.19 0.15 0.14 0.06 0.03 0.01
J01DH Carbapenems 2.13 2.70 3.15 4.02 4.16 3.86 4.02 4.09 4.10 3.93
J01EA                        Trimethoprim and derivatives   0.44 0.44 0.44 0.36 0.36 0.38 0.41 0.52 0.46 0.38
J01EB                        Short-acting sulfonamides       0.34 0.35 0.35 0.33 0.25 0.20 0.20 0.18 0.15 0.11
J01EE                        
Combinations of sulfonamides and 
trimethoprim. incl. derivatives 
1.52 1.95 2.28 3.04 4.11 3.33 4.21 4.70 5.04 5.11
J01FA                        Macrolides                  3.08 3.06 3.42 3.52 3.69 3.56 3.39 3.88 4.56 4.78
J01FF                        Lincosamides                0.35 0.41 0.50 0.47 0.53 0.62 0.64 0.65 0.57 0.62
J01GB Aminoglycosides 1.79 1.64 1.56 1.71 1.91 2.14 2.13 1.61 1.68 1.94
J01MA            Fluoroquinolones            8.16 9.53 10.71 10.44 10.70 10.02 9.77 9.88 9.30 8.11
J01XA Glycopeptides 0.63 0.68 0.99 1.07 1.24 1.29 1.29 1.15 1.07 1.07
J01XB            Polymyxins                 0.05 0.05 0.07 0.10 0.09 0.09 0.16 0.27 0.25 0.29
J01XC                        Steroid antibacterials (fusidic acid)     0.28 0.26 0.31 0.34 0.27 0.23 0.22 0.23 0.16 0.11
J01XD                 Imidazole derivatives 2.62 3.27 3.84 3.93 4.19 4.16 4.08 4.48 4.25 4.51
J01XE Nitrofuran derivatives (nitrofurantoin) 0.28 0.29 0.36 0.31 0.33 0.34 0.38 0.36 0.32 0.24
J01XX05 Methenamine 0.09 0.10 0.09 0.08 0.10 0.09 0.09 0.07 0.10 0.08
J01XX08 Linezolid 0.16 0.21 0.22 0.22 0.32 0.32 0.35 0.34 0.43 0.33
J01XX09 Daptomycin 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.04 0.05
P01AB01
Nitroimidazole derivatives (metroni-
dazole)
2.20 2.43 2.91 2.99 3.12 2.89 2.70 2.48 2.05 2.17
A07AA09 Intestinal antiinfectives (vancomycin) 2,19 2.43 2.93 2.96 3.12 2.98 2.75 2.55 0.47 0.48
J01
Antibacterial agents for systemic use 
(total)
74.33 80.14 90.87 93.67 97.08 98.94 99.88 104.30 103.02 99.98
a) From the 2016 edition of the Anatomical Therapeutic Chemical (ATC) classification system
 DANMAP 2016
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the number of admissions at Danish hospitals was 1,365,311, 
while the number of bed-days was 4,064,079 (data from the 
Danish National Patient Register march 2017). Since 2007, 
the number of bed-days decreased with altogether 19%, while 
the number of admissions increased with 13%. Changes in 
hospital activity were most pronounced from 2008 to 2009, 
where the number of bed-days within one year decreased with 
9.8%, while the number of admissions increased with 5.7%. On 
average, the number of bed-days decreased with 2.2% yearly, 
while the number of admissions increased with 1.3% per year 
(Figure A5.2 in web annex).
In 2016, the four penicillin groups accounted for altogether 
53.36 DBD, corresponding to 54% (Table 5.5, Figure 5.9). For 
the second year in a row the combination penicillins consti-
tuted with 18.04 DID the biggest group consumed (18%), and 
the penicillins with extended spectrum with 16.75 DBD the 
second biggest (17%). Beta-lactamase sensitive penicillins 
accounted for 9.77 DBD (10%) and beta-lactamase resistant 
penicillins for 8.80 DBD (9%). 
Since 2007, the combination penicillins and the penicillins with 
extended spectrum increased with 15.09 DBD and 3.33 DBD, 
respectively, reflecting the changes that have happened in the 
treatment of septic patients. Today, piperacillin with tazobac-
tam or a penicillin with extended spectrum combined with an 
aminoglycoside are often the drug of choice in the treatment 
of the septic patient with a suspected Gramnegative bacte-
remia. Until 2011, it used to be cefuroxime, a second genera-
tion cephalosporin. During the last decade the consumption 
of beta-lactamase sensitive penicillins remained relatively 
stable around 9.5 to 10.5 DBD after decreasing from its top of 
12.17 DBD in 2005. The decade before, from the beginning of 
registration in DANMAP, it had been continuously increasing 
from 8.02 DBD in 1997.  Beta-lactamase resistant penicillins 
had also been increasing for all years, from 4.44 DBD in 1997 
to the top of 9.80 in 2015. The 10% decrease from 2015 to 
2016 was the first marked decrease observed for the whole 
period. 
Although tetracyclines only account for a minor part of the 
antimicrobials consumed at hospitals it is worth noting that 
the drug group has seen continuous increases for the past 
decade; in 2007 they accounted for 0.63 DBD, while in 2016 
this had increased to 2.06. From 2015 to 2016 the consump-
tion increased with 11%. In 2016, the proportion of tigecyclin 
constituted 1.1% of the tetracyclines consumed.
Two other antimicrobial classes that have seen continuous 
increases during the past decade are the combinations of trim-
ethoprim and sulfonamides, including derivatives, and the mac-
rolides. From 2007 to 2016, these increased from 1.52 to 5.11 
DBD (> 200%) and from 3.08 to 4.78 DBD (55%), respectively. 
In 2016, cephalosporins accounted with altogether 10.24 DBD 
for 10%, a marked decrease from the 15% last year. Second 
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generation cephalosporins are the most used at hospitals and 
accounted for 9.16 DBD. In addition to its former important 
role in the treatment of septic patients, cefuroxime has been 
widely used for surgical prophylaxis, but in many clinical set-
tings today, dicloxacillin (a beta-lactamaseresistant penicillin) 
is used instead. Fluoroquinolones accounted for 8.11 DBD, 
another marked (13%) reduction from 9.30 DBD in 2015. The 
consumption of fluoroquinolones topped in the years of 2009 
to 2011 with an average of 10.60 DBD and has since shown 
slight declines. Carbapenems accounted in 2016 for 3.93 DBD, 
a 4% decline from the 4.10 DBD in 2015. This is the second 
time in the ten year period that a decrease in the consumption 
of carbapenems was observed. The last time was from 4.16 
DBD in 2011 to 3.86 DBD in 2012. 
Together the three groups of critically important antimi-
crobials in Denmark (cephalosporins, fluoroquinolones and 
carbapenems) constituted 22%, in 2015 it was 24% and ten 
years ago, in 2007, it was 32%. Trends in the consumption of 
cephalosporins, fluoroquinolones and carbapenems are shown 
in Figure 5.10 and 5.11. The consumption of these three an-
timicrobial groups will be monitored closely also in the future 
due to several local, regional and national initiatives, the most 
important one probably being the implementation of the third 
measurable goal in the National Action Plan on antibiotics from 
2017 aiming at a 10% reduction in the consumption of these 
from 2016 to 2020. Reductions are also aimed at through the 
“National Quality and Learning Teams”, an initiative spanning 
all Danish regions, working on applying principles of antibiotic 
stewardship in many of the acute care hospitals at emergency 
departments and in medical departments with a relatively 
high number of acute patients. In addition, the consumption of 
cephalosporins will be followed with extra interest next year. 
Due to shortages of piperacillin with tazobactam in 2017, it 
may have been necessary to reintroduce cephalosporins in 
the treatment of acutely ill, septic patients at several hospi-
tals. Thus for 2017 an increase of the overall consumption of 
cephalosporins is expected, which will be difficult to counter-
balance through the different national initiatives. 
In 2016, the consumption of the leading groups of antimi-
crobials decreased, mainly due to the mentioned decreases 
observed for cephalosporins and fluoroquinolones. In 2016 
the leading antimicrobials constituted 76.00 DBD of the total 
consumption of 99.98 DBD. In 2015 it was 73.56 DBD out of a 
total of 103.02 DBD. For most antimicrobial classes decreases 
were observed from 2015 to 2016 (Figure 5.10). During the 
last decade the consumption and proportions of many of the 
smaller antimicrobial classes increased, (Figure 5.11)
5.4.3 Other measures of consumption at somatic 
hospitals – DDD per 100 admissions (DAD)
The consumption of antimicrobials at hospitals may also be 
measured in relation to hospital activity calculated in the num-
ber of patients “passing through”, i.e. DDD per 100 admissions 
(DAD). 
In 2016, the consumption was 310.53 DAD, a 2.8% decline 
from the 313.34 DAD in 2015 and 1.2% increase from 306.90 
DAD in 2007. The highest top observed was in 2013 with 
325.20 DAD. 
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The trends in DAD reflect for most antimicrobials the trends 
observed in DBD, yet differences over time may be bigger or 
smaller, compared to hospital activity, the number of pa-
tients treated with the specific drug class and the use of the 
 individual antimicrobials in the treatment of acutely or chroni-
cally ill patients. The observed increases, when calculated in 
per cent, were thus more marked, when measured in DBD than 
in DAD for the following antimicrobial classes: tetracyclines, 
combination penicillins including beta-lactamase inhibitors, 
macrolides, lincosamides, glycopeptides, polymyxins, steroid 
antibacterials (fusidic acid), imidazole derivatives and dapto-
mycin (Tables 5.5 and 5.6). 
For three antimicrobial classes the opposite trends were ob-
served for the past decade: penicillins with extended spectrum 
decreased 3.8%, when measured in DAD, but increased 25%, 
when measured in DBD; third generation cephalosporins de-
creased 25% in DAD, but increased 1.4% in DBD and aminogly-
cosides decreased with 19% in DAD, but increased with 8.3% 
in DBD.
At the regional level the hospital activity mirrors the density of 
the population. Numbers for Regional activity when calculated 
in bed-days and in hospital admissions are shown in Table 5.7. 
For comparison with the usage of antimicrobials in animals, 
human consumption for the different antimicrobial classes 
measured in kg active substance is shown in Table A 5.1 in 
web annex. For comparison with the primary sector consump-
tion at hospital level measured in DID can be found in Table 
A5.4 in web annex.
Maja Laursen from the Danish Health Data Authority, 
Katrin Gaardbo Kuhn and Ute Wolff Sönksen 
from Statens Serum Institut. 
For further information: Ute Wolff Sönksen, uws@ssi.dk
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ATC 
group(a)
Therapeutic group
Year
2007 2008(b) 2009 2010 2011 2012 2013 2014 2015 2016
J01AA            Tetracyclines               2.59 3.19 3.63 3.55 3.66 5.15 4.97 5.37 5.65 6.46
J01CA            Penicillins with extended spectrum 55.39 57.18 53.76 47.46 44.77 48.60 47.90 50.95 51.75 53.26
J01CE            Beta-lactamase sensitive penicillins 44.55 40.90 34.61 30.83 28.98 33.04 33.13 32.03 30.52 30.64
J01CF            Beta-lactamase resistant penicillins 27.64 27.89 25.86 25.04 22.71 27.30 29.64 29.73 29.82 27.77
J01CR            
Comb. of penicillins. incl. beta-
lactamase inhibitors   
12.17 16.37 19.74 23.15 26.47 39.14 44.60 49.81 54.14 55.35
J01DB                  First-generation cephalosporins 0.55 0.72 0.46 0.43 0.41 0.40 0.37 0.20 0.13 0.13
J01DC Second-generation cephalosporins 50.81 54.55 55.12 52.65 50.19 46.17 40.27 36.29 31.53 28.31
J01DD Third-generation cephalosporins 4.24 5.10 4.98 4.10 4.33 3.50 3.53 3.18 3.22 3.16
J01DF Monobactams 0.18 0.27 0.21 0.29 0.60 0.48 0.45 0.19 0.08 0.03
J01DH Carbapenems 8.78 11.08 11.01 13.07 12.55 12.60 13.14 12.70 12.50 11.94
J01EA            Trimethoprim and derivatives   1.81 1.80 1.56 1.17 1.11 1.23 1.33 1.62 1.40 1.29
J01EB            Short-acting sulfonamides       1.41 1.43 1.21 1.09 0.78 0.63 0.62 0.55 0.46 0.38
J01EE            
Comb. of sulfonamides and  
trimethoprim. incl. derivatives 
6.28 7.98 7.96 9.88 12.79 10.87 13.76 14.53 15.32 15.54
J01FA            Macrolides                  12.70 12.53 11.97 11.45 11.47 11.61 11.08 12.04 13.90 14.83
J01FF            Lincosamides                1.46 1.69 1.74 1.52 1.63 2.01 2.09 2.03 1.75 1.88
J01GB Aminoglycosides 7.39 6.71 5.45 5.56 5.95 6.99 6.97 5.01 5.11 5.98
J01MA            Fluoroquinolones            33.66 39.04 37.45 33.92 33.30 32.67 31.96 30.69 28.28 24.89
J01XA Glycopeptides 2.61 2.77 3.48 3.47 3.87 4.20 4.22 3.58 3.25 3.24
J01XB            Polymyxins                 0.22 0.21 0.24 0.32 0.28 0.30 0.54 0.85 0.77 0.88
J01XC            Steroid antibacterials (fusidic acid)     1.17 1.05 1.09 1.12 0.85 0.76 0.71 0.71 0.50 0.34
J01XD                 Imidazole derivatives 10.83 13.39 13.43 12.76 13.03 13.55 13.33 13.93 12.93 13.68
J01XE
Nitrofuran derivatives  
(nitrofurantoin)
1.17 1.19 1.27 1.01 1.02 1.12 1.25 1.13 0.98 0.85
J01XX05 Methenamine 0.38 0.43 0.31 0.27 0.32 0.28 0.30 0.22 0.29 0.28
J01XX08 Linezolid 0.68 0.84 0.76 0.72 0.99 1.04 1.14 1.05 1.31 1.09
J01XX09 Daptomycin 0.03 0.06 0.06 0.07 0.05 0.06 0.07 0.10 0.12 0.15
P01AB01
Nitroimidazole derivatives  
(metronidazole)
9.10 9.99 10.20 9.72 9.70 9.44 8.83 7.72 6.24 6.73
A07AA09
Intestinal antiinfectives  
(vancomycin)
9.10 9.96 10.20 9.73 9.71 9.54 9.00 7.92 1.43 1.46
J01
Antibacterial agents for systemic 
use (total)
306.9 328.3 317.8 304.3 301.9 322.7 325.2 324.1 313.38 310.53
Table 5.6. Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 admitted patients), Denmark
 DANMAP 2016
a) From the 2016 edition of the Anatomical Therapeutic Chemical (ATC) classification system
b) The number of admissions was affectedly low in 2008 due to a major hospital strike
Region No. bed-days  
somatic 
hospitals(a)
No. admis-
sions somatic 
hospitals(a)
The Capital Region of Denmark 1,486,698 484,004
The Sealand Region 603,831 236,853
Region of Southern Denmark 779,140 248,756
Central Denmark Region 809,151 281,664
North Denmark Region 385,259 114,034
Denmark(b) 4,064,079 1,365,311
Table 5.7. Activity in somatic hospitals, Denmark  DANMAP 2016
Source: The Danish Health Data Authority (www.sds.dk)
a) Excluding private hospitals, psychiatric hospitals, specialized clinics, 
rehabilitation centres and hospices
b) Compared to 2015 no. bed-days have decreased by 2% and no. 
admissions remain at the same level
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Textbox 5.1
Reducing antibiotic consumption among children and elderly 
through knowledge building – interventions joining primary and 
secondary health care sector
Introduction
The association between antibiotic use and antibiotic resistance is widely acknowledged. Preschool children and elderly 
residents of nursing homes are among the population groups with the highest antibiotic consumption. It has been estimated 
that a substantial amount of the antibiotics used in these two population groups are either unnecessary or inappropriate. The 
recognition has led to an increased awareness regarding the importance of strategies to reduce antibiotic resistance, including 
the promotion of appropriate use of antibiotics, especially in primary care, where the majority of antibiotics are prescribed. 
The Department of Clinical Microbiology at Herlev and Gentofte Hospital has established collaborations with different players 
in primary health care in the Capital Region of Denmark. The department has designed interventions that apply the knowl-
edge of microbiologists and infection control nurses towards the prevention and treatment of infections and prudent antibiotic 
use.
Education and acquirement of knowledge are the keywords for the interventions carried out at the Department of Clinical 
Microbiology. Below is described four ongoing projects targeted at children and elderly and focusing on knowledge building 
through collaboration with the primary care sector and Copenhagen University, Research Unit of General Practice. 
Reduce antibiotic use among children
The Department of Clinical Microbiology conducted a survey among 1,170 general practitioners (GPs) in 2015 (response rate, 
49%). The GPs were asked about their perceptions on parental knowledge and expectations in relation to antibiotic use. The 
results show that GPs perceived low parental knowledge and the GPs felt that parents, to some degree, explicitly (74 %) or 
implicitly (88 %) indicate that they expect antibiotics. About half the GPs (46%) were positive about the potentials of delayed 
antibiotic prescribing, but they rarely apply this. The results of the survey found that there could be a potential for imple-
menting delayed prescription but also that there is a need for increasing knowledge about infections and antibiotics among 
parents. Based on the results of the survey and international research, two projects were designed to reduce inappropriate 
prescriptions.
Project 1: Is Delayed Prescription a Useful Tool to reduce Inappropriate Antibiotic Prescription among Children? Bar-
riers and Opportunities seen by the GPs and the Parents (May 2016 to August 2017)
Delayed prescribing of antibiotics is one of most important strategies to reduce use of antibiotics, without influencing the 
outcome of the patients. Delayed antibiotic prescribing means that the patient is given a prescription, but it is recommended 
to wait and see if the symptoms will disappear spontaneously within the next few days. Patients are advised that if the symp-
toms get worse or are not reduced, then the prescription should be followed.
A pilot project was carried out among 48 GPs distributed in 17 clinics in the Capital Region of Denmark, primarily in Albert-
slund and Rudersdal municipals. The aim was to test the feasibility of delayed antibiotic prescription in preschool children with 
symptoms of upper respiratory tract infections over a four-month period (November 2016 to February 2017) and subsequent-
ly investigate the barriers and possibilities observed by the GPs and parents.
In total, 1031 children with symptoms on upper respiratory tract infections were seen by the GPs. Of these, 6.1 % received 
a delayed prescription, while 23.3 % got an immediate prescription. Large differences among the GPs were seen (Figure 1). 
About half of those who got a delayed prescription, redeemed it. Most of the delayed prescriptions were prescribed on Fridays.
The satisfaction rate among parents was very high, and most of them were interested in a delayed prescription again if their 
GP recommended it. Qualitative interviews with parents revealed that they were under strain from the labor market when 
their children were sick, and they hoped that antibiotics could hasten the recovery phase. Qualitative interviews with GPs 
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revealed that they found that most parents were willing to wait and see if the symptoms of the child disappeared without 
antibiotics, but also that the parents were fragile in relation to their work–life balance. 
Project 2: Knowledge building among new parents about infections and antibiotic—an  
intervention with child health nurses as mediators (March 2017 to December 2018)
Infants often get sick, causing parents to believe that their child is “always sick”. It is, however, normal that children get several 
infections during their first year of life and that the majority of these infections are respiratory infections. Although, most par-
ents know that antibiotics are not effective in viral infections, many believe that antibiotics decrease the duration or complica-
tions. In order to increase parental knowledge, the aim of the intervention is to increase parental knowledge about infections 
and antibiotics, so they can be prepared for their visit to their GP. 
All parents with newborn children will be visited at their home by a maternal and child health nurse (MCHN). Between 1 
September 2017 to 30 August 2018, three municipalities (Egedal, Gentofte, and Hørsholm) will participate in the intervention, 
where a MCHN will teach the parents the basics of infections and antibiotic use at the 8-month visit. All MCHNs from the three 
municipals will receive education on the topics primarily by staff from the Department of Clinical Microbiology. The parents will 
receive a small book authored by the Department of Clinical Microbiology, with valuable information about bacteria and virus 
and antibiotics. 
The intervention will be evaluated qualitatively and quantitatively.
Reduce antibiotic use among elderly at nursing homes
The growth in the number of elderly and oldest old will increase the demand for long-term care services in nursing homes. 
Elderly at nursing homes have been considered to be at a high risk of developing bacterial resistance because of the high 
prevalence of infections and use of antibiotics.
Results from a European point prevalence survey found wide differences in antimicrobial use in nursing homes between Den-
mark, Norway, and Sweden. In Denmark, 11.3% of the residents received at least one antimicrobial treatment, whereas it was 
8.3% and 2.7% in Norway and Sweden, respectively.  
Antibiotics are most frequently prescribed for treatment of urinary tract infections (UTIs) among elderly at nursing homes. 
About half the antibiotics prescribed for urinary tract infections were for prophylactic use, which makes Denmark among the 
highest ranking country in Europe in the use of prophylactic antibiotics. 
The elderly at nursing homes often have co-morbidities and their clinical history is often difficult to obtain, since many elderly 
have cognitive impairment and may also have hearing and speech difficulties. They are particularly challenged since they 
rarely are capable to consult their own GP and must depend on the judgment of the nursing staff. 
Project 3: Less Antibiotic Use and fewer Urinary Tract Infections among Elderly at Nursing Homes  
through Knowledge building among Health Care Personnel (March 2017 to March 2019)
The aim of the intervention is to reduce the rate of UTIs, increase knowledge about infections and antibiotics, and reduce the 
rate of UTI-related admissions.
All staff at nursing homes in two municipals (Frederikssund and Gentofte) will attend a seminar where they will be educated 
about infections, especially UTIs; hygiene; and antibiotics. Staff from the Department of Clinical Microbiology is primarily 
responsible for the seminar and the education program. 
All participating nursing homes will register the number of antibiotic days, prophylaxis or acute use, and number of UTIs during 
a 17-month period. The nursing home staff will receive education by staff from the Department of Clinical Microbiology and 
survey, with baseline and follow-up measurement of changes in the staff’s knowledge about infections, UTIs, and hygiene. 
continued ... Textbox 5.1
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Project 4: Improving Treatment for Residents with Suspected Urinary Tract Infection  
in Long-Term Care Facilities–Protocol for a Cluster Randomized Trial.
The aim of this project is to reduce the rate of prescribed antibiotics through improved cooperation between nursing home staff 
and GPs and is a collaboration between The Department of Clinical Microbiology at Herlev and Gentofte Hospital, The Research 
Unit for General Practice and the Municipality of Gentofte. Nursing home staff will receive a decision aid consisting of three 
parts: observation of the nursing home resident, communication with the GP and a GP prescribed CRP. The effect of the decision 
aid on antibiotic prescription will be tested in a cluster randomized controlled trial in 20 nursing homes during a 6 month period. 
The decision aid will be based on international literature and national projects and further tailored to implementation through 
interviews, audit and focus groups with relevant stakeholders. 
Jette Nygaard Jensen, Sif Helene Arnold, Tina Marloth, Ida Scheel Rasmussen, 
Ditte Porsbak Krøyer, Lars Bjerrum, Jens Otto Jarløv, Magnus Arpi 
For further information: Jette Nygaard Jensen (jette.nygaard.jensen.01@regionh.dk) 
Figure 1: Participating  clinics (one or more GP), number of registered children, and the distribution of no antibiotics,  
immediate antibiotics, and delayed prescription  
DANMAP 2016
0
10
20
30
40
50
2012 2013 2014 2015 2016
Mecillinams Penicillins Penicillinase -stable penicillins
Ampicillins Ampicillin w/ EI Piperacillin w/ EI
Aminoglycosides Cephalosporins Carbapenems
Quinolones
HUSK Neo Sans 8pt. Ændre til 100% sort - rammer 50% sort
BOX 3
0
20
40
60
80
100
120
140
160
Clinic 1 Clinic 2 Clinic 3 Clinic 4 Clinic 5 Clinic 6 Clinic 7 Clinic 8 Clinic 9 Clinic 10 Clinic 11 Clinic 12 Clinic 13 Clinic 14 Clinic 15 Clinic 16 Clinic 17
Albertslund municipality Rudersdal municipality Others
No antibiotic Antibiotic Delayed prescription
Figure 1: Participating  clinics (one or more GP), number of registered children, and the 
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Textbox 5.2
Incidence of multiresistant bacteria and consumption of 
antimicrobial agents in Greenland
 
Background: Greenland has a population of 55,847 inhabitants (January 2016) and Nuuk is the capital with around 16,000 
inhabitants. Greenland has its own Ministry of Health and the country is divided into five health regions. There are five smaller 
hospitals, one general hospital and 11 health care centres in the five health regions. The general and largest hospital, Dron-
ning Ingrids Hospital, is situated in Nuuk (182 beds). Around 15-16,000 persons are admitted to hospital from once to several 
times a year. Patients with specific/serious diseases that cannot be treated at Dronning Ingrids Hospital are transferred to 
Denmark or Iceland for further treatment (e.g. hemodialysis, cancer treatment, brain surgery etc.).  
Resistant bacteria: From 2000 to 2016, 28 patients were diagnosed with methicillin-resistant Staphylococcus aureus 
(MRSA), 76 patients with ESBL-producing Enterobacteriaceae, two patients with vancomycin-resistant enterococci (VRE) and 
136 patients with Clostridium difficile infection, of which 47 were diagnosed with the 027 type. 
The number of patients with MRSA increased during this last year due to an outbreak in Nuuk. This outbreak consisted of six 
persons from the same family living in two households (a divorced family). The index person was either the mother or the 
father (a) of the eldest child, as both of them had been living and working in Australia some years earlier and the MRSA strain 
was found to be a type which is seldom seen in Denmark or Europe (t3979 CC5). Presumably they had been MRSA-carriers for 
years without any problems. When the mother gave birth to her second child she developed mastitis and the newborn child 
developed conjunctivitis in both eyes – both with the same MRSA-strain. The following examinations found both the first child 
and the new husband and father (b) of the second child to be MRSA-positive. As the first child commuted between both homes 
- the mothers´ and the fathers´ (a) -   the father (a) and his new wife were also examined for MRSA and found to be MRSA-
positive. 
In families with children below the age of two years it can be difficult and cumbersome to treat a MRSA-carrier state. Since 
most children spontaneously “loose” their MRSA strain again before the age of two years, treatment of these families is usu-
ally not undertaken. The mother became pregnant with her third child, before the second child turned two years old; therefore 
an eradication-treatment of the MRSA-strain was attempted in the whole family four weeks before the expected birth. After 
treatment all family-members were MRSA-negative except the second child, who was still carrying MRSA on the perineum (still 
using diapers). No further spread of MRSA in this family was observed, neither was there found any transmission to other rela-
tives, social contacts or to the health care system. The success was due to the family being highly compliant to hand hygiene 
and cleaning in their homes. This outbreak illustrates the fact, that MRSA is mainly spread through close contact in families.
In spite of outbreaks in Denmark with VRE, so far only two patients have been diagnosed with VRE in Greenland. Both patients 
were colonized with VRE in the rectum after being hospitalized in Denmark. No transmission was seen in the wards.
Most of the other resistant bacteria were imported from Denmark or abroad, but in some cases, especially in patients with 
ESBL-producing Enterobacteriaceae, treatment with broad-spectrum antimicrobial agents in Greenland has probably selected 
for these bacteria. From 2012 to 2013, there were outbreaks with C. difficile type 027 in the hospitals, and transmission 
within the country occurred. But due to a great infection control effort these outbreaks were quickly stopped. Of the 17 new 
patients with C. difficile infection diagnosed in 2016, none had the 027 type.
Consumption of antimicrobial agents:  All antimicrobial agents in Greenland are purchased and disseminated from the 
National Pharmacy. Figure 1 a and b show the total purchase of selected antimicrobial agents in DDD per 1,000 inhabitants 
per day (DID) from 2007 to 2016. From 2007–2013, an increase of narrow-spectrum (18%) and broad-spectrum penicillins 
(12%) was observed, but from 2013 to 2014 a decrease of 23% and 4%, respectively, occurred. An increase was seen again 
from 2014 to 2016 of 37% and 23%, respectively. From 2015 to 2016 decreases in broad-spectrum antimicrobial agents such 
as macrolides (7%), fluoroquinolones (20%), and meropenem (31%) were observed. A minor increase in cephalosporins (1%) 
and larger increases in piperacillin-tazobactam (28%), tetracyclines (25.5%), and gentamicin (16.5%) were seen from 2015 to 
2016. 
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Conclusion: The consumption data for antimicrobial agents are based on purchases and fluctuations are therefore seen from 
year to year. However, as a result of the increased focus on prescription of antibiotics (especially at Dronning Ingrids Hospital) 
a continued increase in purchases of piperacillin-tazobactam and gentamicin has been observed. Remarkable decreases were 
also seen for meropenem and fluoroquinolones. It is – however –worrying that the purchase of tetracyclines has increased once 
again.
Continued focus on the use of broad-spectrum antimicrobial agents - both in hospitals and in primary health care - and on the 
incidence of multiresistant bacteria in Greenland is very important also in the future.
Anne Kjerulf, Jette Holt, Anne Birgitte Jensen, Peter Poulsen, Inge Mortensen 
For further information: Anne Kjerulf (alf@ssi.dk)
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Note: Narrow-spectrum penicillins include benzylpenicillin, phenoxymethylpenicillin and dicloxacillin, and broad-spectrum penicillins include 
ampicillin, pivampicillin, amoxicillin and amoxicillin with enzyme inhibitor. 
Figure 1a. Consumption of selected antimicrobial agents in humans in Greenland (DDD/1000 inhabitants/day) 2007–2016: 
consumption of narrow- and broad-spectrum penicillins, macrolides and tetracyclines 
DANMAP 2016
Figure 1b. Consumption of selected antimicrobial agents in humans in Greenland (DDD/1000 inhabitants/day) 2007–2016: 
consumption of cephalosporins, meropen m, fluoroquinolones, piperacillin/tazobactam and gentamicin 
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Textbox 5.3
Antimicrobial resistance and consumption of antimicrobials  
in the Faroe Islands 
Background. The Faroe Islands (FI) consist of 18 islands, inhabited by approximately 49,000 inhabitants, 19,000 of whom 
live in the capital Tórshavn. The main hospital (Landssjúkrahúsið, LS, with 170 beds) is located in Tórshavn, and there are two 
smaller hospitals in Klaksvik (36 beds) and Súðuroy (26 beds). The healthcare system is comparable to the Danish healthcare 
system with general practitioners responsible for primary care and hospitals providing secondary care. LS has a local as well as 
a centralized function. In the case of specified diseases, patients are referred to hospitals in Denmark or other foreign hospi-
tals. 
Data and data sources. Data for antimicrobial consumption for FI and for LS were supplied by the Chief Pharmaceutical Of-
fice. Data on MRSA and other resistant bacteria were obtained from LS, as were bed-days.
Resistant microorganisms. MRSA and ESBL-producing Enterobacteriaceae (Escherichia coli and Klebsiella pneumoniae) are 
continuously surveyed and screening performed according to guidelines. Since April 2015, vancomycin-resistant enterococci 
(VRE) have been an increasing problem – especially at LS. A systematic periodic screening of VRE was performed in the wards 
throughout 2015. From 2016, screening was mainly performed after transfer of patients from hospitals abroad (including Den-
mark). The VRE data for 2016 are therefore based on results of screening and on clinical samples. For details, see Table 1.
Antimicrobial consumption at LS. Total antimicrobial consumption was 60.54 DDD/100 bed-days (DBD), an increase of 13 % 
compared to 2015. Special attention was paid to the use of three broad-spectrum antimicrobials: in 2016 cefuroxim constitut-
ed with 13.55 DBD 21 % of total antibacterial DBD, continuing steady increases since 2012, whereas both meropenem (2.37 
DBD) and ciprofloxacin (4.91 DBD) increases seemed to be levelling off. The use of amoxicillin with betalactamase-inhibitor 
more than doubled during that periode,  from 1.11DBD in 2012 to 2.61 DBD in 2016. Consumption of mecillinams (pivmecil-
linam and mecillinam) increased from 0.45 DBD in 2012 to 3.74 DBD in 2016, with a 170 % increase from 2015 to 2016. For 
details seeFigure 1.
Antimicrobial consumption in primary healthcare. Total antimicrobial consumption in 2016 was 13.87 DDD/1000 inhabit-
ants/day (DID) representing a 6.9 % reduction compared to 2015 (14.90 DID). The distribution of antimicrobial consumption is 
shown in Figure 2. Remarkable is the decrease in the use of penicillin and ampicillins observed, from 5.44 and 1.53 DID (2012) 
to 5.08 and 1.35 in 2015 and with a further decrease to 4.23 and 1.06 DID in 2016, respectively. In contrast, an increase was 
observed in the use of penicillinase-stable penicillins and amoxicillin with betalactamase-inhibitor, from 1.14 and 0.50 DID 
(2012) to 1.19 and 0.77 in 2015 with a further increase to 1.35 and 0.79 DID in 2016, respectively.
Conclusion. Antimicrobial consumption is still increasing at LS, with a 123% increase alone in 2016, while the consumption 
observed in primary healthcare is simultaneously decreasing. Positive trends were the consumption of  meropenem and cip-
rofloxacin, the use of which seems to be levelling off at LS, while the use of mecillinams showed increasing trends both at LS 
and in primary healthcare. Implementation of antibiotic stewardship and a continuous focus on adherence to general infection 
control precautions are the necessary steps in the effort to reduce development and spreading of antimicrobial resistance in 
LS and in primary healthcare.
Elsebeth Tvenstrup Jensen, Anne Kjerulf, Lena Lambaa, Hjørdis Reinert, Shahin Gaïni, Ann Winther Jensen, Niels Joensen. 
For further information: Elsebeth Tvenstrup Jensen
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Time span Methicillin-resistant
S. aureus (MRSA)
ESBL-producing Enterobacteriaceae Vancomycin-resistant enterococci 
(VRE)
2004-2016 50
2006-2016 55
2015-2016 135
Table 1. Total number of cases being colonized or infected with multi-resistant bacteria DANMAP 2016
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Figure 1: Participating  clinics (one or more GP), number of registered children, and the 
distribution of no antibiotics, immediate antibiotics, and delayed prescription
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Figure 1. Consumption of selected antibiotics (narrow- and broad-spectrum) at LS 2012-16
(DDD/100 bed-days)  DANMAP 2016
Figure 2. Consumption of antimicrobials in primary healthcare, 2016
(DDD/1000 patients/day; %)  DANMAP 2016
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6. Resistance in zoonotic bacteria
6.1 Introduction
Zoonoses are infectious diseases that can be transmitted be-
tween animals and humans, either through direct contact with 
animals or indirectly by contaminated food. Zoonotic bacteria, 
such as Salmonella and Campylobacter, can develop resistance 
towards antimicrobial agents, which subsequently may lead to 
limited treatment possibilities, prolonged illness or even treat-
ment failure of human infectious diseases. The development 
and spread of antimicrobial resistance is multi-factorial and 
can happen in many ways, including antimicrobial treatment 
of animals and humans, transfer of genes between bacteria or 
spread of very persistent and strong survivor strains carrying 
resistance genes.
A more detailed description of the trends and sources of 
zoonoses in Denmark and of national surveillance and control 
programmes can be found in the Annual Report on Zoonoses in 
Denmark 2016[www.food.dtu.dk].
S. Typhimurium, S. Enteritidis, C. jejuni and C. coli have been in-
cluded in the DANMAP programme since 1995, where isolates 
were recovered for susceptibility testing in samples from broil-
ers, cattle and pigs as well as from human cases. Sampling of 
fresh meat was initiated from 1997. Since 2014, sampling and 
testing of Salmonella and Campylobacter have been according 
to the EU harmonized monitoring of antimicrobial resistance 
[Decision 2013/652/EU].    
    Highlights: In 2016, Salmonella Typhimurium overtook S. Derby, as the most prevalent 
serotype found in Danish pigs and domestically produced pork. The continued high occur-
rence of multi-resistant monophasic S. Typhimurium resulted in high levels of resistance to 
ampicillin, sulfonamide and tetracycline (61-76%) among porcine S. Typhimurium isolates. 
Similar high levels (68-71%) were observed for domestically acquired human cases. These 
observations highlight the importance of monophasic S. Typhimurium in spreading and main-
taining resistance in Danish pigs and pork as well as in human cases. 
  Among human cases, resistance to quinolones remained higher among isolates from the 
travel-related cases than among cases acquired in Denmark. Due to the highly restrictive use 
of antibiotics critical for human treatment in the pig production, fluoroquinolone (ciprofloxa-
cin) resistance has not been found in S. Typhimurium from pigs or domestically produced 
pork in several years. Resistance to 3rd generation cephalosporins and carbapenems has 
also remained very low in S. Typhimurium from domestically acquired human cases and were 
not found in the Salmonella isolates from Danish pigs and pork.
  Since 2002, resistance to fluoroquinolones has increased to a level of approximately 20% 
among Campylobacter jejuni from Danish broilers; however most isolates remain fully sen-
sitive. The level of fluoroquinolone resistance in C. jejuni continues to be a lot higher among 
isolates from imported broiler meat compared with isolates from Danish broilers. In Campylo-
bacter isolates from cattle the resistance to fluoroquinolone also continued to increase, de-
spite nearly zero use of these antimicrobials in cattle. The occurrence of resistance to cipro-
floxacin and tetracycline in human isolates remained significantly higher in travel associated 
C. jejuni isolates compared to isolates from domestically acquired infections.
63DANMAP 2016
6.RESISTANCE IN ZOONOTIC BACTERIA
6.2 Salmonella
Salmonella is the second most frequent zoonotic bacterial 
pathogen in Denmark and can have a severe impact on both 
animal production and human health [Annual Report on Zoono-
ses in Denmark 2016].
In Denmark and the rest of the Europe, S. Enteritidis and S. 
Typhimurium are the serotypes most frequently found to be 
associated with human illness. Human cases caused by S. 
Enteritidis are most commonly associated with consumption of 
contaminated eggs or poultry meat, whereas S. Typhimurium 
cases are mostly associated with eating contaminated meat 
from pigs, cattle and poultry.
Salmonella isolates for DANMAP 2016 were derived from 
national surveillance and control programmes. Pig isolates 
originate from slaughterhouses, where representative samples 
from healthy pigs (caecum) and pork (carcass swabs) are 
collected each year. Salmonellosis is a notifiable disease in hu-
mans and isolates from all reported S. Typhimurium cases are 
susceptibility tested. Only one isolate per farm, meat sample 
or human case was included in this report. For further details 
see Chapter 9, Materials and Methods.
Salmonella in domestic broilers, layers and cattle as well as 
some other types of Danish and imported meat are also moni-
tored in Denmark each year. However, these are not included in 
DANMAP 2016, as only few isolates were found and thus, fall 
below the inclusion threshold for DANMAP of 15 isolates per 
population. The data are however reported to EFSA, and are 
included in the European Union summary report on antimicro-
bial resistance in zoonotic and indicator bacteria from humans, 
animals and food in 2016.
The DANMAP report focuses on the resistance in S. Typhimuri-
um, because they are the most relevant serotype in public 
health. However, resistance in all Salmonella serotypes from 
pigs and pork is also presented for 2011 and onwards, which 
is the year Denmark started to susceptibility test all serotypes 
according to EU legislation.
In DANMAP, S. Typhimurium includes the monophasic variants 
with antigenic formulas S. 4, [5],12:i:- as recommended by the 
European Food Safety Authority [EFSA journal 2010. 8(10): 
1826]. In the text, the term generic S. Typhimurium refers to 
results on isolates of the non-monophasic variants only.
The antimicrobials recommended by EFSA were used for 
susceptibility testing and MIC distributions and occurrence 
of resistance among isolates from pigs, pork and humans are 
presented in the web annex (Tables A6.1 - A6.5).
6.2.1 Salmonella in pigs and domestically  
produced pork – all serotypes
More than 700 representative pig caeca and 10,000 pig car-
cass swabs (pork) yielded 223 Salmonella isolates, which were 
tested for antimicrobial resistance. As in the previous years, S. 
Typhimurium (including the monophasic variants) and S. Derby 
were the most common serotypes, representing 91% of all the 
isolates (Figure 6.1). For the first time, S. typhimurium (48%) 
overtook S. Derby (43%) as the most prevalent serotype from 
domestically produced pigs and pork. This shift is mainly due 
to a large proportional increase of monophasic variants in Dan-
ish pork and a small drop in S. Derby isolates in pigs. Statistical-
ly significant differences in distribution of serotypes between 
pigs arriving at the slaughterhouses and the contamination of 
carcasses at the end of the slaughter line were also present. 
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Figure 6.1. Relative distribution (%) of Salmonella serotypes from pigs and Danish pork, Denmark DANMAP 2016
Note: Number of isolates included each year is presented in the parenthesis
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It is the first year that this difference is observed and it is too 
soon to conclude on whether this is a trend or within normal 
variation, but this will be monitored in the coming years. 
6.2.2 S. Typhimurium in pigs  
and domestically produced pork
S. Typhimurium remains the most important zoonotic sero-
type originating from pigs. A total of 107 S. Typhimurium (41 
generic) and their monophasic variants (66) were isolated from 
Danish pigs and pork in 2016. The level of fully sensitive S. 
Typhimurium isolates in pigs remained the same as in 2015 
(15% and 16%), but the level decreased in pork (19% to 12%). 
Only 3% of the monophasic isolates were fully sensitive to all 
antibiotics in the panel versus 32% fully sensitive generic S. 
Typhimurium. This illustrates the important role of the mono-
phasic variants in spreading and maintaining resistance and 
attributes some of the increase in resistance in Danish pigs 
and pork to the continuing spread of monophasic Salmonella. 
As in the previous years, the highest resistance levels in S. 
Typhimurium isolates were observed to ampicillin, tetracycline 
and sulfonamide (Figure 6.2). Sulfonamide resistance was 
higher in isolates from pork than from pigs, probably reflect-
ing the larger proportion of monophasic variants in pork (Table 
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Figure 6.2. Resistance (%) in Salmonella Typhimurium(a) in pigs and pork, Denmark DANMAP 2016
Note: Number of isolates included each year is presented in the parenthesis. The ‘-’ indicate data for application of 2016 cut-offs were not 
available or less than 25 isolates were available
a) Includes isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:-
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6.1). Resistance to sulfonamides declined sharply in live pigs 
in 2016. The distinct drop was independent of resistance to 
tetracycline and ampicillin, but seemed to be associated with 
the drop in trimethoprim resistance instead. The reduction was 
only seen in monophasic variants, not in generic S. Typhimuri-
um isolates. A similar reduction was not observed in isolates 
from pork. Notably, the use of sulfonamide/trimethoprim, 
mainly used for sows, has decreased consistently over the past 
three years.
Tetracycline resistance in pork isolates returned to the expect-
ed trend after a sharp decline in 2015, and again reached the 
levels of resistance to ampicillin and sulphonamides, probably 
as part of the ASuT-resistance profile dominating monophasic 
variants. This year 65% of the monophasic isolates carried 
the ASuT resistance profile, occasionally in combination with 
resistance to one or more antibiotics. The ASuT-profile was 
only found in 27% of the generic Typhimurium isolates (11 
of 41 isolates). Low levels of resistance to chloramphenicol 
and trimethoprim were observed in both pigs and pork. Very 
low levels of resistance to azithromycin and gentamycin were 
found in pork, but not in pigs.
Tetracyclines, macrolides (mainly Tylosin and Tilmicosin), 
pleuromutilins and beta-lactamase sensitive penicillins are the 
main antimicrobial agents used in pigs in Denmark (Figure 4.6). 
Overall, the use of these antimicrobials peaked in 2009, but 
has since then been reduced markedly. However the changes 
in usage of tetracycline and macrolides is not reflected in the 
observed levels of resistance in S. Typhimurium from pigs and 
domestically produced pork – as the trends are still dominated 
by the increasing occurrence of monophasic S. 4,[5],12:i:- 
clones (Figure 6.2). 
None of the S. Typhimurium isolates from pigs or domestic 
pork were resistant to quinolones, cephalosporins (cefotaxime 
and ceftazidime) or carbapenems (meropenem), providing 95% 
certainty that these resistances are present in less than 5.2% 
of S. Typhimurium isolates from pigs and 5.7% S. Typhimurium 
from pork (see Textbox 6.2 and Materials and Methods section 
9.7.3) 
6.2.3 Resistance in other relevant Salmonella serotypes 
in pigs and domestically produced pork
S. Derby 
S. Derby was isolated from 63 slaughter pigs and from 34 
Danish pork samples. S. Derby is common among pigs, but 
only few human cases (n=12) were reported in Denmark in 
2016 [Annual Report on Zoonoses in Denmark 2016]. The 
majority of the S. Derby isolates from pigs were fully sensi-
tive (63%), but the proportion of fully sensitive isolates was 
significantly lower than last year (72%), suggesting resistance 
in S. Derby is increasing. Resistance to tetracycline, ampicillin 
and sulphonamide resistance were most common, either alone 
or in combination. Two isolates were also resistant to chloram-
phenicol and one to gentamycin, but no resistance to any other 
antimicrobials was found.
S. Infantis
Only four isolates of S. Infantis was isolated from Danish pigs 
(n=1) and pork (n=3). Three of these were fully sensitive to all 
antibiotics in the panel and one isolate from pork was resistant 
to ampicillin, sulfamethoxazole and trimethoprim. 
6.2.4 Salmonella in humans  
In 2016, Salmonella continued to be the second most frequent 
cause of bacterial intestinal infections in Denmark. A total of 
1,074 human laboratory-confirmed cases of salmonellosis was 
reported (18.8 cases per 100,000 inhabitants). The most com-
mon serotypes were S. Typhimurium (including the monophasic 
variants) and S. Enteritidis with 5.6 and 4.3 cases per 100,000 
inhabitants, respectively [Annual report on Zoonoses in Den-
mark 2016].
6.2.5 S. Typhimurium in humans
Salmonella Typhimurium, including the monophasic variants, 
was the most common serotype among the human cases (300 
cases) and 297 of these isolates were susceptibility tested. 
The monophasic variants represented two thirds of the S. 
Typhimurium cases (192 monophasic versus 108 generic 
Typhimurium).
Antimicrobial 
agent
Pigs Pork Human cases
Danish
%
Danish
%
Domestically 
acquired 
%
Travel 
abroad 
reported
%
Total
%
Tetracycline 64 69 68 68 68
Tigecycline 0 0 <1 0 <1
Chloramphenicol 14 6 10 18 12
Ampicillin 68 73 71 65 70
Cefotaxime 0 0 3 5 4
Ceftazidime 0 0 <1 4 2
Meropenem 0 0 0 0 0
Trimethoprim 9 6 9 15 10
Sulfonamide 61 76 68 69 69
Azithromycin 0 6 0 1 <1
Gentamicin 0 2 <1 4 1
Ciprofloxacin 0 0 <1 18 6
Nalidixic acid 0 0 0 6 2
Colistin 0 0 <1 5 2
Number of 
isolates
56 51 167 78 297
Table 6.1. Resistance (%) among Salmonella  
Typhimurium(a) isolates from pigs, Danish pork  
and human cases(b), Denmark DANMAP 2016
a) Include isolates verified as monophasic variants of S. Typhimurium 
with antigenic formulas S. 4,[5],12:i:- 
b) An isolate was categorised as ‘domestic’ if the patient did not travel 
outside Denmark one week prior to the onset of the disease
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Figure 6.3. Resistance (%) in Salmonella Typhimurium(a) in human cases(b), Denmark DANMAP 2016
a) Include isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:-
b) An isolate was categorised as ‘domestic’ if the patient did not travel outside Denmark one week prior to the onset of the disease
Information on travel history was collected through phone 
interviews and among the 297 human S. Typhimurium isolates, 
included in DANMAP 2016, 26% of the cases were categorised 
as travel associated, whereas 56% most likely were acquired in 
Denmark (Table 6.1). A total 57 human cases were considered 
‘outbreak-related’ and originated from seven outbreaks, one out-
break of S. Typhimurium and six outbreaks of the monophasic 
variant of S. Typhimurium. Domestically acquired human cases 
included both sporadic and outbreak related cases (Table 6.1).
Again this year, high levels of resistance to ampicillin, sul-
fonamide, and tetracycline were observed. Resistance to the 
three different antimicrobials was observed at the same level 
(65-71%) among isolates from domestic and travel-associated 
cases (Table 6.3). For domestically acquired cases the level of 
tetracycline resistance increased significantly from 2015 to 
2016  (from 55% to 68%). 
Resistance to ampicillin, sulfonamide and tetracycline has 
increased since 2008, especially among the isolates from 
domestic acquired cases (Figure 6.3). Starting in 2008 we had 
one of the largest outbreaks ever seen in Denmark that ran 
for two years. The outbreak was caused by a fully sensitive 
S. Typhimurium clone and therefore has a huge impact on the 
trend graph. 
There was a significantly higher level of resistance to quino-
lones and colistin among travel-associated isolates compared 
with domestic ones in 2016. Both ciprofloxacin and nalidixic 
acid resistance were higher in isolates from travel-related 
cases (18% and 6% respectively) compared with isolates 
from domestic cases (1% and 0% respectively). Resistance to 
colistin was also significantly higher in travel-associated cases 
(5%) when compared to domestically acquired cases (1%). 
Johanne Ellis-Iversen, Helle Korsgaard and Mia Torpdahl
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6.3 Campylobacter
Thermotolerant Campylobacter spp. are the most commonly 
reported causes of gastrointestinal bacterial infections in 
humans in Denmark as well as in the European Union [EU Sum-
mary Report 2015, ECDC/EFSA 2016]. In Denmark, 85-95% of 
the human campylobacteriosis cases are caused by C. jejuni.
Campylobacter are widespread in nature and the most impor-
tant reservoirs are the alimentary tract of wild and domesticat-
ed birds and mammals. Among sporadic human cases, broilers 
have been identified as the primary source of infection, though 
other sources such as untreated water and other infected 
animals are also important.
In 2016, most of the Campylobacter isolates for DANMAP was 
supplied by the mandatory sampling of randomly selected 
broilers at slaughter (caecum). However, isolates from cattle 
and from broiler meat were also included. In humans Campy-
lobacteriosis is a notifiable disease, but only a selection of 
isolates from reported human C. jejuni cases are susceptibility 
tested. Only one isolate per farm, meat sample or human case 
was included. For details see Chapter 9, Materials and Meth-
ods. The susceptibility methods follow EFSAs recommenda-
tions and MIC distributions for C. jejuni from broilers and cattle, 
broiler meat and humans are presented in the web annex 
(Tables A6.6- A6.8).
6.3.1 C. jejuni in broilers and domestically produced 
broiler meat
A total of 178 C. jejuni isolates were derived from more than 
700 samples from broilers and domestically-produced poultry 
meat collected throughout the year. This more than doubled 
the number of samples and isolates from 2015 and thus, gen-
erate more precise and reliable estimates in 2016. The isolates 
originated predominately from broilers (n=160) and much 
fewer were isolated from meat (n=18).
The level of fully sensitive isolates from broilers and broiler 
meat was 74%, which was similar to the previous three years. 
Resistance to ciprofloxacin (22-23%) and nalidixic acid (21-
22%) were most frequently observed (Table 6.2). Since 2007, 
a slow increase in proportion of resistant isolates has been 
observed from approximately 10% in 2006 to 23% in 2016. 
This is mainly due to the increase in resistance to ciprofloxa-
cin. Resistance to ciprofloxacin in broilers is fluctuating from 
year to year, but has increased from 7% to 22% over the last 
10 years, despite little or no use of quinolones in the poultry 
industry since 2009. The Danish increasing trend of resistance 
to quinolones is similar to the increasing trend of ciprofloxacin 
resistance in the EU, but the levels in Denmark still remain 
much lower than the EU averages of 62-66% of isolates resis-
tant to quinolones [EU Summary Report 2014]. 
Tetracycline resistance has plateaued around 12% in both 
broilers and broiler meat after a steady increase peaking 
in 2013 followed by a drop back to 2008 level. This does 
not clearly follow the use of tetracyclines in broilers, which 
increased sharply from 2012 to 2015 and decreased in 2016. 
Resistance to streptomycin remains low at 4% in broilers and 
stays within the fluctuations of the last two years between 
5% in 2014 and 2% in 2015. Only very low levels of resistance 
to erythromycin (0.6%) and no resistance to gentamycin were 
observed in 2016. 
6.3.2 C. jejuni from imported broiler meat
As in previous years, the levels of resistance to ciprofloxacin 
(71%), nalidixic acid (69%) and tetracycline (63%) in imported 
poultry meat were higher than the resistance levels observed 
in isolates from domestically produced broilers and meat (Table 
6.2). In 2015, a decreasing trend in resistance to tetracycline 
was observed, but this year the trend had reversed to an 
increase. The increase is most likely due to a change in the 
proportional contribution of poultry meat samples from four EU 
countries from 2015 to 2016. In 2016, a larger proportion of 
sampled imported poultry meat originated from countries with 
higher levels of resistance to tetracycline [EU Summary Report 
2015]. 
Table 6.2. Resistance (%) in Campylobacter jejuni isolates from animals, meat of  
Danish and imported origin and human cases(a), Denmark DANMAP 2016
a) An isolate is categorised as domestically acquired if the patient did not travel outside Denmark one week prior to the onset of disease
Antimicrobial agent
Cattle Broilers Broiler meat Humans
Danish
%
Danish
%
Danish
%
Import
%
Domestically 
acquired
%
Travel abroad
%
Total
%
Tetracycline 13 13 11 63 17 59 23
Erythromycin 0 <1 0 0 1 5 2
Streptomycin 6 4 6 8 3 13 4
Gentamicin 0 0 0 0 <1 10 2
Ciprofloxacin 25 23 22 71 33 80 39
Nalidixic acid 25 21 22 69 33 80 39
Number of isolates 80 160 18 49 241 39 280
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Figure 6.4. Resistance (%) among Campylobacter jejuni from broilers and broiler meat, Denmark DANMAP 2016
Note: Number of isolates included each year is presented in the parenthesis. The ‘-’ indicate data for application of 2016 cut-offs not available or 
less than 25 isolates were available
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6.3.3 C. jejuni in cattle
A total of 82 Campylobacter isolates were derived from more 
than 120 cattle caeca taken from all over Denmark and 80 C. 
jejuni isolates were susceptibility tested. Most of the isolates 
(70%) were fully sensitive to all antibiotics tested and the 
remaining isolates were resistant to ciprofloxacin, tetracycline, 
streptomycin (25%, 13% and 6% of all isolates, respectively) 
and to various combinations of these (Table 6.2).
Resistance to ciprofloxacin continued to increase, despite near-
ly zero consumption of fluoroquinolones in cattle in Denmark 
(Figure 6.5). Initially, quinolone-resistant C. jejuni isolates were 
only found in cattle farms in Southern Jutland, but now the 
resistance is equally distributed all over the country. It is un-
known, whether it is a clonal spread or whether the resistant C. 
jejuni are introduced to cattle from other sources. Resistance 
to streptomycin increased from 2015, but levels remain low 
(1% to 6%). A small increase in resistance to tetracycline was 
also observed and the resistance levels are now almost back to 
2001 levels after many years of low levels (Figure 6.5). 
6.3.4 C. jejuni in humans
Campylobacter continued as the most frequent cause of 
bacterial intestinal infections in Denmark and a total of 4,677 
human laboratory confirmed cases of campylobacteriosis were 
reported (82 per 100,000 inhabitants) [Annual Report on 
Zoonoses in Denmark 2016].
In 2016 Campylobacter isolates were submitted to Statens 
Serum Institut (SSI) by four Clinical Microbiological Laborato-
ries covering four geographically dispersed and representa-
tive areas of Denmark and both urban and rural areas were 
included. The isolates were speciestyped and a total of 280 C. 
jejuni isolates were susceptibility tested. Travel history of the 
patients was collected, when possible, primarily as part of the 
information given to the diagnostic laboratory at submission of 
patient samples. In 2016, priority was given to susceptibility 
testing more isolates from domestically acquired cases (241 
isolates; 86%) compared to isolates from travel-associated 
cases (39 isolates).
Among the domestically acquired infections, 62% were fully 
sensitive to all the antimicrobial agents tested, while the 
percentage of fully sensitive isolates was much lower among 
isolates from travel associated cases (18%). Similar to previous 
years, the occurrence of resistance to ciprofloxacin and tetra-
cycline was significantly higher in travel associated C. jejuni 
isolates (80% and 59%, respectively) compared to isolates 
from domestically acquired infections (33% and 17%, respec-
tively) (Table 6.2 and Figure 6.6). 
Among the 123 resistant isolates, the most frequent resis-
tance profile was resistance to ciprofloxacin alone (70/123) 
or ciprofloxacin in combination with tetracycline (43/123). 
All isolates resistant to gentamicin (six in total) were multi-
resistant, two were acquired domestically and four were travel 
related. Five isolates were found resistant to erythromycin, 
three were acquired domestically and two were from a travel 
associated case.
Johanne Ellis-Iversen, Helle Korsgaard and Eva Møller Nielsen
Figure 6.5. Resistance (%) among Campylobacter jejuni from cattle, Denmark DANMAP 2016
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Figure 6.6. Resistance (%) among Campylobacter jejuni from humans(a), Denmark DANMAP 2016
Note: Number of isolates included each year is presented in the parenthesis. The ‘-’ indicate data for application of 2016 cut-offs not available or 
less than 25 isolates were available
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Textbox 6.1
Resistance in bacteria from diagnostic submissions from pigs
 
Antimicrobial susceptibility testing of veterinary pathogens takes place at two accredited diagnostic laboratories in Den-
mark, at DTU National Veterinary Institute and at SEGES: The Danish Pig Research Centre’s Laboratory for Pig Diseases (VSP) 
in Kjellerup. Data on susceptibility of three important veterinary pathogens Escherichia coli O149, Streptococcus suis, and 
Actinobacillus pleuropneumoniae, were obtained from the routine diagnostic laboratory at Laboratory for Pig Diseases and 
presented here, whereas the number of isolates of other bacterial pathogens were too small.
The antimicrobial susceptibility testing was carried out using the broth microdilution method with SensiTitre. Since approved 
clinical breakpoints are not available for most of the drug-bacterium combinations, the results are presented both as MIC dis-
tributions, which allows for the reader’s own interpretation, and as % resistant isolated according to the clinical breakpoints 
that are agreed by both DTU National Veterinary Institute and Laboratory for Pig Diseases.
E. coli O149
Enterotoxigenic E. coli (ETEC) is one of the most important bacterial causes of diarrhoea in pigs, in particular weaning pigs 
and the most virulent types are haemolytic, enterotoxin and F4 fimbria positive strains. The MIC distributions and resistance 
data are shown in Table 1. High resistance levels were recorded for ampicillin, streptomycin, sulphonamides, tetracyclines 
(ASSuT–resistance pattern also known from Salmonella), and trimethoprim. This is in accordance with figures from 2015, 
and no major differences were recorded compared to 2015 data. Almost 7 out of 10 isolates were resistant to tetracycline, 
sulphonamides, and streptomycin. Resistance to florfenicol remains at 10% like in 2015, which is higher than most recent 
figures from 2012 (3%) and 2011 (0%). In view of the current focus on colistin resistance it is notable, that no resistance 
was recorded to colistin. Resistance to nalidixic acid was recorded in 10% of the isolates, which is in line with the 11% found 
in 2015, in spite of no use of quinolone for treatment of pigs. The result may suggest the persistence of quinolone resistant 
strains.
Actinobacillus pleuropneumoniae
Actinobacillus pleuropneumonia is the cause of a severe pleuropneumonia in pigs with fever, coughing, depression, loss of 
appetite, and bloody discharge from the nose as main clinical findings. In case of an outbreak, it is important to be able to 
initiate proper treatment very quickly. Fortunately, A. pleuropneumoniae still have a predictable resistance pattern and low 
resistance to most compounds. MIC distributions and percent resistance are shown in Table 2. Most isolates were resistant to 
erythromycin, but were susceptible to all other compounds, including penicillin. A single isolate was resistant to tetracycline. 
Resistance patterns did not differ between serotypes.
Streptococcus suis
Streptococcus suis is alfa-haemolytic streptococcus, which cause several infectious conditions in pigs, including meningitis, 
arthritis, pneumonia, and septicaemia, and cause losses to the farmers due to increased mortality and veterinary costs. MIC 
distributions and percent resistant isolates are shown in Table 3. Resistance was high to macrolides (erythromycin) and 
tetracyclines, but low or zero for most other compounds. An important observation was that resistance to penicillin remains 
at zero. 
Karl Pedersen, Birgitta Svensmark and Sven Erik Jorsal 
For further information: Karl Pedersen, kape@vet.dtu.dk
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Note: Interpreted by clinical break-points for E. coli isolate from pigs as applied by DTU National Veterinary Institute and The Danish Pig 
Research Centre’s Laboratory for Pig Diseases. Confidence intervals are calculated as 95% binomial proportions presenting Wilson intervals. 
Vertical solid lines indicate EUCAST epidemiological cut-off values. Breakpoints are indicated as vertical dotted lines if different from the 
corresponding epidemiological cut-off values. White fields represent the range of dilutions tested. MIC values equal to or lower than the lowest 
concentration tested are presented as the lowest concentration. MIC values greater than the highest concentration in the range are presented 
as one dilution step above the range
Table 1. Distribution of MICs and resistance (%) in clinical Escherichia coli O149 from pigs (n=59), Denmark DANMAP 2016
Note: Interpreted by clinical break-points for E. coli isolate from pigs as applied by DTU National Veterinary Institute and The Danish Pig 
Research Centre’s Laboratory for Pig Diseases. Breakpoints are indicated as vertical dotted lines. Confidence intervals are calculated as 95% 
binomial proportions presenting Wilson intervals. White fields represent the range of dilutions tested. MIC values equal to or lower than the 
lowest concentration tested are presented as the lowest concentration. MIC values greater than the highest concentration in the range are 
presented as one dilution step above the range.
Table 3. Distribution of MICs and resistance (%) in clinical Streptococcus suis from pigs (n=43), Denmark DANMAP 2016
Note: Interpreted by clinical break-points for E. coli isolate from pigs as applied by DTU National Veterinary Institute and The Danish Pig 
Research Centre’s Laboratory for Pig Diseases. Breakpoints are indicated as vertical dotted lines. Confidence intervals are calculated as 95% 
binomial proportions presenting Wilson intervals. White fields represent the range of dilutions tested. MIC values equal to or lower than the 
lowest concentration tested are presented as the lowest concentration. MIC values greater than the highest concentration in the range are 
presented as one dilution step above the range.
Antimicrobial  
agent
Clinical 
breakpoint  
μg/ml
%  
Resistant
95%  
Confidence 
interval 
Distribution (isolates) of MICs
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
Tetracycline >4 0.6 [0.6-0.6] 3.1 5.0 50.9 35.2 5.0 0.6
Florfenicol >4 0.0 [0-0] 7.5 88.1 3.8 0.6
Ampicillin >2 0.0 [0-0] 100.0
Penicillin >2 0.0 [0-0] 1.9 8.2 17.6 40.9 28.9 1.3
Ceftiofur >4 0.0 [0-0] 98.7 0.6 0.6
Sulfa-trimethoprim >2 0.0 [0-0] 47.8 49.1 3.1
Erythromycin >0.5 95.0 [95-95] 1.9 0.6 2.5 25.2 46.5 23.3
Tulathromycin >8 0.0 [0-0] 0.6 0.6 7.5 27.7 52.2 11.3
Tilmicosin >16 0 [0-0] 1.9 1.3 10.7 56.6 29.6
Tiamulin >16 0.0 [0-0] 4.4 18.9 37.1 36.5 3.1
Spectinomycin >64 0.0 [0-0] 27.7 50.3 22.0
Antimicrobial  
agent
Clinical 
breakpoint  
μg/ml
%  
Resistant
95%  
Confidence 
interval 
Distribution (isolates) of MICs
0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512
Tetracycline >4 51.0 [42.9-59.2] 6.9 17.9 15.9 8.3 0.7 1.4 49.0
Chloramphenicol >8 0.7 [0-2] 18.6 76.6 4.1 0.7
Florfenicol >16 0.0 [0-0] 35.9 62.8 0.7 0.7
Penicillin >2 0.0 [0-0] 89.7 0.7 1.4 4.8 2.8 0.7
Sulfa-trimethoprim >2 6.2 [2.3-10.1] 80.0 4.1 2.1 7.6 2.1 4.1
Trimethoprim >8 9.0 [4.3-13.6] 77.9 1.4 1.4 6.2 4.1 9.0
Erythromycin >0.5 53.1 [45-61.2] 46.9 0.7 0.7 3.4 48.3
Streptomycin >16 41 [32.7-48.7] 9.7 29.7 20.0 9.7 31.0
Tiamulin >16 25.5 [18.4-32.6] 10.3 8.3 17.2 29.7 4.1 2.8 2.1 25.5
Spectinomycin >64 26.9 [19.7-34.1] 60.0 12.4 0.7 26.9
Antimicrobial  
agent
Clinical 
breakpoint  
μg/ml
%  
Resistant
95%  
Confidence  
interval 
Distribution (isolates) of MICs
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 >1024
Tetracycline >8 67.8 [55.9-79.7] 28.8 3.4 67.8
Chloramphenicol >16 25.4 [14.3-36.5] 3.4 66.1 5.1 5.1 20.3
Florfenicol >16 10.2 [2.5-17.9] 11.9 67.8 8.5 1.7 1.7 8.5
Ampicillin >16 50.8 [38.1-63.6] 13.6 32.2 3.4 50.8
Cefotaxime >0.25 1.7 [0-5] 1.7 1.7
Sulfonamide >256 69.5 [57.7-81.2] 30.5 69.5
Trimethoprim >8 47.5 [34.7-60.2] 52.5 1.7 45.8
Apramycin >16 6.8 [0.4-13.2] 89.8 3.4 6.8
Gentamicin >4 6.8 [0.4-13.2] 71.2 20.3 1.7 6.8
Neomycin >8 11.9 [3.6-20.1] 83.1 5.1 11.9
Streptomycin >16 68 [55.9-79.7] 28.8 3.4 11.9 15.3 40.7
Ciprofloxacin >2 0.0 [0-0] 6.8 8.5 1.7
Nalidixic acid >16 10 [2.5-17.9] 89.8 10.2
Colistin >8 0.0 [0-0] 100.0
Spectinomycin >64 42.4 [29.8-55] 45.8 6.8 5.1 6.8 35.6
Table 2: Distribution of MICs and resistance (%) in clinical Actinobacillus pleuropneumoniae from pigs (n=70), Denmark DANMAP 2016
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Textbox 6.2
DANMAP detecting emerging and rare resistances 
 
DANMAP reports % isolates resistant to each antimicrobial tested without presenting confidence intervals to extrapolate 
these to population such as isolates, samples or animals. Normally, the % resistant isolates will be an indication of the mean in 
the relevant population, because of the carefully designed sampling strategies. However, when DANMAP does not find any re-
sistance to a given antimicrobial agent, the outcome (0%) is harder to interpret. It is tempting to conclude that the resistance 
is not present in Denmark, but in reality the interpretation is complicated. 
To prove that a population is free from a specific disease, pathogen or resistance mechanism is nearly impossible. Firstly, tests 
are rarely 100% sensitive and may misclassify a few infected individuals and secondly, when testing only some individuals 
in a population, we are likely to miss infected animals if only few are infected. Instead, a zero-finding should be expressed in 
the context of the sample size and the level of confidence in the given result. The number of samples or isolates tested for 
resistance will determine the minimum prevalence that could have been present, without finding at least one resistant isolate 
or sample with 95% certainty. The minimum prevalence is called the detection limit or the design prevalence. When MIC test-
ing a number of isolates, the correct interpretation of a zero-finding would be: We can be 95% certain that xx resistance is not 
present in more than yy% of isolates.
Ideally, we would like to interpret the DANMAP outcomes in relation to the animal population or food type that was sampled, 
but since DANMAP only MIC tests one isolate per animal or food, making this leap would be equivalent to sampling one child in 
a school class for head lice, finding no lice and concluding that the whole class is free of head lice. Thus, we cannot interpret 
one isolate as representative for one animal/food sample, especially for indicator bacteria, where it is very likely that multiple 
isolates with different resistance patterns are present in one sample. 
Detection limits in DANMAP 2016 – the example: of carbapenem resistance 
Carbapenem resistance has not yet been identified in Danish animal or food reservoirs via DANMAP surveillance and the an-
timicrobial is not used in animals. Resistance is present in low levels in the human reservoir and has been detected in produc-
tion animals elsewhere in Europe. The risk factors for Danish production animals are not known, but likely introduction routes 
would be humans, imported animals and imported feed. 
Based on the current sampling plans, detection limits of carbapenem resistant bacteria were calculated using a probability 
formula to substantiate freedom from disease, when considering test sensitivity and a confidence of 95% [1]
Table 1. Detection limits for carbapenem resistance in susceptibility tested (MIC)  
isolates at 95% confidence, Denmark DANMAP 2016
Detection limit % 
Isolates Number of isolates Test sensitivity = 100% Test sensitivity = 85%
S. Typhimurium from pigs 56 5.2 6.1
S. Typhimurium from pork 51 5.7 6.7
Indicator E. coli from chicken 186 1.6 1.9
Indicator E. coli from cattle 121 2.5 2.9
E. coli ESBL from poultry[2] 48 6.1 7.1
E. coli ESBL from poultry meat[2] 52 5.6 6.6
Note: E. coli ESBL isolates from poultry and poultry meat detected by the EURL-AR protocol [2]for detection of cefotaxime-resistant E. coli and 
then tested by MIC 
DANMAP 201674
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Table 1 shows that we are 95% confident that carbapenem resistance in S. Typhimurium from pigs is less than 5.2% assuming 
the test sensitivity was 100%. If the test sensitivity of the MIC for meropenem is lower in S. Typhimurium e.g. 85%, we are 
95% certain that carbapenem resistance is not present in 6.1% or more of S. Typhimurium isolates from pigs. Similar results for 
indicator E. coli isolates from different sources are shown in Table 1. Since only one isolate from each sample was susceptibil-
ity tested, the estimates apply to carbapenem resistance in the population of bacterial isolates only, not the animals or meats.  
Some samples were examined for CPE directly via the EURL-AR protocol [2], which looks for carbapenem resistance directly in 
the sample by selective media rather than examining just one isolate. This expands our representativeness and the conclu-
sion now applies to the samples e.g. meat or animal rather than only to the bacterial isolates. We were now 95% certain that 
CPE was not present in 1% or more broiler caeca samples and 1.3% chicken meat samples, if the test was perfect (Table 2). At 
lower test sensitivity, the detection limits increased to 1.2% and 1.5% respectively. 
Understanding surveillance design and data is paramount to interpret its outcomes, as demonstrated by CPE resistance in 
Denmark. With the increasing prevalence of CPE and other rare resistances outside our borders in the EU, it is important to 
evaluate the surveillance programme’s ability to detect these and align detection levels with control action points. 
 
Table 2. Detection limits for carbapenem resistance in samples at 95% confidence, Denmark  DANMAP 2016
Detection limit % 
Samples Number of samples Test sensitivity = 100%  Test sensitivity = 85%
Broiler samples 298 1,0 1,2
Poultry meat samples 229 1,3 1,5
 
Note: Findings in poultry and poultry meat examined by EURL-AR protocol [2] for specific detection of carbapenemase producing E. coli by 
direct plating onto selective media
 
Johanne Ellis-Iversen and Helle Korsgaard
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7.1 Introduction 
Enterococci are included in the DANMAP programme to monitor 
resistance in Gram-positive bacteria, while Escherichia coli are 
included as representatives of Gram-negative bacteria. These 
bacteria species were selected as indicators for occurrence of 
antimicrobial resistance in the different reservoirs through the 
food chain for several reasons: they are ubiquitous and present 
as major commensals in both the animal and human reservoirs; 
they can acquire antimicrobial resistance as a response to 
antibiotic selective pressures, and finally they have the poten-
tial for transferring resistance to pathogenic bacteria and can 
cause infection in humans. From enterococci, both Enterococ-
cus faecium and Enterococcus faecalis were used since these 
species may acquire resistance to different antimicrobials. 
Extended-spectrum beta-lactamase producing (ESBL/AmpC) 
bacteria exhibiting resistance to 3rd generation cephalo-
sporins are one of the fastest emerging resistance problems 
in both humans and production animals worldwide. Lately, 
several studies have found similar ESBL/AmpC genes, plasmids 
and clones of E. coli isolates in animals, meat and human infec-
tions, suggesting a zoonotic link. Furthermore, the occurrence 
of carbapenemase-producing Enterobactericeae (CPE) is an 
even greater threat to human health, since carbapenems are 
the last-line antimicrobial agents for treatment of infections 
caused by multidrug-resistant Gram-negative bacteria.
E. faecalis, E. faecium and E. coli have been included in the 
DANMAP programme since 1995, where isolates were recov-
ered for antimicrobial susceptibility testing in samples from 
broilers, cattle and pigs. Sampling of fresh meat has been 
performed since 1997. Indicator enterococci and E. coli from 
healthy humans were collected from 2002 to 2005. Results 
from surveys of ESBL/AmpC-producing bacteria from animals 
and meat have been presented in DANMAP reports since 
2006-2007. Since 2014, sampling and testing of Enterococ-
cus, indicator E. coli and ESBL/AmpC-producing E. coli have 
been performed according to the EU harmonised monitoring 
of antimicrobial resistance [Decision 2013/652/EU]. In 2016, 
most of the sampling for indicator bacteria for DANMAP was 
allocated to the mandatory sampling of broilers; however, sam-
pling of fattening pigs and cattle were also conducted.
7. Resistance in indicator bacteria
    Highlights: In 2016, resistance to erythromycin and tetracycline was observed in 37% 
and 50% of the Enterococcus faecalis isolates from Danish broilers and has been increas-
ing since 2011. For the first time since DANMAP was established ciprofloxacin resistant E. 
faecalis (n=3) was isolated from Danish produced broilers. These three isolates were also 
resistant to tetracycline, maybe suggesting presence of a clone.
  Occurrence of fluoroquinolone resistance among indicator Escherichia coli from broilers 
and of sulfonamide and trimethoprim resistance among indicator E. coli from pigs increased 
from 2015. Approximately half of the indicator E. coli from broilers and pigs exhibited resis-
tance to at least one of the antimicrobial agents tested, whereas the proportion of antimi-
crobial resistant isolates was remarkably low in isolates from Danish cattle. 
  ESBL/AmpC-producing E. coli was recovered from 16% of the samples from broilers, from 
23% of the samples from domestically produced broiler meat and from 56% of the samples 
from imported broiler meat. The occurrence in broiler meat was comparable to the levels 
observed in 2015. CTX-M-1 was the most common enzyme in ESBL/AmpC- producing E. coli 
from Danish and imported broiler meat, whereas CMY-2 and upregulation of chromosomal 
AmpC expression were predominant in the isolates from broilers. A wide variety of ESBL/
AmpC-producing E. coli sequence types (ST) was identified across the three sources. Of con-
cern is the persistence in imported broiler meat of ST131 that harbour CMY-2, because of its 
potential implications in human infections. Due to the changes in methodology implemented 
in 2015 to enhance the sensitivity of the detection method, comparative evaluations and 
temporal trends between years should be done cautiously.
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7.2 Enterococci
For enterococci, DANMAP 2016 includes only randomly col-
lected Enterococcus faecalis isolates from healthy broilers 
(caecum samples) at slaughter. The antimicrobials recom-
mended by EFSA were used for susceptibility testing and MIC 
distributions and occurrence of resistance among E. faecalis 
from broilers are presented in the web annex (Table A7.1). The 
changes to the DANMAP sampling regime means that all reser-
voirs are no longer sampled each year, reducing the ability to 
spot changes on a yearly basis. 
7.2.1 E. faecalis from domestically produced broilers
A total of 119 E. faecalis isolates from broilers were selected 
from 621 samples and tested for antimicrobial susceptibility 
(Table 7.1). Approximately half of the isolates were resistant 
to tetracycline, 37% were resistant to erythromycin and 3% 
(n=3) were resistant to ciprofloxacin. Resistance to tetracy-
cline and erythromycin increased in prevalence.  (Figure 7.1). 
Ciprofloxacin-resistant E. faecalis from Danish broilers has not 
previously been observed in the DANMAP and the fact that all 
three ciprofloxacin-resistant isolates are also resistant to tetra-
cycline, may suggest the presence of a clone. 
Lars Bogø Jensen and Helle Korsgaard
 
 
7.3 Indicator Escherichia coli
All isolates were randomly collected from healthy pigs, broilers 
and cattle at slaughter (caecum samples). Only one isolate per 
farm was included. For details on methodology, see Chapter 9, 
Materials and Methods. Isolates were not collected from meat 
samples in 2016.
The antimicrobials recommended by EFSA were used for 
susceptibility testing and MIC distributions and occurrence of 
resistance among indicator E. coli are presented in the web 
annex (Table A7.2). These results were obtained using the 
non-selective isolation procedure. Results obtained by using 
selective enrichment procedures for detection of cefotaxime-
resistant E. coli are reported in section 7.4.
Antimicrobial agent Broilers
Danish
%
Tetracycline 53
Tigecycline 0
Chloramphenicol 2
Ampicillin 0
Erythromycin 37
Gentamicin 0
Ciprofloxacin 3
Vancomycin 0
Teicoplanin 0
Linezolid 0
Daptomycin 0
Number of isolates 119
Table 7.1. Resistance (%) among Enterococcus  
faecalis from broilers, Denmark DANMAP 2016
Figure 7.1. Resistance (%) among Enterococcus faecalis from broilers, Denmark DANMAP 2016
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7.3.1 Indicator E. coli from broilers 
A total of 186 indicator E. coli isolates from broilers were 
selected from 193 samples tested for antimicrobial suscep-
tibility (Table 7.2). Approximately half (56%) of these were 
susceptible to all antimicrobials tested. As in previous years, 
the highest occurrence of resistance was observed to ampicil-
lin, sulfonamide and trimethoprim (21-27%). Resistance to 
nalidixic acid, ciprofloxacin and tetracycline was moderate 
(13-16%), whereas resistance to the other compounds in the 
panel was 1-2% or not detected. Occurrence of nalidixic acid 
and ciprofloxacin resistance was significantly higher in E. coli 
from broilers compared to E. coli from pigs and cattle.
Compared to 2015, an increase in resistance to ciprofloxacin 
and a decrease in resistance to ampicillin, tetracycline, trim-
ethoprim and sulfonamide were observed (Figure 7.2), but the 
changes were not statistically signifcant. 
A total of 21 resistance profiles were detected among the 83 
resistant isolates. Co-resistance to ampicillin, sulfonamide and 
trimethoprim (ASuTm resistance profile) was the most common 
profile found in 19% of the resistant isolates.  In additional 
24% of the resistant isolates, the ASuTm resistance profile 
occurred in combination with other resistances.
Resistance to nalidixic acid and ciprofloxacin was observed 
either alone or together with resistance to other antimicrobial 
classes (15% and 16% of the resistant isolates, respectively). 
Eight isolates exhibited co-resistance to fluoroquinolones and 
ASuTm. One isolate exhibited co-resistance to ampicillin, 3rd 
generation cephalosporins, fluoroquinolones and tetracycline. 
Two other fluoroquinolone-resistant isolates exhibited co-
resistance to gentamicin either alone or in combination with 
the ASuTm resistance profile.
Of the three isolates resistant to 3rd generation cephalospo-
rins and clavulanic acid, one was only resistant to these. The 
other two isolates were co-resistant to ampicillin, tetracycline 
and sulphonamide, and ampicillin, fluoroquinolones and tetra-
cycline, respectively.
7.3.2 Indicator E. coli from pigs
A total of 145 indicator E. coli isolates from pigs were selected 
from 150 samples and tested for antimicrobial susceptibility 
(Table 7.2). Approximately half (46%) of the isolates from 
pigs were susceptible to all antimicrobials tested. Resistance 
to ampicillin, sulfonamide, tetracycline and trimethoprim was 
common (30-42%), whereas resistance to the other compounds 
occurred in 5% or less isolates. Colistin, meropenem and 
tigecycline resistance were not detected, suggesting that the 
true prevalence of these resistance phenotypes in E. coli from 
pigs is less than 2% (see Textbox 6.2 and Chapter 9, Materials 
and Methods, section 9.7.3). Occurrence of sulfonamide and 
tetracycline resistance was significantly higher in E. coli from 
pigs than in E. coli from broilers and cattle.
The levels of resistance were comparable to those observed 
in 2015 apart from an increase in resistance to sulphonamide 
and trimethoprim (Figure 7.2). The proportion of isolates re-
sistant to trimethoprim was the highest observed in DANMAP 
since 2008, when the current trimethoprim concentration 
range was introduced.
A total of 25 resistance profiles were detected. The ASuTm 
resistance profile was the most common and detected in 33% 
of the resistant isolates. The majority of isolates with this 
profile exhibited additional resistance to tetracycline alone or 
in combination with resistance to other antimicrobials includ-
ing fluoroquinolones in one isolate and gentamicin in three 
isolates. Third-generation cephalosporin resistance was found 
only in two isolates not expressing resistance to any non-beta-
lactam antibiotic. 
7.3.3 Indicator E. coli from cattle 
A total of 121 indicator E. coli isolates from cattle were se-
lected from 121 samples and tested for antimicrobial suscep-
tibility (Table 7.2). The vast majority of isolates (93%) was 
susceptible to all tested antimicrobials. Ampicillin, chloram-
phenicol, sulfonamide and tetracycline resistance levels were 
low, and no resistance to the remaining antimicrobials tested 
was detected. Occurrence of resistance in 2016 was compa-
rable or slightly lower than in 2015, except for a statistically 
significant decrease in trimethoprim resistance. Five resistance 
profiles were detected. Two profiles consisted of resistance to 
one antimicrobial only (ampicillin or tetracycline resistance). 
Resistance to ampicillin, chloramphenicol, sulfonamide and tet-
racycline was the most common profile of resistance to more 
than one drug detected in 2% (n=3) of isolates.
Antimicrobial agent
Broilers Cattle Pigs
Danish
%
Danish
%
Danish
%
Tetracycline 16 6 34
Tigecycline 0 0 0
Chloramphenicol 2 3 5
Ampicillin 27 5 32
Cefotaxime 1 0 <1
Ceftazidime 1 0 <1
Meropenem 0 0 0
Trimethoprim 21 0 30
Sulfonamide 27 5 42
Azithromycin 0 0 2
Gentamicin 1 0 2
Ciprofloxacin 13 0 1
Nalidixic acid 13 0 1
Colistin 0 0 0
Number of isolates 186 121 145
Table 7.2. Resistance (%) among Escherichia coli  
from animals, Denmark DANMAP 2016
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Figure 7.2. Resistance (%) among E. coli from animals, Denmark DANMAP 2016
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7.4 Extended spectrum beta-lactamase (ESBL), AmpC 
and carbapenemase-producing E. coli
DANMAP 2016 includes ESBL/AmpC- and carbapenemase-
producing E. coli (CPE) from broilers at slaughter (caecal 
samples) and from broiler meat at retail (Danish and imported). 
Samples were collected randomly and analysed using selective 
enrichment procedures for detection of cefotaxime-resistant 
E. coli as well as CPE (including strains producing OXA-48-like 
enzymes) as described in the EURL-AR protocol for detection 
of ESBL/AmpC- and CPE. Whole genome sequencing (WGS) and 
in silico bioinformatics tools were used to determine geno-
types. For details on methodology, see Chapter 9, Materials 
and Methods.
7.4.1 ESBL/AmpC and carbapenemase-producing E. coli 
from broilers and domestically produced broiler meat
A total of 298 samples from broilers and 229 samples from 
domestically produced broiler meat resulted in 48 (16%) and 
52 (23%) isolates, respectively (Table 7.3). Most samples were 
also specifically examined for CPE and no CPE isolates were 
recovered.
Among the 48 ESBL/AmpC-producing E. coli isolates from 
broilers, 38% exhibited an ESBL phenotype, 58% exhibited 
an AmpC phenotype and 2% (n=1) exhibited both ESBL and 
AmpC phenotype. All isolates were resistant to ampicillin and 
3rd generation cephalosporins, and co-resistance was observed 
i) to tetracycline in more than half of the isolates (56%), ii) to 
sulfonamides in 42% of the isolates and iii) to trimethoprim in 
23% of the isolates. Co-resistance to ciprofloxacin was found 
in 40% (n=19) of the isolates, and 16 of these were also resis-
tant to nalidixic acid. Only a few isolates were co-resistant to 
gentamicin (8%, n=4) and azithromycin (2%, n=1). None of the 
isolates was co-resistant to colistin, tigecycline and carbapen-
ems. 
Among the 52 isolates from domestically produced broiler 
meat, the AmpC phenotype (65%) was more common than the 
ESBL phenotype (35%). The CPE phenotype was not observed. 
The isolates from domestically produced broiler meat exhibited 
similar co-resistance patterns and levels of resistance as the 
isolates from broilers, with the exception of significantly lower 
occurrence of co-resistance to fluoroquinolones and cefoxitin, 
and higher occurrence of co-resistance to cefepime and sulfon-
amides. None of the isolates was co-resistant to azithromycin 
and carbapenems (Table 7.3). 
The occurrence of ESBL/AmpC-producing E. coli in domestically 
produced broiler meat in 2016 was similar to the occurrence in 
2015 (23% and 26%, respectively)(Figure 7.3). However, when 
evaluating the trend over time, it must be taken into account 
that the presumptive ESBL/AmpC E. coli from 2015 were not 
further confirmed by susceptibility testing, and only 28 (12%) 
of the ESBL/AmpC phenotypic isolates were verified by WGS. 
No further historical comparisons could be carried out due to 
changes in methodology (Decision 2013/652/EU).
7.4.2 ESBL/AmpC and carbapenemase-producing E. coli 
from imported broiler meat
A total of 66 samples from imported broiler meat resulted in 
37 (56%) ESBL/AmpC isolates (Table 7.3), which was signifi-
cantly higher than the 23% positive samples from domestic 
broiler meat. Most samples (n=63) were also specifically exam-
ined for CPE and no CPE isolates were recovered. 
The ESBL phenotype (73%) was more common that the AmpC 
phenotype (24%) among the 37 isolates from imported 
broiler meat. One isolate exhibited both ESBL and AmpC phe-
notype. Generally, the levels of co-resistance were comparable 
to those observed in ESBL/AmpC isolates originating from 
domestically produced broiler meat apart from a higher propor-
tion of isolates co-resistant to fluoroquinolones (Table 7.3). 
Low level carbapenem (ertapenem) resistance was observed 
among the ESBL/AmpC–producing isolates.
Antimicrobial agent
Broiler Broiler meat
Danish
%
Danish
%
Imported
%
Tetracycline 56 44 65
Tigecycline 0 0 0
Chloramphenicol 10 10 8
Ampicillin 100 100 100
Cefoxitin 63 35 27
Cefotaxime 100 100 100
Ceftazidime 100 100 97
Cefepime 67 90 97
Meropenem 0 0 0
Ertapenem 0 0 5
Imipenem 0 0 0
Trimethoprim 23 39 30
Sulfonamide 42 73 73
Azithromycin 2 0 0
Gentamicin 8 14 14
Ciprofloxacin 40 15 41
Nalidixic acid 33 15 38
Colistin 0 0 0
ESBL phenotypes 38 65 73
AmpC phenotypes 58 35 24
ESBL/AmpC phenotypes 2 0 3
CPE phenotypes 0 0 0
Other phenotypes 2 0 0
Number of isolates 48 52 37
Number of samples 298 229 66
Table 7.3. Resistance (%) and 3rd gen.-cephalosporin resistance 
phenotype among ESBL/AmpC-producing Escherichia coli from 
broilers and meat thereof, Denmark DANMAP 2016
Note: Isolates recovered by the selective enrichment methods 
described in the EURL-AR laboratory protocol (October 2015)
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The occurrence of ESBL/AmpC-producing E. coli in imported 
broiler meat in 2016 was comparable to the 64 % found in 
2015 (Figure 7.3). Further historical comparisons were not 
carried out due to changes in methodology over the last few 
years. 
7.4.3 ESBL/AmpC enzymes detected in E. coli isolates 
from broilers and domestically produced broiler meat
From broilers, only 34 of the 48 ESBL/AmpC-producing E. coli 
were sequenced. ESBL/AmpC enzymes were detected in all 34 
isolates and one isolate had two different enzymes (Table 7.4). 
Among the 34 ESBL/AmpC-producing E. coli isolates from 
broilers, CMY-2 (n=12) was the most common enzyme and 
was detected in isolates belonging to nine sequence types 
(ST); including ST429 (n=3), ST1286 (n=2) and ST10, ST295, 
ST371, ST718, ST1056, ST2040, and ST4663 (one isolate 
each). Additional 11 isolates expressing the AmpC phenotype 
by upregulation of chromosomal ampC expression belonged 
to ST4663 (n=9), ST23 (n=1) and an unknown ST (n=1). The 
CTX-M-1-encoding gene was the most common ESBL gene 
detected in seven isolates (belonging to five STs; ST752 and 
ST4980 (two isolates each), and ST162, ST1640, and ST1850 
(one isolate each). One ST57 isolate carried the gene encoding 
SHV-12. Four isolates producing TEM-52B/C belonged pairwise 
to ST115 and ST155 (Figure 7.4). 
All 52 ESBL/AmpC-producing E. coli isolates from domesti-
cally produced broiler meat were available for sequencing 
and ESBL/AmpC enzymes were detected in all strains (Table 
7.4). The predominance of CTX-M-1 in isolates in domestic-
produced broiler meat seemed to continue in 2016 followed 
by CMY-2 enzymes, which were the most frequent resistance 
determinants until 2014 (Table 7.4).
Among the 52 ESBL/AmpC-producing E. coli isolates from 
domestically produced broiler meat, more than half harboured 
the CTX-M-1-encoding gene (n=22) and belonged to seven 
STs; ST4980 (n=14), ST295 (n=2), ST57, ST117, ST155, 
ST351,ST1463, and an unknown ST (one isolate each). CMY-
2-encoding gene (n=16) and upregulation of chromosomal 
ampC expression (n=3) were observed in strains belonging to 
ST429 (n=8), ST10 (n=3), ST155, ST355, ST1011, ST1144, 
and ST1640 and ST120, ST4512, and unknown ST (one 
isolate each). All four SHV-12 enzymes belonged to ST57 
whereas the seven isolates harbouring the TEM-52B-encoding 
gene belonged to ST155 (n=6) and ST5183 (Figure 7.4). 
Eight STs out of 28 were observed in both broilers and do-
mestically produced broiler meat: ST10, ST57, ST155, ST295, 
ST429, ST1640, ST4980, and an unknown ST. Three of these 
STs were linked to one enzyme: ST10 and ST429 associated 
with CMY-2, and ST4980 associated with CTX-M-1. 
Of the 10 different STs associated with CTX-M-1 in domesti-
cally produced broiler meat in 2015, only ST295 and ST4980 
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Figure 7.3. Occurrence (%) of samples with Escherichia coli from broiler meat, cattle and  
pigs containing ESBL and AmpC enzymes, Denmark  DANMAP 2016
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were also found in 2016. In 2015, two isolates of ST295 and 
three isolates of ST4980 were found. In 2016, two isolates 
of ST295 and 14 isolates of ST4980 were detected, thus 
suggesting clones persisting over time. No similarities were 
observed among STs associated with CMY-2 and upregulation 
of chromosomal ampC in 2015 and 2016.
7.4.4 ESBL/AmpC enzymes detected in Escherichia coli 
isolates from imported broiler meat
All 37 ESBL/AmpC-producing E. coli isolates from imported 
broiler meat were sequenced. ESBL/AmpC enzymes were 
detected in all strains and six different ESBL/AmpC genes or 
mutations were identified (Table 7.4).
Among the 37 ESBL/AmpC-producing E. coli isolates from 
imported broiler meat the CTX-M-1-encoding gene (n=22) 
was the most common and occurred in isolates belonging to 
12 STs; three isolates of each of ST10, ST38, and ST212, two 
isolates of each of ST57, ST93, ST155 and ST515, and one 
isolates each of ST48, ST746, ST1011, ST4512 and ST5363 
(Figure 7.4). One CTX-M-14b isolate belonged to ST1011, 
and three SHV-12 isolates belonged to ST117, ST1944, and 
ST57 (one isolate each). CMY-2-producing E. coli (n=8) and E. 
coli with upregulation of chromosomal ampC expression (n=1) 
were observed in strains belonging to ST131, ST429, ST1706, 
ST2701 and unknown STs. As in 2015, the important human 
pathogen E. coli ST131 was observed among the imported 
broiler meat isolates. Persistence of this E. coli clone as well 
as its increasing occurrence among poultry sources and human 
infections in other European countries raise some concern. 
Comparing strains from imported broiler meat and domestically 
produced broilers and meat thereof, ST429 coding for CMY-2 
was present in all three sources.
7.4.5 Perspectives 
In general, the most common ESBL/AmpC enzymes identified 
across the broiler sources were the ESBL enzyme CTX-M-1 
and the AmpC enzyme CMY-2. CTX-M-1 was the most com-
mon enzyme in E. coli from Danish and imported broiler meat. 
The CMY-2 and upregulation of chromosomal ampC expression 
were the most common genotypes detected in ESBL/AmpC E. 
coli from Danish broilers. In the previous surveys from 2009 to 
2013, CMY-2 was the predominant enzyme among the ESBL/
AmpC E. coli isolates from domestically produced and imported 
broiler meat. However, in the surveys from 2014 to 2016, CTX-
M-1 became increasingly prevalent [DANMAP 2014 and 2015].
Large variation of the E. coli STs harbouring the ESBL/AmpC 
genes or mutations leading to chromosomal ampC overexpres-
sion was observed across the three sources of isolates. A few 
STs producing the same ESBL/AmpC enzyme were present in 
both domestically produced broilers and meat thereof. Similar-
ly, a few identical STs were observed between Danish and im-
ported broiler meat, though the ESBL/AmpC enzymes produced 
were not always identical. Of concern is the persistence of a 
low number of E. coli ST131 that harbour CMY-2 in imported 
broiler meat due to its possible role in human infections. This 
ST type was not found in Danish broilers or meat thereof. 
Valeria Bortolaia, Rene S. Hendriksen and Helle Korsgaard
Table 7.4. Distribution (%) of ESBL and AmpC enzymes detected 
in E. coli isolates(b) from animals and meat of Danish and 
imported origin, Denmark DANMAP 2016
Enzyme
Broilers Broiler meat
Danish 
%
Danish 
%
Imported
%
CMY-2 34 31 22
CTX-M-1 20 42 59
CTX-M-14b 0 0 3
SHV-12 3 8 8
TEM-52B 9 13 5
TEM-52C 3 0 0
Up-reg. AmpC 31 6 3
Total number of :
Enzymes 35 52 37
Number of isolates 34 52 37
ESC positive samples (a) 48 52 37
Samples tested 298 229 66
Note: Proportion of total number of enzymes. In one isolate from 
broilers, chromosomal ampC upregulation and CMY-2 co-existed 
(a) Total number of enzymes present. Each enzyme is counted based 
on the number of strains in which it is present and not based on the 
type (e.g. CTX-M-1 present in two strains counts as 2) 
(b) Samples were processed according to the EURL-AR laboratory 
protocol (October 2015), thus number of samples and number of 
isolate coincide. Whole genome sequencing was only performed on 
a selection of the presumptive ESBL/AmpC from broilers (34 of 48 
isolates)
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Figure 7.4. Distribution (%) of ESBL and AmpC enzymes in E. coli MLST types in isolates from broilers and broiler meat, Denmark
 DANMAP 2016
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Textbox 7.1 
ESBL/pAmpC-producing Escherichia coli - comparison of isolates of 
animal origin with isolates obtained from human bloodstream infections
 
Background: ESBL/pAmpC-producing bacteria are widespread in both humans and production animals worldwide. Studies 
have found similar ESBL/pAmpC genes, plasmids and clones of E. coli in animals, meat and human infections, suggesting a 
zoonotic link.
Materials and methods: ESBL/pAmpC-producing E. coli isolates from production animals and meat (section 7.4) obtained in 
2015 and 2016 were compared with ESBL/pAmpC-producing E. coli isolates from human bloodstream infections (Textbox 8.1) ob-
tained during 2016. For isolates sharing the same combination of ESBL/pAmpC genes and sequence types (STs), clonal relation-
ships were investigated by whole-genome-based SNPs analyses. The combination was further investigated if < 100 SNPs were 
observed between isolates from animal and human origin. Thus, six ST131 CMY-2-producing E. coli isolates were compared with 
309 ST131 ESBL/pAmpC-producing E. coli isolates obtained from 2015 and 2016 (DANMAP 2015 and Textbox 8.1).
Results: On five occasions, the same combinations of ESBL/pAmpC genes and STs were detected in E. coli of human and ani-
mal origin; ST131 CMY-2-producing E. coli isolates, CTX-M-1-producing E. coli belonging to ST1431, ST23 or ST767, and ST12 
CTX-M-14-producing E. coli isolates. SNP-based comparisons were performed for each of the five combinations.
The ST131 CMY-2-producing E. coli isolates represented five isolates from imported broiler meat (three isolates from 2016 
and two from 2015) and one human bloodstream isolate from 2016 (Figure A7.1 SNP phylogeny of ST131 CMY-2, web annex). 
Between the E. coli isolate of human origin and the five E. coli isolates from broiler meat, a range of 78-206 SNPs were de-
tected. Comparing the six ST131 CMY-producing isolates with the 309 ST131 E. coli isolates from bloodstream infections from 
2015-2016 in Denmark, a distinct clade with these six CMY-2-producing E. coli isolates was observed (Figure A7.2, ST131 and 
ST12, web annex).
The ST1431 CTX-M-1-producing E. coli encompassed one imported broiler meat isolate from 2015 and one human blood-
stream isolate from 2016, with 3,756 SNPs detected between them.
The ST23 CTX-M-1-producing E. coli represented one isolate from a pig caecal sample from 2015 and one human bloodstream 
infection isolate, which differed by 3,389 SNPs.
The ST767 CTX-M-1-producing E. coli represented one isolate from pork from 2015 and one human bloodstream infection 
isolate from 2016, which differed by 640 SNPs.
The ST12 CTX-M-14-producing E. coli encompassed one pig isolate from 2015 and eight human bloodstream isolates from 2016 
(Figure ST12 CTX-M-14, web annex). More than 900 SNPs were detected between the pig isolate and the human isolates.
Discussion and conclusion: ST131 E. coli has been the most frequently detected ST among the ESBL/pAmpC-producing E. coli 
isolates from human bloodstream infections in Denmark in the past years, with most of them being CTX-M-15-producers (Textbox 
8.1). In 2016, an ST131 CMY-2-producing E. coli was observed for the first time causing bloodstream infection in a Danish patient. 
The pAmpC enzyme CMY-2 has often been detected among E. coli of animal origin in Denmark, but only rarely for E. coli 
belonging to ST131. During 2015-2016, five ST131 CMY-2-producing E. coli were detected from imported broiler meat by the 
DANMAP surveillance [DANMAP 2015, section 7.4], and when investigating the clonal relationship to the ST131 CMY-2-pro-
ducing E. coli human bloodstream isolates, the pairwise comparison did not indicate any direct link. However, when broadening 
the comparison to include all known ST131 E. coli cases from bloodstream infections in Denmark during 2015-2016 in a phylo-
genetic analysis, it appears that the six ST131 CMY-2-producing E. coli constitute a sub-clone, thus suggesting a potential 
zoonotic link between imported broiler meat and bloodstream infections in humans.
SNP analysis did not support indications of any zoonotic link for the other ESBL/pAmpC-producing E. coli isolates with the 
same combination of ST obtained from both human and animal samples (CTX-M-1-producing isolates belonging to ST1431, 
ST23, or ST767, and CTX-M-14 belonging to ST12), as no similar SNP profiles were detected 
The observation of phylogenetically related ST131 CMY-2 E. coli from imported meat and from a human bloodstream infection 
should be noted. However, larger studies are needed to investigate and quantify the possible zoonotic link between ESBL/
pAmpC-producing E. coli from meat/animals and human severe infections.
Louise Roer, Anette M. Hammerum, Marc Stegger, Helle Korsgaard, Valeria Bortolaia, 
Pimlapas Leekitcharoenphon, Henrik Hasman and Rene S. Hendriksen
For further information for the human isolates: Anette M. Hammerum (ama@ssi.dk) 
For further information for the meat isolates: Rene S. Hendriksen (rshe@food.dtu.dk)
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8. Resistance in human clinical bacteria
   Highlights:  DANMAP 2016 includes resistance data from human invasive infections (iso-
lates from blood and cerebrospinal fluid) reported from the Danish clinical microbiological departments 
for the last decade. In general, the number of blood isolates has increased during the last ten years, while 
resistance rates for most invasive species show decreasing trends. This is not the case for the multi-
resistant species isolated from other clinical samples, eg carbapenemase-producing organisms (CPO) and 
methicillin-resistant Staphylococcus aureus (MRSA) as well as for vancomycin-resistant enterococci (VRE) 
from all clinical samples. For all of these, the increasing trends observed during the last years continued 
(textboxes 8.1, 8.2, 8.3 and 8.4 and section 8.7). 
For Escherichia coli, resistance data for isolates from blood stream infections showed a significant 
increase in the resistance rates to gentamicin, and cefuroxim for 2007 to 2016. In 2016 the resistance 
to gentamicin was 6%, ciprofloxacin 11%, cefuroxime 9%, and 3rd generation cephalosporins 7%, respec-
tively. One carbapenemase-resistant and two intermediary resistant E.coli isolates were reported. In urine 
cultures, a significant increase in the proportion of ciprofloxacin E. coli isolates was reported since 2007, 
however with a decrease and stabilization since 2009 reported from both hospital samples and samples 
from primary health care, respectively.
For Klebsiella pneumoniae, a significant decrease in the resistance rates in blood isolates to gentamicin, 
ciprofloxacin, and cefuroxim was observed from 2008 to 2016. In 2016 the resistance to gentamicin was 
3%, ciprofloxacin 5%, cefuroxime 11%, and 3rd generation cephalosporins 7%, respectively. Three car-
bapenemase-resistant and one intermediary resistant K.pneumoniae isolates were reported. In urine cul-
tures, the proportions of ciprofloxacin-resistant and 3rd generation cephalosporin-resistant K.pneumoniae 
isolates have decreased since 2009.
Enterococci isolates from bloodstream infections were, together with Streptococcus pneumonia, the only 
species were a slight decline in the number of isolates reported was observed for 2016. In general the 
number of bloodstream infections with E. faecium has increased during the last decade from 352 in 2007 
to 692 in 2016, while the number of infections with E. faecalis has fluctuated slightly but remained more 
or less stable around 600 (606 in 2016). Thus, the ratio between bloodstream infections with E. faecalis 
and E. faecium has changes considerably from 1.6 in 2007 to 0.9 in 2016. The prevalence of vancomycin-
resistant E. faecium in isolates from bloodstream infections was 7.3% in 2016 compared to 0.6% in 2007. 
None vancomycin-resistant E. faecalis were reported. Linezolid-resistance was reported in one of each 
species for 2016. 
DANMAP 2016 includes for the first time, the numbers of highly resistant Acinetobacter spp. isolates 
from human bloodstream infections. During 2012 to 2016 between 69 and 83 Acinetobacter blood iso-
lates were reported annually. In this period the resistance rates to ciprofloxacin, gentamicin and merope-
nem decreased significantly, thus in 2012, ten isolates were resistant to either one or more of the three 
tested agents (corresponding to 10-12%), in 2016 two isolates were resistant to ciprofloxacin (3%), while 
none of the invasive isolates were resistant to meropenem. In contrast, 26 carbapenemase-producing A. 
baumannii from other clinical sites (all specimen types) were sent to SSI for wholegenome-sequencing, 
which is an increase from 19 isolates sent in 2015 (see textbox 8.2 for further information). 
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Introduction
Statens Serum Institut receives data on 
the resistance in isolates for the seven 
most frequently occuring species obtained 
from human invasive infections, either 
obtained from blood or cerebrospinal fluid. 
These include: Escherichia coli, Staphylo-
coccus aureus, Streptococcus pneumoniae, 
Klebsiella pneumoniae, Pseudomonas 
aeruginosa, Enterococcus faecium and 
Enterococcus faecalis. For all species the 
first isolate per patient per year is report-
ed, which corresponds to the method used 
by Ears-Net. All reporting is performed by 
the Danish Clinical Microbiological Depart-
ments (DCM) situated at regional hospi-
tals. Data is reported once yearly. Until 
2009 all invasive infections were counted 
in 30-day periods. Since only a very minor 
part of the patients has recurring periods 
of bacteraemia within one calendar year, the difference in the 
number of patients and species between the two methods is 
negligible and is thus not commented on in this chapter. 
In addition to the reporting of data, for several species strains 
are also sent to the reference laboratory at SSI for descrip-
tive and/or surveillance purposes. For invasive infections with 
Streptococcus pneumoniae surveillance is mandatory. For 
invasive infections with either  Staphylococcus aureus, beta-
haemolytic streptococci or ESBL-producing E. coli as well as for 
carbapenemase-producing organisms (CPO) and vancomycin-
resistant enterococci (VRE) from all clinical sites and samples 
strains are referred to the reference laboratory on a voluntary  
basis. Finally, the submission of all clinical strains of methicillin- 
resistant S. aureus (MRSA) and Neisseria gonorrhoea is also 
mandatory.
In 2016, the number of DCM changed from 11 to 10, but in 
most chapters in this DANMAP report we still refer to 11 DCM, 
since the reporting on many strains continued as usual from 
the different geographical settings.  
From 2009 until 2014, DANMAP received data from all but 
one DCM, covering approximately 95% of the population; from 
2015 all DCM had joined the reporting thus giving coverage of 
the total Danish population. From 2009 to 2016, the number 
of isolates reported increased by 26%, from altogether 8,277 
to 10,442 isolates. The biggest increase observed was for E. 
faecium with 65 %, followed by K. pneumoniae, S. aureus and 
E. coli with 41%, 40% and 37%, respectively. Ps. Aeruginosa 
increased with 7%, while S. pneumoniae and E. faecalis de-
creased with – 27% and – 11%, respectively. Figure 8A shows 
the changes in the distribution of species among the invasive 
isolates reported for 2009 and 2016, respectively. Figure 8B 
shows the trends from 2009 to 2016, E. coli accounts for al-
most 50% of the cases. The increases can neither be explained 
through changes in the reporting nor through increases in the 
population size alone (which increased from 5.5 million to 5.7 
million inhabitants corresponding to an increase of 3.6%), but 
probably also other important factors contribute: demographic 
changes with a growing population of elderly, changes in 
hospital workflow with more blood culturing bottles taken per 
patient and finally changes in logistics with more effective 
transport of the samples to microbiological laboratories as well 
as improved culturing systems.
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8.1 Escherichia coli
Escherichia coli (E. coli) is the most frequent cause of com-
munity- and hospital acquired urinary tract infections and of 
bacteraemia in Denmark. It is part of the normal intestinal 
flora in both animals and humans, where it comes into close 
proximity to many other bacterial species. Transferred resis-
tance mechanisms from other bacterial species to E. coli are 
frequently seen. Some E. coli contain virulence factors that 
dispose for gastrointestinal illnesses of varying severity, such 
as traveller’s diarrhoea and gastrointestinal illness associated 
with the development of haemolytic uremic syndrome.
As for 2015, DANMAP received resistance data from all 11 De-
partments of Clinical Microbiology (DCM) in Denmark for 2016, 
thus representing 100% of the Danish population.
8.1.1 Blood isolates from hospital patients  
For 2016, DANMAP received data on the antibiotic susceptibil-
ity of 4,841 E. coli isolates from blood cultures from all 11 DCM 
in Denmark. Eight of the 11 DCM routinely tested for mecil-
linam resistance (> 75% of isolates) and all 11 DCM routinely 
tested for all the other presented antibiotics (Table 8.1.1). As 
in previous years resistance testing was mainly performed 
by disc diffusion. The presented data consist of the reported 
interpretation results, performed by the DCM and based on the 
S-I-R system.
A continuous increase in the number of E. coli isolates from 
blood cultures was observed throughout the years (Figure 
8.1.1). As discussed in the introduction, this may be caused by 
several factors such as, demographic changes, improved cultur-
ing methods and changes in hospital workflow. 
Overall, there was a tendency towards a more stationary 
resistance level for the last four to seven years (Figure 8.1.1). 
The same pattern was observed when looking at the concrete 
numbers of resistant E. coli blood isolates instead of the pro-
portional resistances (data not presented). For gentamicin and 
cefuroxime, resistance has increased significantly since 2007, 
from 3.9% to 6.1% and 5.7% to 8.6%, respectively (Table 8.1.1). 
The resistance towards ciprofloxacin was 11% and is now 
at the same level as in 2007 after the peak of 13% in 2009. 
This trend mirrors the pattern in consumption, where also a 
decrease in the overall use of ciprofloxacin has been observed 
since 2009 (p. 38, table 5.1). Interestingly, the proportion of 
reported ciprofloxacin resistant invasive E. coli isolates varied 
significantly between some of the DCM, with 27% as the high-
est resistance level and 4.1% as the lowest resistance level 
reported. Likewise, there was a significant discrepancy in the 
reported resistance level towards piperacillin/tazobactam, with 
the highest proportion being 8.6% and the lowest proportion 
being <1%. These data are based on the interpretations of the 
individual DCM’s, where local interpretation rules may apply. 
HUSK Neo Sans 8pt. Ændre til 100% sort - rammer 50% sort
0
2
4
6
8
10
12
14
16
07 08 09 10 11 12 13 14 15 16
%
 re
si
st
an
t 
is
ol
at
es
Cefuroxime (n=40055)
Ciprofloxacin (n=45007)
Gentamicin (n=44901)
3rd gen. cephalosporin (n=44915)
Mecillinam
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0
2
4
6
8
10
12
14
16
07 08 09 10 11 12 13 14 15 16
%
 re
si
st
an
t 
is
ol
at
es
Piperacillin/tazobactam (n=4,834)
Gentamicin (n=4,838)
Ciprofloxacin (n=4,820)
Cefuroxime (n=4,825)
3rd gen. cephalosporin (n=4,782)
Carbapenem (n=4,823)
Number of positive blood isolates
N
um
be
r o
f 
po
si
ti
ve
 b
lo
od
 is
ol
at
es
0
10
20
30
40
50
06 07 08 09 10 11 12 13 14 15 16
%
 re
si
st
an
t 
is
ol
at
es
Ampicillin (n=67,600)
Sulfonamide (n=44,432)
Ciprofloxacin (n=67,256)
3rd gen. cephalosporin (n=67,448)
0
2
4
6
8
10
12
14
16
07 08 09 10 11 12 13 14 15 16
%
 r
es
is
ta
nt
 i
so
la
te
s
Cefuroxime (n=40,055)
Ciprofloxacin (n=45,007)
Gentamicin (n=44,901)
3rd gen. cephalosporin (n=44,915)
HUSK Neo Sans 8pt. Ændre til 100% sort - rammer 50% sort
0
2
4
6
8
10
12
14
16
07 08 09 10 11 12 13 14 15 16
%
 re
si
st
an
t 
is
ol
at
es
Cefuroxime (n=40055)
Ciprofloxacin (n=45007)
Gentamicin (n=44901)
3rd gen. cephalosporin (n=44915)
Mecillinam
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0
2
4
6
8
10
12
14
16
07 08 09 10 11 12 13 14 15 16
%
 re
si
st
an
t 
is
ol
at
es
Piperacillin/tazobactam (n=4,834)
Gentamicin (n=4,838)
Ciprofloxacin (n=4,820)
Cefuroxime (n=4,825)
3rd gen. cephalosporin (n=4,782)
Carbapenem (n=4,823)
Number of positive blood isolates
N
um
be
r o
f 
po
si
ti
ve
 b
lo
od
 is
ol
at
es
0
10
20
30
40
50
06 07 08 09 10 11 12 13 14 15 16
%
 re
si
st
an
t 
is
ol
at
es
Ampicillin (n=67,600)
Sulfonamide (n=44,432)
Ciprofloxacin (n=67,256)
3rd gen. cephalosporin (n=67,448)
0
2
4
6
8
10
12
14
16
07 08 09 10 11 12 13 14 15 16
%
 r
es
is
ta
nt
 i
so
la
te
s
Cefuroxime (n=40,055)
Ciprofloxacin (n=45,007)
Gentamicin (n=44,901)
3rd gen. cephalosporin (n=44,915)
Figure 8.1.1 Resistance (%) in Escherichia coli  
invasive isolates from humans, Denmark  DANMAP 2016
Figure 8.1.2 Resistance (%) in Escherichia coli urine  
isolates from humans in hospitals, Denmark  DANMAP 2016
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2016 
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2016
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We assume that especially the interdepartmental variance in 
piperacillin/tazobactam resistance would be smaller, if a stan-
dardized interpretation method was to be used. Still, local dif-
ferences in resistance levels probably exist, and should be kept 
in mind in the development of empirical antibiotic guidelines.
The number of carbapenem (including meropenem) resistant 
E. coli isolates is continuously very low (Figure 8.1.1) with 
only one carbapenem resistant and two intermediary resis-
tant E. coli isolates reported in 2016. In 2015, there were 
one carbapenem resistant and five intermediary resistant E. 
coli (DANMAP 2015). Although still at a low level, the risk of 
increasing levels of carbapenem resistance in the future is 
worrisome. A larger proportion of isolates (1.6–2.0% through 
the years 2014–2016) had combined resistance to 3rd genera-
tion cephalosporins, ciprofloxacin, and gentamicin (hereafter 
referred to as multi-resistant) (Table 8.1.2). Fewer than 75% of 
all isolates were tested for all three antibiotics before 2014, so 
the previous level of multi-resistance is not known. Situations 
may arise in the future in which only colistin, tigecykline and 
phosphomycin are left as treatment options for patients with 
severe E. coli infections. Susceptibility testing towards these 
antibiotics are not routinely done in Denmark. One colistin 
resistant E. coli isolate from 2015 was detected through whole 
genome-sequencing of all referred resistant strains from Dan-
ish human blood cultures from 2014 to 2016. 
The overall resistance level towards mecillinam was 13%, 
which was a significant increase compared with 2007 and 
2015 (Table 8.1.1). However, some DCM only performed mecil-
linam resistance testing on very few isolates and others re-
ported resistance data using more restrictive breakpoints than 
EUCAST. As discussed in DANMAP 2015, even though it is not 
optimal for surveillance purposes, more restrictive breakpoints 
may be sensible in a clinical situation. As in previous years, 
approximately half of all E. coli isolates were resistant towards 
ampicillin (Table 8.1, DANMAP 2015).
8.1.2 Urine isolates from hospital patients 
For 2016, results of resistance testing were submitted to 
DANMAP from all 11 DCM for altogether 46,865 E. coli isolates, 
cultured in urine samples from hospitalised patients. All 11 DCM 
routinely tested their E. coli urine isolates from hospitalised 
patients for resistance to mecillinam and gentamicin; 10 DCM 
routinely tested for resistance to ampicillin, ciprofloxacin, cefu-
roxime, and 3rd generation cephalosporins; nine DCM routinely 
tested for piperacillin/tazobactam resistance; eight DCM rou-
tinely tested for carbapenem resistance; and six DCM routinely 
tested for sulfonamide resistance. Overall, the proportions of 
isolates tested at the different DCM varied for the different 
antibiotics, from 100% (mecillinam) to 60% (sulfonamide).
Throughout the years, there has been a slight but significant 
increase in the proportions of resistance towards cefuroxime 
and gentamicin, from 4.0% in 2008 to 6.8% in 2016 and from 
3.7% in 2010 to 5.3% in 2016, respectively (Figure 8.1.2). The 
proportion of resistance to 3rd generation cephalosporins has 
not changed since 2009 and was 5.9% in 2016. After a steep 
increase in the proportion of ciprofloxacin resistance observed 
from 8.4% in 2007 to 13% in 2011, the proportion of resis-
tance has decreased slightly ever since and reached 11% in 
2016. This is still significantly higher compared to the level in 
2007 (Table 8.1.1). In contrast to 2015, there was a slight but 
significant decrease in the proportion of piperacillin/tazobac-
tam resistance (DANMAP 2015, Table 8.1). The reason for this 
is not known.
Table 8.1.1 Resistance (%) in Escherichia coli isolates from humans, Denmark 2016 DANMAP 2016
Substance
Blood isolates, hospitals
%
Urine isolates, hospitals
%
Urine isolates, primary health care
%
Ampicillin 45 41# 38$
Mecillinam 13* ¤ 7$ 6¤
Piperacillin/tazobactam 4 3# 4#
Sulfonamide 35* 29# $
Gentamicin 6¤ 5 4
Ciprofloxacin 11 11¤ 10* ¤
Cefuroxime 9¤ 7 6
3rd generation cephalosporins a) 7 6 4
Carbapenem <1 <1 <1
Max. number of isolates tested for 
resistance to the presented antibiotics
4838 46780 67765
For all isolates, statistical comparison of proportions of resistant isolates between 2015 and 2016 was calculated for all antibiotics. Statistical 
comparison between 2007 and 2016 of proportions of resistant isolates was calculated for ampicillin, gentamicin, ciprofloxacin and cefuroxime on 
blood isolates and for ampicillin, mecillinam, sulfonamide and ciprofloxacin on urine isolates.   
* Indicates a significant increase from 2015 to 2016
# Indicates a significant decrease from 2015 to 2016
¤ Indicates a significant increase from 2007 to 2016
$ Indicates a significant decrease from 2007 to 2016
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime and cefotaxime
DANMAP 201690
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The level of carbapenem resistance is continuously low among 
urine isolates from hospitalized patients in Denmark but seems 
to be increasing, with no carbapenem resistant isolates and one 
intermediary resistant isolate reported in 2014, three carbape-
nem resistant isolates and 11 intermediary resistant isolates 
reported in 2015, and eight carbapenem resistant E. coli isolates 
and eight intermediary resistant isolates reported in 2016. The 
apparent increase is worrisome although a significant difference 
still cannot be measured (p = 1.00, Fischer’s exact test).
As previously reported, approx. 40% of the isolates were re-
sistant to ampicillin, although a slight but significant decrease 
in the resistance level was observed from 2015 to 2016. The 
proportion of sulfonamide resistance was also continuously 
high and with a slight but significant increase since 2015. No 
significant change was observed in the proportion of mecil-
linam resistance since 2015. However, the resistance propor-
tion has increased significantly since 2007. This is possibly 
caused by an increased use of mecillinam as first choice treat-
ment of urinary tract infections as recommended by Danish 
treatment guidelines. Mecillinam is the antibiotic available for 
oral administration that most E. coli isolates are susceptible to.
8.1.3 Urine isolates from primary health care 
For 2016, results from antibiotic resistance testing were 
submitted to DANMAP for 67,798 E. coli isolates that were 
cultured from urine samples from primary health care. One of 
the DCM does not receive any samples from primary health 
care, thus results were only submitted from 10 of the 11 DCM 
in Denmark. All 10 DCM routinely tested their E. coli urine 
isolates from primary health care for resistance to ampicillin, 
mecillinam and 3rd generation cephalosporins; seven DCM 
routinely tested for sulfonamide resistance; five DCM routinely 
tested for cefuroxime resistance; four DCM routinely tested 
for resistance to gentamicin and carbapenem and three DCM 
routinely tested for piperacillin/tazobactam resistance. Overall, 
the proportion of isolates tested for the presented antibiotics 
varied from 31% (piperacillin/tazobactam) to 100% (ampicil-
lin and mecillinam). In Denmark many general practitioners 
perform urine culturing and thus only submit urine samples 
for culturing at the local DCM in case of e.g. treatment failure 
or difficulties in interpretation of their locally acquired results 
from resistance testing. Thus, besides the selection of samples 
that are tested for the different antibiotics, a selection in the 
samples submitted to the DCM for culturing occurs.
From 2007 to 2016, a significant increase in the proportion 
of ciprofloxacin resistant E. coli isolates was observed in urine 
cultures from primary health care (Table 8.1.1). As for resis-
tance levels in urine cultures from hospitalised patients, this 
increase happened primarily from 2007 to 2009 and resis-
tance levels have remained stable since 2009 (Figure 8.1.3). 
This coincides with a decrease in the consumption of fluoro-
quinolones, which has been observed since 2010 (DANMAP 
2016, chapter 5). Since 2007 and 2009, respectively, the level 
of resistance to gentamicin and 3rd generation cephalosporins 
did not change.
In 2015, four carbapenem resistant and nine intermediary resis-
tant E. coli isolates from primary health care were reported. In 
2016, there were two carbapenem resistant and seven interme-
diary resistant E. coli isolates. As mentioned earlier, the actual 
number of resistant isolates may have been higher, as routine 
carbapenem resistance testing on E. coli urine isolates from 
primary health care was only performed at four DCM in 2016.
Even though a significant decrease in comparison with 2007 
was seen, the proportion of resistance to ampicillin and sulfon-
amide remained continuously high, with approximately a third 
of all isolates being resistant towards these two antibiotics. 
Since 2007, a significant increase in the proportion of mecil-
linam resistant isolates has been observed (moving from 3.9 to 
5.6%) (Table 8.1.1). This may also be due to the present recom-
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Figure 8.1.3 Resistance (%) in Escherichia coli urine isolates from 
humans in primary health care, Denmark  DANMAP 2016
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2016
2014  
% (N)
2015 
% (N)
2016 
% (N)
Resistance 2 (72) 2 (93) 2 (87)
Percentage (no.) of isolates tested for 
combined resistance (multiresistance) a)
90 
(4039)
88 
(4071)
98 
(4763)
Total number of blood isolates 4495 4614 4841
a) Tested 3rd generation cephalosporins were ceftazidime,  
ceftriaxone, cefpodoxime and cefotaxime.
Table 8.1.2 Combined resistance to 3rd generation cephalosporins, 
ciprofloxacin, and gentamicin (multiresistance) in blood 
Escherichia coli isolates from humans, Denmark        DANMAP 2016
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mendations to use mecillinam as a first choice antibiotic in the 
treatment of urinary tract infections. A discrete but significant 
decrease (from 4.0 to 3.5%) in the proportion of piperacillin/
tazobactam resistance was observed from  
2015 to 2016.
Kristina Træholt Franck, Stefan S. Olsen 
For further information: Ute Wolff Sönksen, uws@ssi.dk 
8.2 Klebsiella pneumoniae
Klebsiella pneumoniae (K. pneumoniae) is part of the gastro-
intestinal flora in humans. It may cause infections such as uri-
nary tract infections, pneumonia, and blood stream infections.
As for 2015, DANMAP 2016 includes resistance data for K. 
pneumoniae from all 11 Departments of Clinical Microbiology 
(DCM) in Denmark, thus representing 100% of the Danish 
population.
8.2.1 Blood isolates from hospital patients 
For 2016, DANMAP received resistance results from 1,156 
tested blood isolates of K. pneumoniae. In total 94%–100% 
of isolates were tested for the presented antibiotics. Nine of 
the 11 DCM routinely (>75% of isolates) tested for resistance 
to all the presented antibiotics (Table 8.2.1). Two of the DCM 
routinely tested for all the presented antibiotics except mecil-
linam. As in the previous years, resistance testing was mainly 
performed by disc diffusion. The presented data consists of 
the reported interpretation results, made by the DCM and 
based on the S-I-R system.
Resistance in K. pneumoniae from bloodstream infections 
has been included in DANMAP since 2008. As for many other 
species the number of bacteremias with K. pneumoniae has 
shown continuous moderate increases in all years, but an 
unexpected steep increase from 922 reported isolates in 2015 
to 1,156 in 2016 (Figure 8.2.1). The cause of this is unknown. 
A similar steep increase from 2015 to 2016 was not observed 
for E. coli (Figure 8.1.1) or for S. aureus (p. 106) and thus 
cannot be explained by demographic changes or changes in 
hospital workflow.
Resistance levels in 2016 were similar to the reported resis-
tance levels in 2015 for all antibiotic classes. Overall the levels 
of resistance have decreased significantly since 2008 (Figure 
8.2.1, Table 8.2.1). Resistance to ciprofloxacin, gentamicin, and 
3rd generation cephalosporins increased from 2008 to 2009 
and have decreased thereafter to levels below those of 2008. 
Except for 3rd generation cephalosporins, this decrease was 
significant (Table 8.2.1). A slight increase in the proportion of 
piperacillin/tazobactam resistant isolates from 4.6% to 5.8% 
was observed since 2010. Significant variations between 
resistance proportions reported from the different DCM were 
noticed for cefuroxime (spread 0.0%–20%) and piperacillin/
tazobactam (spread 1.1%–17%). As for E. coli these data are 
based on the interpretations from the individual DCM. We 
expect that especially the interdepartmental variance in piper-
acillin/tazobactam resistance would be smaller, if a standard-
ized interpretation method was to be used.
The proportion of carbapenem (including meropenem) resis-
tant isolates is continuously very low, with only three resistant 
and one intermediary resistant isolates in 2016. In 2015, no 
carbapenem resistant and two intermediary resistant K. pneu-
moniae blood isolates were reported (DANMAP 2015). The 
proportions of isolates with combined resistance towards 3rd 
generation cephalosporins, ciprofloxacin, and gentamicin (here 
after referred to as multi-resistant isolates) have only been 
reported systematically for at least 75% of blood isolates since 
2014. Luckily, the proportions of multiresistant isolates are 
still relatively low with only 1.6% resistant isolates in 2016 
(Table 8.2.2). The preferred antibiotic for treating patients with 
serious infections caused by multiresistant K. pneumoniae 
is meropenem. Thus, when bearing in mind the potential risk 
of spread of plasmids that contain genes encoding for car-
bapenemases in the near future, even 1.6% multi-resistant 
isolates is worrisome. In case of infection with a combined 
multi-resistant and meropenem resistant isolate, drugs such 
as colistin, fosfomycin, and tigecykline can be used for treating 
serious infections. No systematically surveillance of resistance 
towards these antibiotics is performed.
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Figure 8.2.1 Resistance (%) in Klebsiella pneumoniae blood 
isolates from humans, Denmark                                
DANMAP 2016
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2016.
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Substance Blood isolates, hospitals Urine isolates, hospitals Urine isolates, primary health care
% % %
Mecillinam 9 8# ° 9°
Piperacillin/tazobactam 6 6 5
Sulfonamide 17° 19°
Gentamicin 3$ 3 2
Ciprofloxacin 5$ 6° 6°
Cefuroxime 11$ 9 6
3rd generation cephalosporins a) 7 7° 5°
Carbapenem <1 <1 0
Max. number of isolates tested for 
resistance to the presented antibiotics
1152 7142 7358
For all isolates, statistical comparison of proportions of resistant isolates between 2015 and 2016 was calculated for all antibiotics. On blood 
isolates, statistical comparison of proportions of resistant isolates between 2008 and 2016 was calculated for ciprofloxacin, gentamicin, 
cefuroxime, 3rd generation cephalosporins and carbapenem. For urine isolates, statistical comparisson of proportions of resistant isolates 
between 2009 and 2016 was calculated for for sulfonamide, mecillinam,ciprofloxacin, 3rd generation cephalosporins and carbapenem.
# Indicates a significant decrease from 2015 to 2016.   
$ Indicates a significant decrease from 2008 to 2016.   
° Indicates a significant decrease from 2009 to 2016.   
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime and cefotaxime.
Two of the 11 DCM reported results from mecillinam resis-
tance testing on 13% and 26% of their isolates, respectively. 
All other DCM reported mecillinam resistance results in 91% 
of isolates, with seven DCM reporting mecillinam resistance 
results on 98%–100% of their isolates. In total, 8.6% of blood 
isolates were reported resistant to mecillinam, varying from 
2.9% to 31%. However, as with piperacillin/tazobactam we 
suspect that local interpretation of zone diameters is the 
cause of these variations. To lower the use of cefuroxime and 
piperacillin/tazobactam, some DCM recommend treating  
K. pneumoniae blood stream infections with mecillinam, if the 
isolates are susceptible according to local interpretations.
8.2.2 Urine isolates from hospital patients 
For 2016, DANMAP received resistance results from altogether 
7467 K. pneumoniae isolates cultured in urine samples from 
hospitalised patients. Results were submitted from all 11 
DCM in Denmark. All 11 DCM routinely tested for gentamicin 
resistance; ten DCM routinely tested for resistance to mecil-
linam, ciprofloxacin, cefuroxime and 3rd generation cephalospo-
rins; nine DCM routinely tested for resistance to piperacillin/
tazobactam and six DCM routinely tested for resistance to 
sulfonamide.
Overall a decrease in the resistance levels was seen for all 
the tested antibiotics (Figure 8.2.2). As in blood isolates, a 
significant decrease in the proportion of ciprofloxacin resistant 
isolates was seen, from 17% resistant isolates in 2009 to only 
6.1% in 2016 (Table 8.2.1). Significant decreases in the pro-
portions of gentamicin and cefuroxime resistance since 2010 
(from 7.3% to 3.2% and from 13% to 9.1%, respectively) and 
in the proportions of 3rd generation cephalosporin resistance 
since 2009 (from 13% to 6.8%) were also observed.
Four carbapenem resistant isolates and seven intermediary re-
sistant isolates were reported in 2015. In 2016, four carbape-
nem resistant isolates and six carbapenem intermediary resis-
tant isolates were reported. As not all DCM routinely tested for 
carbapenem resistance on K. pneumoniae urine isolates from 
hospitalized patients, the carbapenem resistance data is based 
on a selected population.
In contrast to the previous year (DANMAP 2015), a significant 
decrease was seen in the level of mecillinam resistance, from 
10% mecillinam resistant isolates in 2015 to 7.7% resistant 
isolates in 2016 (Table 8.2.1). A steep increase in the level of 
sulfonamide resistance was observed in 2011 (from 27% in 
2009 to 33% in 2011) but since then, the level has decreased 
to the present 17% resistant isolates (Figure 8.2.2).
2014  
% (N)
2015 
% (N)
2016 
% (N)
Resistance 3 (26) 1 (9) 2 (18)
Percentage (no.) of isolates tested for 
combined resistance (multiresistance) a)
91 
(859)
89 
(840)
98 
(1131)
Total number of blood isolates 943 943 1156
a) Tested 3rd generation cephalosporins were ceftazidime,  
ceftriaxone, cefpodoxime and cefotaxime.
Table 8.2.2 Combined resistance to 3rd generation cephalosporins, 
ciprofloxacin, and gentamicin (multiresistance) in Klebsiella 
pneumoniae blood isolates from humans, Denmark 
 DANMAP 2016
Table 8.2.1 Resistance (%) in Klebsiella pneumoniae isolates from humans, Denmark  DANMAP 2016
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8.2.3 Urine isolates from primary health care 
For 2016, DANMAP received results from antibiotic resistance 
testing on 7615 K. pneumoniae isolates cultured in urine 
samples from primary health care. Results were only submitted 
from 10 DCM, as one hospital did not receive samples from pri-
mary health care. All 10 DCM routinely tested for ciprofloxacin 
resistance, nine DCM routinely tested for resistance to mecil-
linam and 3rd generation cephalosporins, seven DCM routinely 
tested for sulfonamide resistance, four DCM routinely tested 
for gentamicin and cefuroxime resistance, three DCM routinely 
tested for carbapenem resistance and two DCM routinely 
tested for piperacillin/tazobactam resistance.
The changes in the antibiotic resistance pattern of K. pneu-
moniae that were isolated from blood, hospital urine samples, 
and urine samples from the primary health care were similar 
throughout the years. Since 2009, a significant decrease 
in the resistance levels of ciprofloxacin and 3rd generation 
cephalosporins was observed, from 13% and 8.1% in 2009 to 
5.6% and 5.4% in 2016, respectively (Table 8.2.1 and Figure 
8.2.3). Likewise, a significant decrease in the proportions of 
cefuroxime and gentamicin was observed from 8.6% and 3.5% 
in 2010 to 5.6% and 2.2% in 2016, respectively (Table 8.2.1, 
trend not shown).
In 2015, one carbapenem resistant and three intermediary 
resistant K. pneumoniae isolates from primary healthcare urine 
samples were reported. In 2016, no K. pneumoniae isolates 
were reported resistant or intermediary resistant to carbape-
nem. As in 2015, the tested population was selected as only 
three DCM routinely tested for carbapenem resistance.
After a steep increase in the proportion of sulfonamide resis-
tance observed from 30% in 2009 to 35% in 2011, the propor-
tion decreased to 17% in 2014 (Figure 8.2.3). The proportion 
of sulfonamide resistance has increased slightly since then to 
the present level of 19% in 2016. The level of both sulfonamide 
and mecillinam resistance was significantly lower in 2016 than 
in 2009. All DCM routinely tested for sulfonamide resistance in 
2009.
Kristina Træholt Franck and Stefan S. Olsen 
For further information: Ute Wolff Sönksen, uws@ssi.dk
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Figure 8.2.2 Resistance (%) in Klebsiella pneumoniae urine 
isolates from humans in hospitals, Denmark DANMAP 2016
Figure 8.2.3 Resistance (%) in Klebsiella pneumoniae urine isolates 
from humans in primary health care, Denmark DANMAP 2016
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2016
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2016
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Textbox 8.1 
Characterization of ESBL/pAmpC- and carbapenemase producing 
Escherichia coli from bloodstream infections, 2016 Denmark 
Background: The prevalence of third-generation cephalosporin-resistant Escherichia coli (3GC-R Ec) is still increasing in Europe 
[EARS-Net report, 2015]. The resistance mechanisms detected for third-generation cephalosporin-resistance in E. coli are the 
production of extended-spectrum beta-lactamases (ESBLs), plasmid-mediated AmpC (pAmpCs) and hyperproduction of the chro-
mosomal AmpC gene due to mutations within the promoter/attenuator region.  
The occurrence of 3GC-R among E. coli isolated from bloodstream infections in Danish patients was low before 2007, but has 
since increased, most notably from 2007 to 2011. 
The pandemic clone O25b:-ST131 is in part responsible for the worldwide spread of ESBL-producing E. coli. This clone is strong-
ly associated with the presence of antimicrobial resistance genes, particular CTX-M-15, but other ESBL enzymes and virulence 
factors as well.  
The aim of the present study was to characterize ESBL, pAmpC and carbapenemase-producing E. coli from bloodstream infec-
tions according to resistance genes and Multilocus Sequence Types (MLSTs).
Material and Methods: During January 2016 through December 2016, all Danish departments of clinical microbiology col-
lected their 3GC-R Ec (reported as ceftazidime, ceftriaxone, cefpodoxime or cefotaxime resistance) from bloodstream infections. 
Furthermore, carbapenemase producing E. coli from bloodstream infections were included in the study. The isolates were sent 
to Statens Serum Institut for further characterization. Only one isolate per patient per year was included in the study. 
Since 2014, whole genome sequencing (WGS) and in silico bioinformatics analysis have been used for characterization of the 
genetic background of the ESBL and AmpC phenotypes.  
The Bacterial Analysis Pipeline – Batch upload version 1.0 from Center of Genomic Epidemiology (https://cge.cbs.dtu.dk/ser-
vices/cge/) was used for in silico detection of acquired ESBL genes, pAmpCs, carbapenemase genes and MLST from assembled 
WGS data. 
For isolates with no ESBL-, pAmpC-, or carbapenemase-encoding genes detected, the sequences were investigated for promotor 
mutations presumed to up-regulate chromosomal AmpC by the use of MyDb-Finder version 1.2 (https://cge.cbs.dtu.dk/services/
MyDbFinder-1.2/).
Results: Whole genome sequence data were obtained from 317 E. coli isolates, compared to 294 in 2015 and 261 in 2014. 
Genes encoding ESBL, pAmpCs and/or carbapenemase production were detected in 312 isolates in 2016, compared to 275 in 
2015. Five isolates were hyperproducers of chromosomal AmpC only; these isolates were not investigated further.  
Isolates with ESBL, pAmpC- and carbapenemase production were observed in all the five Danish regions (Table 1). 
Demographic data was available for all 312 E. coli isolates; 166 (53%) of the patients were men and 146 (47%) were woman. 
The average age at diagnosis was 70 years, ranging from below one to 98 years. 
Among the 312 isolates, 25 different ESBL, pAmpC and carbapenemase-enzymes were detected (Table 2), including two novel 
CTX-M- and one novel CMY-variant (CTX-M-127, CTX-M-203 and CMY-154).  CTX-M-15 dominated (50%) followed by CTX-M-27, 
CTX-M-14 and CTX-M-101 (Table 2). Different plasmid-mediated AmpC producers (CMY- and DHA-variants) were detected in 18 
isolates (6%). Only one isolate carried a carbapenemase producing gene, OXA-181 together with CTX-M-15 and CMY-2. In sev-
eral of the E. coli isolates more than one gene encoding ESBL/pAmpC and/or carbapenemases were detected (Table 2). Plasmid-
mediated colistin resistance genes (mcr-1, mcr-2, mcr-3 and mcr-4), were not observed in 2016. 
In 2016, the 312 E. coli isolates belonged to 43 different MLSTs. ST131 was still the most common sequence type (ST), with 
177 (57%) of the isolates belonging to this type. Other frequent sequence types were ST38 (7%), ST69 (5%), ST12 (4%), 
ST1193 (3%), ST405 (2%), and ST410 (2%), whereas the remaining isolates belonged to STs, which only were detected in 1-5 
isolates (<1-2% per type) (Table 3).  
Among the 177 E. coli isolates belonging to ST131, CTX-M-15 (55 %) was most common, followed by CTX-M-27 (20%), CTX-
M-14 (11%) and CTX-M-101 (8%). The carbapenemase producing OXA-181, CTX-M-15 and CMY-2 isolate belonged to ST410.
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Conclusion: From 2015 to 2016, the reported cases of 3GC-R Ec increased 13% from 275 to 312 (out of 294 and 317 referred 
suspected resistant strains, respectively). Comparing the distribution of ESBL/pAmpC, carbapenemases and MLSTs, from the 
results reported in DANMAP 2015 to 2016, no remarkable changes were observed. As in previous Danish studies of ESBL-
producing E. coli from bloodstream infections, most of the isolates produced a CTX-M enzyme, with CTX-M-15 being the most 
predominant enzyme [DANMAP 2009, DANMAP 2011, Roer et al. JAC. 2016, Hansen et al. Microb. Drug Res. 2014]. Additionally, 
three novel ESBL-encoding genes were observed; CTX-M-127 (3/312), CTX-M-203 (1/312) and CMY-154 (1/312). Only a minor 
part (13/312) of the isolates carried CMY-variants.
As observed in the studies by Roer et al. and by Hansen et al. the worldwide disseminated ST131 clone carrying CTX-M-15 
was strongly represented in this study, however other international STs (e.g., ST38, ST405, ST410, ST69 and ST648) related to 
spread of ESBLs were observed among the Danish E. coli isolates. 
Louise Roer, Frank Hansen, Anette M. Hammerum and Henrik Hasman 
For further information: Louise Roer (loro@ssi.dk)
Table 1. Distribution of ESBL, pAmpC and Carbapenemase producing E. coli from 
bloodstream infections, Denmark 2016 DANMAP 2016
 2014 2015 2016
Region Numbers Numbers Numbers
The Capital Region of Denmark 110 116 111
The Zealand Region 27 14 36
Region of Southern Denmark 43 45 67
Central Denmark Region 43 59 66
North Denmark Region 22 41 32
Total Numbers 245 275 312
DANMAP 2014 DANMAP 2015 DANMAP 2016
Enzyme Number % Number % Number %
CTX-M-151 121 49 139 51 157 50
CTX-M-271 25 10 33 12 44 14
CTX-M-141 38 16 33 12 40 13
CTX-M-101 12 5 15 5 14 4
CMY-21 10 4 6 2 10 3
CTX-M-14b 5 2 5 2 9 3
CTX-M-1 10 4 7 3 8 3
CTX-M-31 4 2 4 1 7 2
CTX-M-551 8 3 14 5 6 2
Other CMY variants1 4 2 10 4 3 1
Other ESBL enzymes 14 6 16 6 27 9
OXA-48-group1 3 1 3 1 1 0
 DANMAP 2014 DANMAP 2015 DANMAP 2016
MLST Numbers % Numbers % Numbers %
ST131 124 51 135 49 177 57
ST38 18 7 23 8 21 7
ST405 13 5 12 4 7 2
ST410 4 2 11 4 6 2
ST69 10 4 10 4 16 5
ST648 7 3 10 4 5 2
ST12 5 2 9 3 14 4
ST354 1 < 1 4 1 5 2
ST95 5 2 3 1 5 2
ST1193 2 1 5 2 10 3
Other STs1 56 23 53 19 46 15
Table 2. Most common ESBL/pAmpC enzymes and 
carbapenemases detected in E. coli from  
bloodstream infections, Denmark 2016 DANMAP 2016
1In some isolates more than one enzyme was detected in 2016
Table 3. Distribution of MLSTs in E. coli from bloodstream 
infections      
 DANMAP 2016
1 less than 5 isolates per ST in 2016
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8.3 Pseudomonas aeruginosa
Pseudomonas aeruginosa is an opportunistic pathogen of 
immunocompromised individuals. P. aeruginosa typically 
infects the pulmonary tract, urinary tract, burns, wounds, and 
also causes bloodstream infections. It is a relatively frequent 
colonizer of medical devices (e.g. indwelling catheters). P. ae-
ruginosa infection is a serious problem in patients hospitalised 
with cancer, cystic fibrosis and burns. The case fatality rate in 
these patients is high. P. aeruginosa is intrinsically resistant to 
the majority of antimicrobial agents. The antimicrobial classes 
which can be used for treatment include some fluoroquino-
lones, some aminoglycosides, some beta-lactams (piperacillin-
tazobactam, ceftazidime and carbapenems) and colistin.
8.3.1 P. aeruginosa blood isolates obtained from  
hospitalised patients 
For P. aeruginosa, DANMAP 2016 includes data from 11 out of 
11 Departments of Clinical Microbiology (DCM), covering the 
total Danish population. DANMAP received data of 460 P. aeru-
ginosa isolates from blood. Resistance levels to all the tested 
antimicrobial agents was not significantly different from the 
levels in 2015 (Figure 8.3.1). EARS-Net 2015 reported an 
increasing resistance rate for the EU/EEA population–weighted 
mean for piperacillin/tazobactam (18.1% in 2015) and decreas-
ing rates for the EU/EEA population–weighted mean for fluoro-
quinolones (19.3% in 2015) as for aminoglycosides (13.3% in 
2015). Denmark stayed below 5% resistance rates in invasive 
P. aeruginosa isolates in 2016.
Sissel Skovgaard and Stefan S. Olsen 
For further information: SIssel Skovgaard, sisk@ssi.dk
Figure 8.3.1. Resistance (%) in Pseudomonas aeruginosa blood 
isolates from humans, Denmark  DANMAP 2016
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2016
HUSK Neo Sans 8pt. Ændre til 100% sort - rammer 50% sort
0
2
4
6
8
10
12
14
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
%
 re
si
st
an
t 
is
ol
at
es
Ciprofloxacin (n=460)
Gentamicin (n=460)
Ceftazidime (n=453)
Meropenem (n=460)
Piperacillin/tazobactam (n=459)
97DANMAP 2016
8.RESISTANCE IN HUMAN CLINICAL BACTERIA
8.4 Acinetobacter spp.
The genus Acinetobacter includes several species and is found 
widespread in nature, where the different species are present 
in soil, water and/or animals and humans. In humans Acineto-
bacter can colonize the skin and wounds but may also be the 
cause of hospital-acquired infections like central line-associ-
ated bloodstream infections, nosocomial pneumonia, urinary 
tract infections and wound infections. Many of the different 
subspecies are phenotypically alike, and thus identification at 
species level can be difficult. Spp. belonging to the A. bauman-
nii group are considered being the most clinically important. 
Acinetobacter spp. possess an inherent resistance to a broad 
range of antibiotics because of a low membrane perme-
ability and constitutive expression of efflux systems. The 
antimicrobial classes which can be used for treatment include 
some fluoroquinolones, aminoglycosides, carbapenems and 
colistin. Especially for A. baumanii multiresistant clones are 
widespread. Of worldwide concern are severely war-wounded 
soldiers infected with multiresistant A. baumannii.
Resistance in invasive Acinetobacter spp. in Denmark has been 
monitored and reported to EARS-Net since 2012, but 2016 is 
the first year where these data are presented in the DANMAP-
report. 
8.4.1 Acinetobacter blood isolates obtained  
from hospitalised patients  
During 2012 to 2016 between 69 and 83 Acinetobacter blood 
isolates were reported yearly. From 2012 to 2014 about 95% 
of the Danish population were covered in the reporting and 
since 2015 the total Danish population has been covered. 
Most DCM reported on resistance testing to ciprofloxacin and 
gentamycin throughout the whole period and in 2015 and 
2016  most also reported on meropenem resistance. Data are 
presented in table 8.4.1 and in figure 8.4.1. 
In 2012, significantly more Acinetobacter blood isolates were 
resistant towards ciprofloxacin, gentamycin and meropenem 
(resistance rates 10-12%) than in 2016 (resistance rates 
0-3%). For the period in-between no significant changes were 
observed. Resistance rates varied from 3% to 7% for ciproflox-
acin and 0 to 4.4% for gentamycin and meropenem. In EARS-
Net markedly differences in resistance profiles across Europe 
have been reported with especially high resistance rates 
reported from the Baltic, southern and south-eastern countries 
in Europe. For example, in 2015 87% of invasive Acinetobacter 
spp. in Croatia were reported with combined resistance to 
flouroquinolones, aminoglycosides and carbapenems, while 
Sweden reported 3.8% combined resistance.
In the Danish invasive Acinetobacter spp. from 2016 approxi-
mately half of the 72 reported isolates were reported as  
Acinetobacter spp., while the other half consisted of A. baumannii, 
A. haemolyticus, A. johnsonii, A. junii and A. Iwoffii. None of the 
isolates were resistant to meropenem. In contrast, as described 
in textbox 8.2, 26 carbapenemase-producing A. baumannii 
isolates from all specimen types were detected in Denmark 
in 2016, which was an increase from 19 detected isolates in 
2015. One of these referred 2016 isolates was invasive.
Sissel Skovgaard and Stefan S. Olsen 
For further information: Sissel Skovgaard, sisk@ssi.dk
Tabel 8.4.1 Invasive Acinetobacter spp, Denmark 2012 - 2016. Number of resistant isolates per year per antibiotic and number of 
tested isolates per year per antibiotic DANMAP 2016
Substance 2012 2013 2014 2015 2016
Resistent Tested Resistent Tested Resistent Tested Resistent Tested Resistent Tested
Ciprofloxacin 10 83 5 72 2 69 4 71 2 72
Gentamicin 8 77 1 65 1 70 3 71 0 70
Meropenem 6 58 1 52 1 62 3 68 0 69
Max. Number of isolates testet 83 72 69 71 72
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Figure 8.4.1 Resistance (%) in Acinetobacter spp.  
Blood isolates from humans, Denmark  DANMAP 2016
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2016
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Textbox 8.2 
Carbapenemase producing bacteria in Denmark, 2016
 
Background: Carbapenems comprise one of the only classes of antimicrobial agents that can be used for treatment of infec-
tions with multi-resistant Gram-negatives like Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa and Acineto-
bacter baumannii. Treatment options for infections with carbapenem resistant bacteria are often none or suboptimal. Resistance 
can be caused by the presence of various carbapenemases of which the most frequently occurring are K. pneumoniae carbapen-
emase (KPC), Oxacillinase (OXA), Verona integron-encoded metallo-β-lactamase (VIM), New Delhi metallo-β-lactamase (NDM), 
and Imipenemase (IMP).
In recent years, Danish Departments of Clinical Microbiology (DCM) have on a voluntary basis submitted carbapenem resistant 
isolates for verification and genotyping at Statens Serum Institut. The present textbox describes carbapenemase-producing 
Enterobacteriaceae (CPE), carbapenemase-producing P. aeruginosa and carbapenemase-producing Acinetobacter spp. 
During 2016, 115 carbapenemase producing organisms (CPO) were detected from 99 patients. More than one isolate from the 
same patient were included, if the isolates belonged to different bacterial species and/or if the isolates harboured different car-
bapenemases. Among the 115 CPO, 94 were from clinical samples and 21 were from screening samples. Nine of the CPOs were 
from bloodstream infections (eight CPE, and one A. baumannii) compared with eight CPO in 2015. 
Enterobacteriaceae: In 2016, 82 CPE from 72 patients were detected compared to 63 CPE in 2015 (Figure 1). In 2016, 16 
of the patients had been travelling abroad prior to detection of the CPE, 28 of the patient did not report any travel and for the 
remaining 28 patients no travel information were obtained (Figure 2). Since 2012, an increasing number of cases have been 
related to spread between patients in Denmark. 
Seven isolates of 82 CPE isolates produced both NDM and OXA-48 group enzymes, 44 produced OXA-48-like enzymes and 27 
were NDM-producing (Figure 1). Furthermore, two KPC-producing isolates and two VIM-producing isolates were detected. 
The NDM-1 producing C. freundii outbreak, which started in 2012 in the North Denmark Region, continued in 2016 (Table 1). 
Until the end of 2016, 14 patients were involved in this outbreak. None of these patients had a prior history of travel noted in 
their hospital records. The origin of the NDM-1 producing C. freundii was unknown. NDM-1 plasmid transfer was also detected to 
other CPEs with the patients involved in the outbreak [Hammerum et al. 2016, J. Antimicrob. Agents, 71:3117-3124]. 
Besides the NDM-1 C. freundii outbreak, possible clonal spread of CPE were detected for NDM-1 producing K. pneumoniae, KPC-
3 producing K. pneumoniae, OXA-181 producing K. pneumoniae, NDM-5/OXA-181 E. coli and OXA-48 E. coli during 2016 (Table 
1). In all cases, the CPE isolates had highly similar SNP-profiles, indicating a possible spread between the patients or a common 
origin. Furthermore, it seems very likely that the increase in OXA-48 producing CPE was due to plasmid transfer, but this was 
not investigated further.
Year No. of Patients Carbapenemase Species Region
2012-16 14 NDM-1 ST18 C. freundii North Denmark Region
2015-2016 4 NDM-1 ST15 K. pneumoniae Region Zealand, Region of Southern Denmark 
2015-2016 2 KPC-3 ST101 K. pneumoniae Region Zealand
2015-2016 4 OXA-181 ST571 K. pneumoniae The Capital Region of Denmark
2016 6 NDM-5/OXA-181 ST410 E. coli The Capital Region of Denmark/Region Zealand
2016 3 OXA-48 ST354 E. coli Region Zealand /The Capital Region of Denmark 
Table 1. Possible clonal spread of carbapenemase producing Enterobacteriaceae (CPE) during 2016, Denmark DANMAP 2016
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Acinetobacter spp: In 2016, 26 carbapenemase producing A. baumannii isolates were detected compared to 19 isolates in 
2015. In 2016, 23 OXA-23 producing A. baumannii isolates were detected. Furthermore, two OXA-72 producing A. baumannii 
and one OXA-58 producing A. baumannii were detected. 
P. aeruginosa: In 2016, five VIM-2 producing P. aeruginosa, one IMP-7 P. aeruginosa and one NDM-1 producing P. aeruginosa 
were detected.
Conclusion: The occurrence of carbapenemase producing bacteria in Denmark is still increasing, a trend worrisome to patients 
and clinicians. Especially the spread of CPE is of concern, since Enterobacteriaceae can be carried in the intestine for a long time 
without any symptoms of infections, which makes outbreak control difficult.    
Anette M. Hammerum, Frank Hansen, Louise Roer and Henrik Hasman 
For further information: Anette M. Hammerum (ama@ssi.dk)
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Figure 1. Numbers of carbapenemase-producing Enterobacteriaceae (CPE) DANMAP 2016
Figure 2. Travel information for patients with carbapenemase-producing  
Enterobacteriaceae (CPE) during 2008-2016 DANMAP 2016
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8.5 Enterococci
Enterococci constitute a part of the normal intestinal micro-
biota in humans and animals and colonise the host in beneficial 
co-existence. More than 54 species belonging to the genus 
enterococcus have been described, but the majority of the 
human infections are caused by E. faecalis and E. faecium, 
with considerable differences in susceptibility to the different 
antimicrobial agents. 
Most common clinical infections caused by Enterococcus 
species include: urinary tract infections, bacteraemia and 
bacterial endocarditis (an inflammation process of the inner 
tissues of the heart, usually of the valves). As an opportunistic 
pathogen it causes severe illness in the immunocompromised 
host. Found in hospital environment, bacteria can lead to 
colonization or infection of a hospitalized patient. The source 
of hospital infection is often associated with use of medical 
supplies, such as catheters, as well as other instruments and 
medical devices. 
Therapy of enterococcal infection is complicated and has 
limited variations due to a high level of natural antimicrobial 
resistance. In severe cases enterococcal infections are treated 
with vancomycin. Combinational therapy based on a synergis-
tic effect of beta-lactam antibiotic (penicillin/ampicillin) with 
aminoglycoside (gentamicin) or glycopeptide (vancomycin) is 
required in cases of endocarditis. More recent antibiotics, such 
as linezolid (oxazolidinone) and daptomycin (lipopeptide) are 
the only options for treatment of multiresistant pathogen, 
vancomycin-resistant Enterococcus (VRE), which adapt to per-
sist in the health care facilities. A new antibacterial from the 
oxazolidinone-class with restrictive indications for usage was 
introduced to the Danish market in 2015. 
All DCM performed susceptibility testing for ampicillin and 
vancomycin on all strains of E. faecalis and E. faecium popula-
tions isolated from blood cultures. As in previous years, only 
one DCM investigated all invasive E. faecalis and E. faecium 
isolates for occurrence of high-level resistance to gentamicin. 
More than half of all DCMs (6/11) performed phenotypical 
susceptibility testing to linezolid for all invasive E. faecium 
isolates.  Furthermore, 5/11 laboratories examined all invasive 
E. faecalis isolates for susceptibility to linezolid. 
In 2016, a total of 606 E. faecalis and 692 E. faecium isolates 
were reported from all DCM, thus representing the entire 
bacterial populations of invasive E. faecium and E. faecalis in 
Denmark. 
From 2015 to 2016, the total number of invasive isolates de-
clined slightly from 617 to 606 for E. faecium and from 711 
to 692 for E. faecalis. Throughout the 15-years period the 
ratio of E. faecalis to E. faecium dropped markedly from 2.9 
in 2002 to 0.9 in 2016. These variations equally can be ex-
plained by a significant rise of E. faecium infections, as well 
as by a decrease of E. faecalis infections. From 2015 to 2016 
the ratio of E. faecalis to E. faecium remained unchanged 
(Figure 8.5.1). 
Ampicillin-resistance  
The national rate of ampicillin-resistance in invasive E. faecalis 
was reported to 1.6 % in 2016. Prevalence of non-suscepti-
bility to ampicillin in E. faecium isolates dropped from 95.0 % 
in 2015 to 91.5 % in 2016, which is the lowest level verified 
since 2009. 
Vancomycin-resistance  
Prevalence of transferable vancomycin-resistance in E. faecium 
was 7.3% in 2016, this is a two-fold increase compared to 
2015. Rates of resistance to vancomycin increased during the 
9-years period from 0.6 % in 2007 to 3.7 % in 2015. The van-
comycin-resistant E. faecium were part of hospital outbreaks, 
which is described in textbox 8.3 on VRE (p.102). The level of 
vancomycin-resistant E. faecium was above the level reported 
to EARS-Net 2015 from the other Nordic countries [EARS-Net 
2015]. No vancomycin-resistant E. faecalis from bloodstream 
infections were reported in 2016. 
High-level gentamicin resistance  
The rate of high-level gentamicin resistance (> 128 mg/L) 
was biased, due to the small number of analysed isolates. Still 
in 2016, 11 out of 54 (20%) E. faecalis isolates showed high 
level resistance to gentamicin.  
Linezolid-resistance in invasive isolates  
In 2016, linezolid-resistance was for the first time reported to 
DANMAP. Among the tested 417 E. faecium and 310 E. faeca-
lis isolates, a single linezolid-resistant isolate of each species 
was detected. 
Linezolid-resistance in non-invasive isolates  
Due to an increased use of Linezolid at the clinical depart-
ments at Rigshospitalet during the later years, since November 
2015 all clinical enterococcal strains found resistant to line-
zolid through routine susceptibility testing with disc diffusion 
have been confirmed by Etest® (BioMérieux) at the local DCM. 
There were no findings of linezolid-resistance in invasive 
isolates. Among the 641 non-invasive E. faecium isolates 27 
(4 %) were resistant to linezolid in addition to ampicillin. Nine 
of the 27 E. faecium isolates were co-resistant to vancomycin 
in addition to linezolid and ampicillin. Among the 1,074 non-
invasive E. faecalis isolates fourteen (1%) were phenotypically 
resistant to linezolid.. Only a few isolates were examined for 
acquired mechanisms of resistance. In one of these strains 
presence of transferable linezolid-resistance due to the 
plasmid-mediated optrA gene was found for the first time 
in Denmark [Vorobieva et al. 2017, J Glob Antimicrob Resist., 
published online].This finding has lead to an increased focus 
on the use of linezolid in the Hospital.
In conclusion, the two-fold increase of transferable vancomy-
cin-resistance in E. faecium blood culture isolates is worrying. 
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A national surveillance, as well as strict infection control mea-
sures shall be continued. Due to the limited options of treat-
ment of VRE-infections, as well as the risk of rapidly acquired 
resistance to oxazolidinones and lipopeptides, an introduction 
of a national surveillance to linezolid and daptomycin in clinical 
enterococcal isolates should be considered.
From 2007 to 2009 the presented data covers 75% of the 
Danish population. From 2010 to 2014 data covers 95% of the 
Danish population and from 2015 the total Danish population 
is covered.
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Textbox 8.3 
Emergence of clinical ST203-CT859 vanA E. faecium  
in Denmark, 2016
 
Background: Enterococcus faecalis and Enterococcus faecium are commensal bacteria in the intestine of humans. E. faecalis 
and E. faecium can also cause urinary tract infections (UTI) and fatal infections like sepsis and endocarditis, especially among 
older and/or chronically ill patients. Enterococci are intrinsically resistant to a number of first-line antimicrobial agents including 
cephalosporins. Therefore, therapy of enterococcal infections may be difficult. Vancomycin is an important drug for the treat-
ment of severe enterococcal infections, but an increase in the occurrence of vancomycin-resistant enterococci (VRE) has been 
observed in Denmark and internationally. Many of the VRE are also resistant to ampicillin and gentamicin thus limiting the treat-
ment possibilities. Newer antibiotics such as linezolid and daptomycin can be used for treatment of VRE, but both antimicrobial 
agents have many side effects. 
Surveillance of VRE: Since 2005, Danish Departments of Clinical Microbiology (DCM) have on a voluntary basis, submitted VRE 
for species identification, genotyping and surveillance to the Antimicrobial Resistance Reference Laboratory at Statens Serum 
Institut. 
In 2012 and 2013, an increase in clinical vanA E. faecium isolates were observed (Figure 1 and Figure 2). They were primarily 
detected at hospitals in the Capital Region, but also from the Zealand Region and the Central Denmark Region. VRE was also 
detected in the two remaining regions of Denmark, but to a much lower extent (Figure 2). This trend continued in 2014-2016. 
In 2016, 434 clinical VRE isolates were detected and 88% of these were from hospitals located in the Zealand Region and the 
Capital Region (Figure 2). 
In 2016, 434 clinical VRE were detected compared to 371 clinical VRE in 2015. Most of the clinical VRE were vanA E. faecium, 
which increased with 15%, from 367 in 2015 to 422 in 2016 (Figure 1). Furthermore, two vanB E. faecium isolates were de-
tected in 2016, and for the first time two E. faecium isolates with both vanA and vanB were detected. Besides this, seven vanB 
E. faecalis and one vanA E. faecalis were detected.
From 2015, all clinical VRE isolates have been whole-genome sequenced. From the WGS data, MLSTs were extracted in silico. 
Core genome MLST (cgMLST) analysis was performed for the vancomycin-resistant E. faecium isolates. The majority of the E. 
faecium isolates belonged to three sequence types, ST80, ST117 and ST203, whereas the rest of the isolates belonged to 
ST17, ST18, ST78, ST294, ST192, ST787 and novel STs (ST1297, ST1298, ST1300, ST1301). The STs were all part of the CC17 
complex, which are commonly detected in hospitals outside of Denmark. 
In 2016, cgMLST subdivided the 422 vanA E. faecium isolates into 42 cluster types (CTs), ST203-CT859 was most prevalent 
(64%), followed by ST80-CT14 (9%), ST117- CT24 (5%), ST117-CT873 (3%), ST80-CT993 (3%), ST80-CT860 (3%) and ST80-
CT866 (2%). 
Comparison to the cgMLST.org database, previous studies, and personal communications with neighboring countries revealed 
that the novel cluster ST203-CT859 emerged in December 2014,  and spread to the South of Sweden and the Faroe Islands 
during 2015 [Hammerum et al. 2017 J. Antimicrobial. Chemother.]. In 2015, 187 (51%) of the Danish clinical vanA E. faecium 
belonged to ST203-CT859, this increased to 268 (64%) in 2016. 
vanA E. faecium isolates belonging to ST80-CT14 were also detected in the Capital Region in 2013 and 2015 (www.cgMLST.
org), however the cgMLST database did not contain any non-Danish ST80-CT14 isolates.
In contrast to this, vanA E. faecium isolates belonging to ST117-CT24 were detected in Danish hospitals both in 2010 and in 
2016, and have been reported from clinical samples from Sweden and Germany as well. 
The two vanB E. faecium isolates belonged to ST17-CT29 and to ST80-CT880, whereas the two vanA/vanB E. faecium isolates 
belonged to a ST80-CT1064.
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Figure 1. Numbers of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis  
isolates and vanA and vanB genes from clinical samples, 2005-2016 Denmark DANMAP 2016
Figure 2. Distribution of the clinical VRE isolates according to the  
five Danish regions, 2005-2016 DANMAP 2016
 
Conclusion: The continued increase in vanA E. faecium cases in 2016 in Denmark is worrying, and especially the further 
emergence of ST203-CT859 vanA E. faecium needs further investigation. VRE can be carried in the intestine for a long period 
without any symptoms of infection and likewise persist in the hospital environment, which makes infection control difficult but 
should include proper cleaning, good hand hygiene, screening for VRE and subsequent isolation of patients.
Anette M. Hammerum, Louise Roer and Henrik Hasman 
For further information: Anette M. Hammerum (ama@ssi.dk) 
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8.6 Streptococci 
Streptococci include Streptococcus pneumoniae (pneumococci), 
beta-haemolytic streptococci (BHS), and non-haemolytic strepto-
cocci (NHS). All streptococci are Gram-positive bacteria that belong 
to the human nasopharyngeal flora and may in varying degree and 
frequency be the cause of both common and severe infections. In 
the following section the surveillance of pneumococci and beta-
haemolytic streptococci causing invasive disease is presented. 
8.6.1: Pneumococci 
Pneumococci are the most common bacterial cause of pneumo-
nia in all age groups but are also a frequent cause of otitis-
media and bacterial sinusitis in children. They may also cause 
severe invasive infections and are among the leading causes 
of bacteremia, endocarditis and meningitis.
The prevalence of asymptomatic carriership with pneumococci 
in the nasopharynx varies with age.
Infections with pneumococci are treated with either beta-
lactam antibiotics – in Denmark the drug of choice is beta-
lactamase sensitive penicillins – or macrolides.  
The surveillance of pneumococci causing invasive disease in 
Denmark occurs through mandatory submission of clinical iso-
lates to Statens Serum Institut (SSI), in order to enable surveil-
lance of vaccine coverage and the prevalent type distribution. 
At SSI, the isolates are serotyped and tested for antimicrobial 
susceptibility.
Susceptibility testing of isolates from cases occuring in 2016 
was performed on 714 isolates of S. pneumoniae found in 
Danish patients and from either blood (658 isolates), cerebro-
spinal fluid (56 isolates) or from blood where the patients also 
had pneumococci in the cerebrospinal fluid (17). The isolates 
belonged to 39 different serotypes, of which isolates belong-
ing to 18 serotypes showed non-susceptibility (resistant or 
intermediary resistant) to either penicillin or erythromycin or 
both (62 isolates, 8.7%).
For penicillin, 44 isolates (6.2%) were non-susceptible of which 
3 isolates (0.4%) were resistant. For erythromycin, 34 isolates 
(4.8%) were resistant (Figure 8.6.1).
For pneumococci, antibiotic susceptibility is closely connected 
to serotypes. Serotypes are again influenced by vaccines as well 
as natural fluctuation. For example, serotype 1 was dominant 
in the years 2009 to 2013 encompassing 17% of all of the 
received isolates. Serotype 1 has gradually decreased after the 
introduction of the PCV13 childhood vaccine in 2010, and was 
at just 0.8% of all of the received isolates in 2016. In contrast, 
the non-vaccine serotype 8 is now dominant with 21% of the 
received isolates in the years 2014 to 2016, while in the years 
2009 to 2013 it was at 7.4%. When comparing the percentage 
of non-sensitive isolates between different years, the differ-
ences in serotype-distributions should therefore be kept in mind. 
All of the received isolates of serotypes 7C, 14 and 9V (n=5) 
were non-susceptible to either erythromycin or penicillin or 
both. In contrast, 21 different serotypes (n=470) were always 
fully susceptible to both of these antibiotics. Serotypes with 
more than 25% non-susceptibility to erythromycin were 6B, 
7C, 9V, 14, 15A, 24F and 33F. Serotypes with more than 25% 
non-susceptibility to penicillin were: 1, 6B, 7C, 9V, 14, 15A, 
17F and 23B.
The levels of penicillin non-susceptibility in Denmark is similar 
to the levels reported in 2015 to EARS Net by the neighbour-
ing countries Sweden (6.8%), Norway (5.4%) and Germany 
(6.2%). Correspondingly, the levels of erythromycin non-sus-
ceptibility in Denmark is similar to the levels reported in 2015 
from Sweden (6.6%) but lower than the levels reported from 
Norway (10.7%) and Germany (8.1%).
8.6.2: Beta-haemolytic streptococci
Beta-haemolytic streptococci (BHS) can be divided into groups 
according to antigenic properties of the polysaccharide cap-
sule. In human infections, groups A, B, C and G are the most 
frequent species. Approximately 10 % of humans are asymp-
tomatic throat carriers of BHS of any group. 
Streptococcus pyogenes (group A streptococci; GAS) cause 
pharyngitis, tonsillitis, otitis media, wound infections, and 
superficial skin infections, but also more severe infections, e.g. 
bacteraemia, necrotizing myofasciitis, and rarely meningitis. 
The rate of asymptomatic throat carriage of GAS is approxi-
mately 2%.
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Streptococcus agalactiae (group B streptococci; GBS) may be 
present in the vaginal flora of 20-25 % of women in the child-
bearing age and may therefore cause meningitis and septi-
caemia in the newborn. Such infections also occur in elderly or 
immuno-compromised patients. 
Streptococcus dysgalactiae subsp. equisimilis (group C strepto-
cocci; GCS, and group G streptococci; GGS) predominantly cause 
soft-tissue infections and sometimes bacteraemia. 
This report presents data on antimicrobial resistance in non-
duplicate invasive isolates (i.e. from blood or cerebrospinal 
fluid) of BHS submitted in 2016 to the Neisseria and Strep-
tococcus Reference laboratory. Isolates are received from all 
DCMs in Denmark. It is voluntary to submit isolates of BHS, and 
not all DCMs submit BHS of all groups. 
Infections with BHS are usually treated with penicillins or  
macrolides. All submitted isolates of BHS group A, B, C and G 
are therefore tested for susceptibility to penicillin, erythromy-
cin, clindamycin as well as inducible clindamycin resistance.
Table 8.6.1 shows the resistance findings for the years 2013 
through 2016. The numbers of submitted isolates of GAS, GBS, 
and GGS increased substantially in 2016 compared to 2015: 
GAS, +13%; GBS, +30%, and GGS, +28%, while the number 
of GCS increased by 4%. All isolates were fully susceptible 
to penicillin. The erythromycin resistance rate was virtually 
unchanged for GBS and GCS, but had increased from 1.9% to 
5.2% for GAS and from 9.8% to 16% for GGS. The clindamycin 
resistance rate showed only minor increases, but the percent-
age of strains with inducible clindamycin resistance increased 
for GGS and especially GAS. The percentage of fully suscep-
tible isolates was unchanged for GBS and GCS, but decreased 
for GAS (from 98 % to 95 %) and in particular for GGS (from 
91% to 84%).
Conclusions
The number of submitted isolates increased for all four groups 
of BHS, in particular for GBS (+28%) and GGS (+30%). An in-
crease of resistance at varying levels was observed for all four 
groups, being most pronounced for GGS.  
Steen Hoffmann 
For further information: Steen Hoffmann (hof@ssi.dk)
Table 8.6.1. Beta-haemolytic streptococci: Antimicrobial resistance testing results, 2013-2016 DANMAP 2016
BHS Resistance testing results 2013 2014 2015 2016
GAS Number of isolates 177 149 154 174
Erythromycin resistant 5 (2.8%) 1 (0.7%) 3 (1.9%) 9 (5.2%)
Clindamycin resistant 3 (1.7%) 1 (0.7%) 0 (0%) 1 (0.6%)
Additionally, inducible clindamycin resistance 1 (0.6%) 0 (0%) 2 (1.3%) 7 (4.0%)
Susceptible to penicillin, erythromycin and clindamycin 172 (97%) 147 (99%) 151 (98%) 165 (95%)
GBS Number of isolates 113 139 140 182
Erythromycin resistant 20 (18%) 31 (22%) 30 (21%) 35 (19%)
Clindamycin resistant 14 (12%) 16 (11%) 14 (10%) 17 (9.3%)
Additionally, inducible clindamycin resistance 1 (0.9%) 4 (2.9%) 7 (5.0%) 11 (6.0%)
Susceptible to penicillin, erythromycin and clindamycin 92 (81%) 107 (77%) 111 (79%) 147 (81%)
GCS Number of isolates 68 80 103 107
Erythromycin resistant 3 (4.4%) 3 (3.8%) 8 (7.8%) 9 (8.4%)
Clindamycin resistant 2 (2.9% 3 (3.8%) 2 (1.9%) 4 (3.7%)
Additionally, inducible clindamycin resistance 1 (1.4%) 1 (1.3%) 4 (3.9%) 6 (5.6%)
Susceptible to penicillin, erythromycin and clindamycin  65 (96%) 76 (95%) 95 (92%) 97 (91%)
GGS Number of isolates 145 183 183 234
Erythromycin resistant 17 (12%) 19 (10%) 18 (9.8%) 38 (16%)
Clindamycin resistant 6 (4.1%) 3 (1.6%) 5 (2.7%) 3 (1.3%)
Additionally, inducible clindamycin resistance 6 (4.1%) 13 (6.9%) 9 (4.9%) 29 (12%)
Susceptible to penicillin, erythromycin and clindamycin 128 (88%) 165 (90%) 167 (91%) 196 (84%)
Resistance findings for erythromycin and clindamycin are shown as number (%)
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8.7 Staphylococcus aureus
Staphylococcus aureus is part of the normal flora of the skin 
and mucosa in approximately 50% of humans. Some people 
only carry S. aureus intermittently whereas others carry S. 
aureus for longer time. However, in addition S. aureus also 
causes infections ranging from superficial skin infections, i.e. 
impetigo and boils, to more invasive infections such as post-
operative wound infections, infections related to intravenous 
catheters and prosthetic devices, septic arthritis osteomyelitis, 
endocarditis and bacteremia. Some of these may have a fulmi-
nant progress and are associated with high mortality.
In Denmark, a voluntary surveillance program of all S. aureus 
bacteremia cases was established in 1957. By comparison 
with the numbers of bacteremia cases registered in the Danish 
Microbiology Database (MiBa) since 2010, the number of 
cases reported to SSI has been almost complete (94-97%). 
Laboratory and clinical notification of methicillin-resistant S. 
aureus (MRSA) has existed since November 2006. At SSI, all 
isolates are initially tested using a multiplex PCR detecting: 
the spa, mecA, hsd, scn and pvl gene (LukF-PV). spa is used as 
S. aureus specific marker and for subsequent typing by Sanger 
sequencing, mecA to determine MRSA status, and scn and 
hsd as markers for human adaptation and relation to CC398, 
respectively. PVL has been closely linked to skin abscesses 
and the very rare condition of severe necrotizing pneumonia. 
PVL is found both in methicillin-susceptible S. aureus (MSSA) 
and MRSA. Presence of PVL genes has been closely associated 
with community acquired (CA) MRSA strains, although not all 
CA-MRSA carry PVL. Isolates positive for mecA and the CC398 
specific hsd fragment but negative for scn (human adaptive 
factor) and pvl genes are considered typical livestock MRSA 
(LA-MRSA) and are not spa typed. All others including human-
adapted CC398 isolates are spa typed. All bacteremia cases 
and mecA negative presumed MRSA are tested for presence of 
the mecC gene.
A representative selection of bacteremia isolates, every sec-
ond received in the first half of the year (n=560), were tested 
for antimicrobial  susceptibility against 17 antimicrobials. In 
addition demographic and epidemiological information is reg-
istered. Based on the epidemiological information each case is 
classified with respect to possible place of acquisition: hospital 
(HA), community (CA), healthcare-associated with a community 
onset (HACO), import (IMP) and livestock contact (LA) MRSA. 
For CA and HACO classification is separated into known and 
unknown exposure.
8.7.1.Surveillance of bacteraemia
In 2016, 1,981 S. aureus bacteremia (SAB) cases correspond-
ing to 34.7 cases per 100,000 inhabitants were reported from 
the Departments of Clinical Microbiology (DCM) in Denmark. 
The number of cases have stabilized at this level after a steep 
increase from approximately 1,500 annual cases before 2014. 
Forty (2.1%) of the SAB cases were caused by MRSA. Thus, the 
MRSA frequency among SAB isolates continues to be very low 
compared to most other countries participating in EARS-Net 
[EARS-Net 2015]. Seven of the 40 MRSA cases were caused 
by LA-MRSA CC398 (compared to three in 2015). Four hundred 
and fifty two (23%) patients died within 30 days of the diag-
nosis of bacteremia. The mortality for the MRSA bacteremia 
cases was 15% (n=6). Antimicrobial resistance in SAB isolates 
from 2005–2016 is presented in Table 8.7.1. The highest 
frequency of resistance to other antimicrobials than penicil-
lin was observed for fusidic acid (12%), erythromycin (7%), 
clindamycin (6%) and norfloxacin (4%). Susceptibility to the 
tested antimicrobial agents was lower for several antimicrobi-
als  compared to 2015, resistance to fusidic acid decreased 
Table 8.7.1 Resistance (%) in isolates from S. aureus bacteraemia cases, Denmark DANMAP 2016
Notes: nt = not tested. In chapter 9, table 9.2, the distribution of MICs and resistance for all tested antimicrobial agents are shown.
Antimicrobial 
agent
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
% % % % % % % % % %
Methicillin 0.6 1.3 1.6 1.4 1.4 1.2 1.7 2.9 1.5 2.1
Penicillin 78 77 77 75 77 74 76 77 71 71
Erythromycin 4 5 7 5 7 6 7 8 7 7
Clindamycin 3 4 6 4 6 6 6 8 7 6
Tetracycline 2 3 2 3 2 2 3 5 4 3
Fusidic acid 9 9 9 13 13 14 15 15 16 12
Rifampicin <1 <1 <1 <1 <1 <1 0 <1 <1 <1
Norfloxacin 1 2 2 3 4 4 5 6 6 4
Kanamycin <1 1 1 1 <1 1 2 2 3 1
Linezolid nt 0 0 0 0 0 0 0 0 0
Mupirocin <1 <1 <1 <1 <1 <1 <1 <1 <1 0
Trimethoprim-
sulfamethoxazole
nt nt nt nt <1 1 1 1 <1 <1
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from 16 % in 2015 to 12% in 2016. Resistance to fusidic acid 
has otherwise increased steadily from 2007 to 2015 (Table 
8.7.1). Typing identified 578 different spa types distributed 
in 28 different CC groups (the ten most prevalent spa types 
representing 31% of the total are presented in Table 8.7.2). 
The PVL toxin was demonstrated in 22 (1.1%) cases of which 
six were MRSA. None of cases with a PVL positive MRSA were 
reported to have pneumonia. The 22 PVL containing isolates 
belonged to 15 different spa types and 7 different CC groups.
Surveillance of MRSA
In 2016, 3,550 new MRSA cases were detected (62.2 per 
100,000 inhabitants). This was 20% higher than observed 
in 2015 in Denmark (Figure 8.7.1). A case was defined as a 
person found positive for the first time with a specific MRSA 
strain regardless whether the patient was infected or colo-
nized only. MRSA isolates were confirmed by detection of 
either the mecA, or more uncommonly, the mecC gene.
After the number of new cases had stabilized in 2015, the 
observed increase in 2016 followed the increasing trend reg-
istered since 2009. CC398 cases constituted 35% (n=1,297) 
of new MRSA cases in 2016, of which 1,249 belonged to the 
LA-MRSA CC398 and 48 to the human adapted PVL- posi-
tive variant. The number of LA-MRSA CC398 increased in 
2016 compared to 2015, but is at the same level as in 2014. 
It should be noted, that this trend may be influenced by the 
fact that only new cases are registered and that many people 
with livestock contact, in particular pig farmers, have already 
been tested positive in previous years; therefore, they are not 
counted as new cases, even though most of them will still be 
LA-MRSA CC398 carriers.
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Table 8.7.2 The ten most prevalent spa types demonstrated in SAB and in non-CC398 MRSA cases, Denmark 2016 DANMAP 2016
SAB MRSA
spa type CC group(a) No. of cases spa type CC group(a) No. of cases No. causing 
 infections (%)
t002 CC5 87 t304 CC8 223 69 (31)
t127 CC1 80 t223 CC22 212 64 (30)
t230 CC45 80 t002 CC5 188 98 (52)
t084 CC15 78 t127 CC1 135 58 (43)
t091 CC7 61 t008 CC8 105 72 (69)
t012 CC30 61 t019 CC30 96 69 (72)
t008 CC8 53 t044 CC80 84 44 (52)
t021 CC30 39 t437 CC59 46 30 (65)
t015 CC45 38 t005 CC22 39 22 (56)
t701 CC8 37 t657 CC97 36 20 (56)
a) CC = Clonal complex
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MRSA isolates carrying mecC were demonstrated in 45 cases 
(1.3%) in 2016 (9 in 2009, 21 in 2010, 37 in 2011, 24 in 
2012, 41 in 2013,  53 in 2014 and 61 in 2015). Thirty of the 
cases (67%) had infections at the time of diagnosis. No live-
stock contact was reported for the 45 mecC cases.
The total number of cases and the number of cases presenting 
with infection according to epidemiological classification are 
shown in Table 8.7.3. Most of the cases (80%) were acquired 
in Denmark. At the time of diagnosis, 38% (n=1,356) of cases 
had infection, which was similar to 2015 but lower than in pre-
vious years due to a much lower fraction of infections among 
LA-MRSA CC398 cases (n=208, 16%).
The epidemiological classification of MRSA infections 2007–
2016 is shown in Figure 8.7.2. Despite the increasing number 
of cases, the number of HA-MRSA infections (n=30) and HACO-
MRSA infections (n=155) remained low. The number of CA and 
imported infections continued the increasing trend in 2016 
and were by far the two largest groups (n = 607 and n= 325, 
respectively) while infections caused by LA-MRSA CC398 was 
similar (n=218) to the number in 2015 (n=208) (Figure 8.7.2). 
The number of infections among health care workers increased 
from 31 cases in 2015 to 40 cases in 2016 (Table 8.7.3).
Molecular typing of non-CC398 MRSA isolates
In total, typing revealed 322 different spa types not associated 
with CC398, of which 233 types were associated with clinical 
infections. The 10 dominating non-CC398 spa types in 2016 are 
shown in Table 8.7.2. They constituted 52% of the total number 
of non-CC398 MRSA isolates. Among the MRSA causing clinical 
infections at time of presentation, ten spa types constituted 
49% of the 1,115 clinical cases with MRSA. These most preva-
lent spa types were t002/CC5 (n=98), t008/CC8 (n=72), t019/
CC30 (n=69), t304/CC6/CC8 (n=69), t223/CC22 (n=64) t127/
CC1 (n=58), t044/CC80 (n=44), t437/CC59 (n=30), t657/CC1 
(n=20) and. PVL was found in 39.5% of isolates related to infec-
tions and in 20.8% of isolates from asymptomatic carriers. PVL 
was predominant in isolates belonging to spa types t019 (n=86), 
t008 (n=81),  t002 (n=37), t044 (n=79) and t437 (n=41).
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Table 8.7.3 Epidemiological classification of new  
MRSA cases, Denmark 2016 DANMAP 2016
Epidemiologic 
classification
Exposure No. of 
cases (% of 
total)
No. (%) of 
cases with 
infections 
Imported (IMP) 712 (20) 325 (46)
Hospital-
acquired (HA)
43 (1) 30 (70)
Health-care 
associated,  
community 
onset (HACO)
211 (6)
with known exposure 29 14 (48)
without known 
exposure
182 141 (77)
Health care 
worker
40 (1) 21 (53)
Community-
acquired (CA)
1280 (36)
with known exposure 674 153 (23)
without known 
exposure
606 454 (75)
LA-MRSA CC398 1249 (35)
with known exposure 1040 120 (12)
without known 
exposure
209 98 (47)
Unknown/
missing
15
Figure 8.7.2 Number of MRSA infections according to epidemiological classification, Denmark DANMAP 2016
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Resistance among non-CC398 MRSA isolates
Resistance data is presented for non-CC398 isolates in 
Table 8.7.4. Every second non-CC398 isolate received in the 
laboratory in 2016 was tested (n=1,184). Human adapted 
Resistance to at least one, two or three other antimicrobials 
in addition to β-lactam antibiotics (cefoxitin/penicillin) was 
demonstrated in 64%, 45% and 31% of non-CC398 cases, 
respectively.
In Table 9.2, (chapter 9, material and methods) the distribution 
of MICs and resistance for all tested antimicrobials are shown.
Andreas Petersen and Anders Rhod Larsen 
For further information: Anders Rhod Larsen (arl@ssi.dk)
Table 8.7.4 Resistance (%) in non- CC398 MRSA isolates, 
Denmark 2015 DANMAP 2016
%
non-CC398 
Erythromycin 34
Clindamycin 25
Tetracycline 26
Fusidic acid 18
Rifampicin 1
Norfloxacin 19
Kanamycin 28
Linezolid <1
Mupirocin <1
Trimethoprim-sulfamethoxazole 2
Number of tested isolates 1184
 Advisory Service for LA-MRSA
This national advisory service was established on July 1, 2014 with the purpose of providing help regarding the handling of 
livestock associated (LA)-MRSA for citizens, people working with livestock, and relevant institutional bodies in Denmark. LA-MRSA 
differs from ordinary MRSA in a number of areas, including infection control and relevance for different sectors of health care. The 
aim of the advisory service is to reduce the spread of livestock-MRSA into the community. This is done by increasing the under-
standing of the connection between hygiene, carriage and infection risks among people who work with farm animals and thus 
reduce further transmission to humans without direct contact with domestic animals. 
 
Since 2006, there has been a focused Danish strategy for the prevention of MRSA, with the Danish Health Authority maintain-
ing the guidelines. The strategy is based on a search and destroy principle including i) monitoring MRSA positive cases by clinical 
microbiology laboratories, ii) mandatory reporting of new MRSA cases and risk factors to SSI iii) typing of new MRSA cases iv) in-
vestigating outbreaks and v) providing relevant treatment for persons infected or colonized with MRSA. Transmission in hospitals 
is prevented by isolation precautions, and healthcare professionals can get advice from regional infection control units. In most 
regions, patients receive free treatment of carrier status. 
The strategy has focused on limiting spread in hospitals but has most likely also helped to limit the number of infected persons in 
the community. 
 
The Advisory Service is communicating about infection control, medical and social issues related to livestock-MRSA for both 
employees in pig production, persons who come into contact with domestic animals e.g. craftsmen, other citizens and health pro-
fessionals. The Advisory Service offers teaching / lectures about livestock-MRSA in farmers associations, educational institutions 
e.g. agricultural schools, and to health care providers. Evidence-based information is prepared based on a systematic knowledge 
capture and analysis of data from LA-MRSA positive persons. The Advisory Service is now setting up a mandatory e-learing course 
for all persons working with live pigs. The course is expected to be completed by the end of 2017.
 
For more information visit www.ssi.dk/MRSA
  
The Advisory Service is co-financed by the Ministry of Health and the Elderly and the Ministry of the Environment and Food and is 
a temporary function that has been provisionally extended until the end of 2018
DANMAP 2016110
Textbox 8.4 
LA-MRSA CC398 in animals and humans
The number of LA-MRSA CC398 infection in people with livestock contact continued to decrease in 2016, from 132 cases in 
2015 to 121 cases in 2016. This trend may be due to the fact that new MRSA cases are only registered once - regardless of 
whether these are healthy carriers or have infections. Thus, many people with livestock contact, in particular pig farmers, have 
already been tested positive for LA-MRSA CC398 and will not be counted again as new cases, even when being infected with 
LA-MRSA CC398. In contrast, the number of LA-MRSA CC398 infections in people with no livestock contact, i.e. the general 
population, continued to increase in 2016, from 73 cases in 2015 to 98 cases in 2016, which seems to follow the increasing 
prevalence of positive pig herds, as illustrated in Figure 1. This is worrisome because the general population includes a higher 
proportion of elderly and immunocompromised people with an elevated risk of developing invasive staphylococcal illnesses. In 
a recent Danish study, Statens Serum Institut investigated the occurrence and origin of bloodstream infections (BSIs) caused by 
LA-MRSA CC398 between 2010 and 2015 (Larsen et al., Clin Infect Dis., 2017, May 30). The analysis showed that the annual 
number of LA-MRSA CC398 BSIs increased, peaking in 2014, where LA-MRSA CC398 accounted for 16% (7/44) of all MRSA BSIs, 
which corresponds to 1.2 cases per 1,000,000 person-years. LA-MRSA CC398 BSIs and associated deaths were more common in 
people with no livestock contact (10 BSIs and 6 deaths) than in people with livestock contact (7 BSIs and 0 deaths). In addi-
tion, whole-genome sequence analysis showed that most of the BSI isolates were closely related to Danish pig isolates. These 
findings support a causal relationship between the continued spread of LA-MRSA CC398 into the general population and the 
increasing number of serious infections and deaths. 
MRSA in conventional pig herds
In 2016, the Danish Veterinary and Food Administration conducted a screening of conventional pig herds for LA-MRSA. Alto-
gether 221 herds were tested; 57 of these were randomly selected for an estimate of the present prevalence. In addition, herds 
from two geographic areas (Southeast Zealand and Bornholm), not represented in the 2014 survey (N = 53), and some herds 
whose MRSA status already was known from the 2014 survey (N = 117, among these 111 production herds and six breeding 
herds) were included. The purpose of re-testing herds from the 2014 survey was to estimate the proportion of negative herds 
that had become positive during the 2-year period, and to see if any of the previously positive herds had become negative. The 
results are presented in Table 1.
The overall prevalence of LA-MRSA in the randomly 
selected herds was 88%, an increase from 68% in 
2014. The prevalence was lower in Southeast Zealand 
(59%) and on Bornholm (62%). In 2014, the propor-
tion of positive herds among herds tested in other 
parts of Zealand (53%) was also lower than in Jutland 
(70%) and on Funen (69%).
It is interesting that all six breeding herds were posi-
tive for LA-MRSA, including the three herds that were 
negative in 2014. These herds had become positive 
although no animals had been introduced, suggesting 
that LA-MRSA can be introduced via human carriers 
or other sources. It is also interesting that 62% of 
the herds, which were negative in 2014, had become 
positive in 2016.
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An important observation is that all herds, which were positive in 2014, were still positive in 2016, suggesting that spontane-
ous elimination of LA-MRSA from conventional pig herds is unlikely to occur.
A total of 179 LA-MRSA isolates obtained from the 2016 survey were subjected to spa-typing. The CC398-associated spa-types 
t034 (n=109) and t011 (n=53) were by far the most prevalent, while nine other spa-types and an unknown spa-type were 
found in 1-4 isolates. In one of the breeding farms, two different clones, a CC398 and a CC1 were found.
MRSA in organic and free-range pigs
A survey of organic pig herds carried out by the Danish Veterinary and Food Administration in 2015 revealed that only 6% of 
the tested herds were positive for LA-MRSA. In 2016, six free-range pig farms (five organic and one conventional) were tested 
multiple times to examine the population dynamics of LA-MRSA after introduction of positive conventional breeding pigs. Al-
though five of the farms received MRSA-positive conventional breeding pigs, four of them tested MRSA-negative in all sections 
after 3 months. This indicates that LA-MRSA is less well maintained in free-range pig farms pigs, compared to conventional pig 
farms.
MRSA in pork
The increased prevalence of LA-MRSA in pigs is mirrored by an increasing prevalence of LA-MRSA in domestically produced 
pork. Among 163 conventional pork meat samples collected at retail level, LA-MRSA was detected in 78 (48%). This is a marked 
increase compared to previous sampling in 2009 (5%), 2010 (6%) and 2011 (10%) (Figure 2). 
Of the LA-MRSA isolates from conventional pork, 76 belonged to CC398, one was CC9, and CC1, respectively. The CC1 isolate 
belonged to spa-type t127, while the CC9 isolate belonged to t1430. The CC398 isolates were vastly dominated by t034 (n 
= 46) and t011 (n = 23), while a single isolate belonged to each of the spa-types t108, t571, t898, t1255, t2123, t2997 and 
t4652. 
Interestingly, among 97 samples from organic pork, 31 (32%) were LA-MRSA positive with CC398. These were also dominated 
by spa-types t034 (n = 18) and t011 (n = 11), while one isolate was t1255 and t1606, respectively. Considering that only 6% 
of the organic pig farms were found positive for LA-MRSA in the 2015 survey (see above), which suggests a low prevalence in 
organic and free range pigs, the observed prevalence of positive organic pork products is surprisingly high. One possible expla-
nation is that cross-contamination from conventional pigs may take place at the slaughterhouse.
Imported pork from conventional production was also sampled and LA-MRSA was detected in 13 of 45 samples (29%). As in 
the domestically produced meat, CC398 was most common belonging to spa-type t034 (n = 5), t011 (n = 3), t11374 (n=1) and 
t1451. Three isolates belonged to CC9 (t899, t1200 and t1430).        
Table 1. Prevalence of pig herds positive for LA-MRSA in 2014 and 2016 DANMAP 2016
Pig herd type   Pig herds positive for LA-MRSA 
in 2014 
Pig herds positive for LA-MRSA 
in 2016 
Slaughter pigs randomly selected herds 68 % (N = 205)1 88 % (N = 57)2
  geographic area Bornholm Not tested 62% (N = 26)
  geographic area Southeast 
Zealand
Not tested 59% (N = 27)
Breeding herds   66% (N = 70)
  positive in 2014   100% (N = 3)   
  negative in 2014   100% (N = 3) 
Production herds positive in 2014   100 % (N = 58)
  negative in 2014   62 % (N = 53)
1 Geographic areas; Jutland: 70% (N = 147), Funen: 69% (N = 39), Zealand: 53% (N = 19)
2 All samples were from herds from Jutland or Funen
DANMAP 2016112
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MRSA in mink
In 2016, the National Veterinary Institute conducted a survey of all submissions of mink to the laboratory. The mink were 
submitted for diagnostic laboratory investigations due to disease outbreaks. Previous studies had revealed that LA-MRSA 
in mink is most often located on the paws and in the pharynx. A total of 89 submissions were examined and LA-MRSA was 
found in 30 (34%). This is equivalent to the prevalence found in a survey conducted in 2015 (Hansen et al., Vet. Microbiol. 
2017;207:44-9). In addition, two cases of methicillin-resistant Staphylococcus pseudintermedius (MRSP) were found.  
MRSA in bulk tank milk
In November and December 2016, bulk tank milk samples were collected from 236 dairy cattle herds. LA-MRSA was found 
in seven of these samples (3%). This prevalence is slightly higher than those in 2014 (2%) and 2012 (1.8%), but this is not 
statistically significant. Of the seven positive samples, six isolates carried the mecA gene, while one isolate carried the mecC 
gene. This is the first record of mecC in bulk tank milk in Denmark. The six mecA-isolates had spa-type t034 associated with 
CC398, whereas the mecC-isolate had spa-type t843 associated with CC130.
MRSA in horses
Between April and August 2015, University of Copenhagen and Statens Serum Institut performed a screening survey for LA-MRSA 
in horses (Islam et al., Front. Microbiol. 2015;8:543). In total, 17 of 401 horses (4%) from seven of 74 farms (9%) were positive 
for LA-MRSA, including 14 mecA-carrying CC398 isolates with spa-types t011 (N = 10) and t034 (N = 4) and three mecC-carrying 
CC130 isolates with spa-type t528. Whole-genome sequence analysis showed that the ten CC398 isolates with spa-type t011 
belonged to a separate horse-adapted sublineage within CC398, whereas the four CC398 isolates with spa-type t034 were closely 
related to CC398 isolates from Danish pigs, suggesting that CC398 is able to spread between different animal species.
Conclusions
The results presented above show that conventional pig farms are still the primary reservoir for LA-MRSA, especially CC398. 
However, there is a growing body of evidence that LA-MRSA CC398 is spreading to other animal species, such as cattle, mink, 
and horses, and to people in contact with those animals. In addition, the number of infections, including life-threatening BSIs, 
among people with no contact to livestock is increasing.
Anders Rhod Larsen, Jesper Larsen, Julie Elvekjær Hansen, Andreas Petersen, 
Anna Irene Vedel Sørensen, Lærke Boye Astrup, Zohorul Islam, Mariann Chriél, Karl Pedersen 
For further information: Anders Rhod Larsen arl@ssi.dk and Karl Pedersen kape@vet.dtu.dk
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Figure 2. Occurence (%) of MRSA in pork, Denmark DANMAP 2016
Note: Confidence intervals are calculated as 95% binomial proportions presenting Wilson intervals.
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8.8 Neisseria gonorrhoeae 
Background: Neisseria gonorrhoeae is the causative agent 
of the sexually transmitted infection gonorrhoea, which is 
usually located in the urethra in males and cervix in females. 
N. gonorrhoeae (gonococci) may sometimes be demonstrated 
in specimens from the pharynx or rectum in either gender. In 
females, the finding of gonococci in rectal specimens is usually 
due to contamination with vaginal secretion, while in men who 
have sex with men (MSM) it is due to unprotected anal sex 
leading to infection. In both genders the condition is gener-
ally asymptomatic. Pharyngeal gonorrhoea is virtually always 
asymptomatic. 
Complications of gonorrhoea include e.g. salpingitis, epididy-
mitis, orchitis, and prostatitis. Furthermore, conjunctivitis may 
occur in newborns after transmission from an infected mother 
during labour and rarely in adults following direct inoculation.
Methods: Since 1962, the Departments of Clinical Microbiol-
ogy in Denmark have submitted isolates of gonococci to the 
Neisseria and Streptococcus Reference (NSR) laboratory at 
Statens Serum Institut for national surveillance of antimicro-
bial resistance. 
At the NSR laboratory ceftriaxone, ciprofloxacin and azithro-
mycin MICs are determined using the Etest® on chocolate agar 
incubated at 35 °C in 5% CO2. The breakpoints used are those 
defined by EUCAST. Both resistant and intermediary suscepti-
ble isolates are categorized as resistant in this report. Penicil-
linase production is tested for using the Nitrocephin assay.
As part of NSR’s participation in ECDC’s surveillance of sexu-
ally transmitted infections since 2009, approximately 110 
gonococcus isolates are collected consecutively each year and 
investigated for susceptibility to an expanded panel of anti-
microbial agents. This panel includes cefixime and in selected 
years also spectinomycin and sometimes gentamicin. 
Results and discussion: Most of the received isolates are 
from urethra or cervix, while clinicians only rarely obtain speci-
mens from rectum and pharynx. Occasionally, the NSR labora-
tory receives strains isolated from other anatomical sites, such 
as conjunctivae, joint fluid, blood, Bartholin’s abscess, etc.
In 2016, isolates from 1,493 unique cases of gonorrhoea 
were received. The annual number has increased considerably 
from 2011 through 2016 (Figure 8.8.1), partly because the 
widespread use of combined nucleic acid amplifications tests 
for Chlamydia trachomatis and N. gonorrhoeae has identified 
unexpected cases of gonorrhoea (followed by culture), and 
partly due to an increasing incidence of gonorrhoeae, espe-
cially among young heterosexual persons, among whom an 
increasing proportion are women.
The ciprofloxacin resistance rate was 18% in 2016 (29% in 
2015 and 46% in 2014), thus showing a steady decline since 
the peak of 75% in 2009 (Figure 8.8.1). The percentage of 
strains producing penicillinase was 7 % in 2016. It has fluctu-
ated between 22% in 2005 and 8% in 2015. Azithromycin 
resistance was found in 1% of the isolates and intermediary 
susceptibility in 6% (1% and 10%, respectively, in 2015).
Ceftriaxone resistant gonococci (MIC > 0.125 mg/L) as well as 
ceftriaxone treatment failure in patients with gonorrhoea have 
occurred in several countries during recent years.  During 2003 
through 2009 the proportion of isolates with ceftriaxone MIC 
≥  0.008 mg/L gradually increased from 40% to nearly 75% 
(Figure 8.8.2), but during recent years this shift has nearly 
reversed (44% in 2014 and 17% in 2015). Thus, there is no 
evidence of emerging ceftriaxone resistance in Denmark.
The National Board of Health issued guidelines in 2015 for the 
diagnosis and treatment of sexually transmitted infections. 
A combination of high dose ceftriaxone (500 mg i.m.) and 
azithromycin (2 g) is recommended for the treatment of gonor-
rhoea. Ciprofloxacin 500 mg p.o. may be used for treatment if 
the strain is fully susceptible. 
In a subset of 111 isolates, resistance against cefixime (MIC > 
0.125 mg/L) was 0% in 2016 (0% in 2015). Cefixime is an oral 
cephalosporin that has never been used in Denmark. Resistance 
against spectinomycin was 0% in 2016 as well as in 2015. 
Conclusions: The incidence of gonorrhoea is increasing substan-
tially. The ciprofloxacin resistance rate continues to decrease, 
concomitantly with an increasing proportion of gonorrhoeae 
cases being among heterosexual patients and among females. 
Although resistance problems are still not present in Denmark, 
the emerging ceftriaxone treatment failures in other countries 
underlines the importance of maintaining the centralised national 
surveillance of antimicrobial resistance in gonococci. 
Steen Hoffmann 
For further information: Steen Hoffmann (hof@ssi.dk)
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Figure 8.8.1 The number of submitted gonocccus isolates from males and females, and the percentage of isolates  
with ciprofloxacin resistance, azithromycin resistance, and penicillinase production, Denmark, 2003-2016   DANMAP 2016
Figure 8.8.2 Distribution of ceftriaxone MIC (mg/L) values in gonococci, Denmark, 2003–2016 DANMAP 2016
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Textbox 8.5  
Clostridium difficile surveillance
 
C. difficile is an important human pathogen and the primary cause of pseudomembranous colitis and antibiotic-associated diar-
rhoea. Since the beginning of the millennium, C. difficile has caused large outbreaks in hospitals worldwide, coinciding with the 
emergence of epidemic strains such as PCR-ribotypes RT027 and RT078 associated with increased incidence, severity, mortal-
ity and recurrence. The main virulence factors of pathogenic C. difficile are the toxins TcdA and TcdB, but in addition, C. difficile 
027 and other important clones also produce a binary toxin (CDT).  
In Denmark, more than 5,000 C. difficile infections are diagnosed each year; the majority of these are hospital-acquired. In 
recent years, more than 1,000 isolates have been submitted annually from the regional hospital laboratories to Statens Serum 
Institut for typing and further characterization. Since 2013, Statens Serum Institut has replaced PCR-ribotyping with tandem-
repeat sequence typing (TRST) [1] for the routine typing of C. difficile. There is a good correlation between the two methods; 
e.g. RT027, RT078, RT023, RT066 and RT014 correspond to TRST types tr027, tr070, tr016, tr067 and tr014, respectively. 
Due to the severity of disease related to the multi-resistant and epidemic C. difficile 027 clone, many laboratories use diagnos-
tic methods that detect specific genetic markers for this clone incl. the binary toxin. Since 2012, the guidelines for submission 
of isolates have focused on the isolates harboring the binary toxin gene. Therefore, approximately 90% of the isolates typed 
at Statens Serum Institut in recent years were binary toxin positive, mainly tr027, tr070, tr016 and tr067. While several suc-
cessful measures, like hygiene, patient isolation and efficient diagnosis have reduced the number of C. difficile 027 infections, 
other important clones seem to increase.
In order to improve the future surveillance of C. difficile, a study was carried out in 2016 with the objectives of determining 
the distribution of types and antimicrobial resistance profiles among all toxigenic C. difficile, irrespective of the presence of 
the binary toxin. Each of the 10 clinical microbiological laboratories in Denmark participated by submitting all toxigenic strains 
or samples in a 2-week period in the spring and again in the autumn. The isolates were typed by TRST, the toxin profile was 
determined by PCR and the antimicrobial resistance profile was determined for a selection of the isolates. A total of 417 iso-
lates were characterized. Of these, 72.2% were positive only for tcdA and tcdB, while 23.8% were additionally positive for the 
binary toxin. The distribution of the 10 most prevalent TRST types in the spring (P1) and autumn (P2) period is shown in the 
figure, indicating similar distribution in the two different periods. Among the 10 most prevalent types, seven did not contain 
Figure 1. Clostridium difficile. Percentage of the 10 most prevalent TRST types in unbiased  
surveillance project in spring (P1, n=199) and autumn (P2, n=218) in 2016 DANMAP 2016
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the binary toxin. Among all types, tr014 (binary toxin negative) was the most prevalent at both the national level and at each 
of the five Danish regions. Preliminary antimicrobial resistance testing showed that tr014 isolates are generally susceptible, 
whereas tr027 are resistant to moxifloxacin and erythromycin and in varying degree resistant to clindamycin and rifampicin.
The role of the binary toxin has been a controversial subject as some studies have shown increased mortality among patients 
infected with binary toxin positive strains, while other studies have not confirmed this [2–5]. In this study, 30 days mortality 
was 13.2% and 12.9% among patients with and without the binary toxin, respectively. Based on this study, we recommend that 
future surveillance should include the binary toxin negative isolates for two reasons; several highly prevalent types of binary 
toxin negative isolates are dominating the Danish reservoir and the binary toxin negative isolates are associated with 30 days 
mortality similar to the binary toxin positive isolates. Consequently, the surveillance of C. difficile has been changed. Starting in 
2017, the clinical laboratories are referring all diagnosed toxigenic C. difficile samples in two periods of one month to Statens 
Serum Institut for characterization. In addition, samples related to suspected outbreaks or severe clinical manifestations can also 
be referred. The new surveillance scheme will enable detection of all toxigenic types, including emerging types and new resistant 
clones.
  Eva Møller Nielsen and Søren Persson 
  For further information: Søren Persson, SPN@ssi.dk
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9. MATERIALS AND METHODS
9. Materials and methods
9.1 General information
For the DANMAP 2016 report, population sizes and geographi-
cal data were obtained from Statistics Denmark [www.dst.
dk] and data on general practitioners from the Danish Medical 
Association [www.laeger.dk].
The epidemiological unit for pigs and cattle was defined as 
the individual farm level, meaning that only one isolate per 
bacterial species per farm was included in the report. The 
same epidemiological unit was applied for broilers, except for 
Salmonella where the individual flock of broilers was defined 
as the epidemiological unit. For food, the epidemiological unit 
was defined as the individual meat sample. 
For humans, the epidemiological unit was defined as the 
individual patient and the first isolate per patient per year was 
included.
Unless stated otherwise, all differences and temporal trends 
were tested for statistical significance (p<0.05) using Chi- 
square tests (see Section 9.7.3).
9.2 Data on antimicrobial consumption
An overview of all antimicrobial agents used for humans and 
animals in Denmark is presented in Table 3.2.
9.2.1 Antimicrobial usage for animals
In Denmark, all antimicrobial agents used for treatment are 
available only on prescription. Until 2007, antimicrobial agents 
were only sold by pharmacies or as medicated feed from 
the feed mills. However, from April 2007, the monopoly was 
suspended and private companies (four in 2016) were given 
license to sell prescribed veterinary medical products for 
animals, when following strict guidelines, identical to those 
applied by pharmacies. Furthermore, in 2007 price setting 
of antibiotic was liberalised, which allowed for discounts to 
veterinarians, when buying larger quantities.
A pharmacy or company either sells the medicines to veterinar-
ians for use in the practice or for re-sale to farmers, or sells the 
medicines directly to the animal holder on presentation of a 
prescription. By law, veterinarians are allowed only very small 
profits on sale of medicine (5%), to limit the economic incen-
tive to overprescribe.
In 2016, 98% of antimicrobial agents were purchased through 
pharmacies and the drug trading companies, while 2% were 
purchased from the feed mills. These numbers did not include 
prescribed zinc oxide from the feeding mills for the pigs. 
For cattle, 43% of antimicrobial agents used in 2016 were 
purchased from pharmacies, whereas 10 years ago where 
more than 80% of the antimicrobial agents used in cattle was 
purchased through the veterinarian. In aquaculture, more than 
80% is purchased through the feed mills.
Data registration
In addition, data on coccidiostatics as feed additives (non-pre-
scription) and antimicrobial growth promoters (not in use since 
2000) were also collected by VetStat, providing an almost 
complete register of all antimicrobial agents used for animal in 
Denmark each year. In very rare instances medicines are pre-
scribed on special license and will not be included in VetStat 
(i.e. medicines not approved for marketing in Denmark).
Data on all sales of veterinary prescription medicine from the 
pharmacies, private companies, feed mills and veterinarians are 
sent electronically to a central database called VetStat, which 
is hosted by the Danish Veterinary and Food Administration. 
Prior to 2001, all data on antimicrobial sales were derived from 
pharmaceutical companies. Veterinarians are required by law 
to report all use of antibiotics and prescriptions for produc-
tion animals to VetStat monthly. For most veterinarians, the 
registration of data is linked to the writing of invoices. The 
electronic registration of the sales at the pharmacies is linked 
to the billing process and stock accounts at the pharmacy, 
which ensures a very high data quality regarding amounts and 
identity of drugs. Data are transferred daily from pharmacies 
to The Register of Medicinal Product Statistics at SSI and on to 
VetStat also daily. However, VetStat does not have any valida-
tion on data entry and slight typing errors from vets may occur.
The VetStat database contains detailed information about 
source and consumption for each prescription item: date of 
sale, identity of prescribing veterinarian, source ID (identity 
of the pharmacy, feed mill, or veterinarian practice reporting), 
package identity code and amount, animal species, age-group, 
disease category and code for farm-identity (CHR Danish 
Central Husbandry Register). The package code is a unique 
identifier, relating to all information on the medicinal product, 
such as active ingredient, content as number of unit doses (e.g. 
number of tablets), package size, and code of the antimicro-
bial agent in the Veterinary Anatomical Therapeutic Chemical 
(ATCvet) classification system.
Knowledge of the target animal species enables the presen-
tation of consumption data in “defined animal daily doses” a 
national veterinary equivalent to the international defined 
daily doses (DDDs) system applied in the human field [www.
whocc.no].
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Methods
DANMAP reports usage of antimicrobials in different animal 
populations and in veterinary and human sectors. To allow for 
quantitative comparison in the different populations, the quan-
tity of antimicrobials used, their potency, their formulation, 
the route of administration, and the age of the animals (where 
relevant) are accounted for by generating Defined animal 
daily doses (DADDs).
DADD - Defined animal daily dose 
DADD is the average maintenance dose per day for 
a drug used for its main indication in the appropriate 
animal species. The DADD is not defined at product 
level but for each antimicrobial agent, administration 
route and animal species and when appropriate, also 
age group. DADD has been specifically defined for use 
in DANMAP and does not always completely match the 
“prescribed daily dose” or the recommended dosage in 
the Summaries of Product Characteristics (SPC).
 
The basic principles for the DADD are similar to the principles 
previously described for the ADD [DANMAP 2011, DANMAP 
2012]. The DADD is based on the VetStat ADDs, but re-defined 
for each group of antimicrobial agents, adding adjustments for 
each combination of active compound, administration route, 
formulation, according to following principles:
1. A DADD group is defined for each antimicrobial agent by ad-
ministration route, pharmaceutical form and animal species; 
and when appropriate also age group;
2. Minor inconsistencies have been corrected e.g. due to 
rounding of numbers;
3. Approved dosage for the most widely used antimicrobial 
products were given priority above dosage for products that 
are rarely used;
4. Approved dosage for older products within the group were 
maintained as the common DADD even if a new product is 
approved with a higher dosage;
5. If the dosage for a group with large variation in approved 
dosages of the products, the dosages provided by ”The 
Veterinary Formulary” [British Veterinary Association 2005, 
6th edition] were applied;
6. Dosages may vary within active compound and administra-
tion route, if different dosages have been approved for 
different age group/indication or formulation.
 
When principle 3 and 4 are conflicting, principle 5 is applied. 
Denominator
Trends in antimicrobial consumption in pigs are presented in 
DADD per 1,000 animals per day (DAPD). The number of ani-
mals in a population (in epidemiological terms: the population 
at risk) is represented by their live biomass. The biomass of a 
species is calculated, taking into account average live body-
weight and the average lifespan in each age group. In 2016, 
DAPD calculations were carried out for pigs only. 
Due to a relative high number of pigs exported around 30 kg; 
an adjusted measure of consumption per pig was calculated. 
The adjustment is based on the assumption that pigs exported 
at 30 kg, on average, received the same amount of antimicrobi-
al agents before export, as other pigs from farrowing to 30 kg. 
Antimicrobial use per pig produced (adjusted) is calculated as: 
[DADDs + DADDw + (1+Q)*DADDf] / (biomass-days-total + 
Nw*5,800(kg*days)), where
DADDs = amount of antimicrobial agents used in sows;
DADDw = amount of antimicrobial agents used in weaners; 
DADDf = amount of antimicrobial agents used in finishers; 
Q is the proportion of weaning pigs exported around 30 kg. 
Nw = number of pigs exported at 30 kg bodyweight, 
Nw*5,800 is the number of biomass days the exported pigs 
would have contributed to the live biomass if not exported.
Estimation of live biomass of animals
The estimation of live biomass and thus the number of stan-
dard animals at risk per day depends on the available data 
sources for each species. 
DAPD - DADD per 1,000 animals per day 
The number of DADDs administered to an animal species during a year (in thousands) divided by the number of stan-
dard animals at risk per day. The number of standard animals at risk per day takes into account species differences in 
average body-mass and life-span. When relevant, the numbers of DADDs and standard animals at risk are estimated 
for specific age groups, or simply as number of doses (DADDs) used to treat one kg of animal divided with the total 
estimated biomass (in tonnes). 
DAPD is a statistical measure, providing a rough estimate of the proportion of animals treated daily with an average 
maintenance dose of a particular antimicrobial agent. For example, 10 DAPDs indicate that an estimated 1% of the 
population, on average, receives a certain treatment on a given day. The DAPD is also referred to as the treatment 
proportion. In principle, the metric DAPD is parallel to the metric used in pharmaco-epidemiology for the human sec-
tor, Defined daily dose per 1,000 inhabitants per day (DID), see Section 9.2.2.
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Pig production. The estimation was based on the number of 
pigs produced, including exports at different ages [Statistics 
Denmark; Danish Agriculture and Food Council], productiv-
ity data for each year [Danish Agriculture and Food Council, 
2016] and census data for breeding animals [Statistics Den-
mark, 2016]. The average weight and life span for the grow-
ing animals (piglets, weaners and finishers) were estimated 
from the annual productivity numbers. The estimation meth-
ods were developed in cooperation with Danish Agriculture 
and Food Council. There are no statistics on average weight 
of breeding animals available, so an estimated average 
weight had to be assumed. However, the size of the breeding 
animals has probably increased over the last decade, but this 
could not be accounted for.
Cattle production. The live biomass of the cattle population is 
estimated from census data [Statistics Denmark] and the aver-
age live weight of the different age groups. The Danish cattle 
population is mainly dairy, particularly Holstein Friesian, but 
also other breeds such as Jersey and a small population of beef 
cattle. Most of the cattle slaughtered are dairy cows and bull 
calves of dairy origin. The average live weight was estimated 
for 10 different age and gender categories.
Broiler (Gallus gallus). The live biomass was estimated based 
on number of broilers produced [Statistics Denmark; Danish Ag-
riculture and Food Council], an average live weight at slaughter 
of 1.97 kg after an estimated average life span of 30 days. 
The mean live biomass per broiler is assumed to be half of the 
weight at slaughter. 
Turkey production. The live biomass is estimated based on 
the number of turkeys produced [Statistics Denmark; Danish 
Agriculture and Food Council] and an average live weight at 
slaughter of 21 kg for male turkeys and 11 kg for hens after 
an estimated average life span of 20 weeks and 15.5 weeks, 
respectively [Danish Agro; S. Astrup, personal communication]. 
The estimated mean live biomass per turkey is assumed to be 
half of the weight at slaughter.
Fur animals. The live biomass of mink is estimated from 
production data [Statistics Denmark, Kopenhagen Fur] and the 
average weight at pelting was 2.45 kg [Kopenhagen Fur]. The 
progeny live for approximately 7 months. The biomass for the 
breeding animals (female) was estimated based on census 
data and an assumed average live weight of 2 kg.
Pet animals. Only dogs and cats are taken into account, as the 
other population sizes are negligible in Denmark, and relatively 
rare in veterinary practice. The population is based on census 
data [Statistics Denmark, 2000] estimating 650,000 cats 
and 550,000 dogs. The number of dogs in Denmark has been 
relatively stable during the last ten years [Danish Dog regis-
ter, 2012]. The average live weight for cats and dogs were 
estimated to 4 kg and 20 kg, respectively (based on pedigree 
registration data).
Aquaculture. The estimation is based on data from the Danish 
AgriFish Agency (Ministry of Environment and Food) on pro-
duced amounts in each subtype of production, and information 
on the typical lifespan and entrance and exit body weights, 
and were calculated in cooperation with Danish Aquaculture 
[N.H. Henriksen, Danish Aquaculture].
9.2.2 Antimicrobial consumption in humans
Data on consumption of antibacterial agents in humans were 
obtained from The Register of Medical the Department of Data 
Delivery and Medicinal Product Statistics, at Statens Serum In-
stitut. The Register receives monthly reporting of consumption 
from all pharmacies in Denmark, including hospital pharmacies. 
Data from primary health care sector have been collected since 
1994, whereas data on consumption in hospitals are available 
from 1997.
Only somatic hospitals were included, when the consumption 
was measured by occupied bed-days and admissions. Data 
from private hospitals and clinics, psychiatric hospitals, special-
ised non-acute care clinics, rehabilitation centres and hospices 
were excluded from DANMAP (representing approximately 
3% of the antimicrobial consumption at hospitals and of the 
number of bed-days).
In the primary health care in Denmark, all antibacterial agents 
for human use are prescription-only medicines and are sold 
by pharmacies in defined packages. Each package is uniquely 
identified by a code, which can be related to package size, con-
tent as number of unit doses (e.g. number of tablets), content 
as number of Defined Daily Doses (DDDs), code of the antimi-
crobial agent in the Anatomical Therapeutic Chemical (ATC) 
classification system, and producer. In addition, the following 
information is collected for each transaction: social security 
number (CPR number) of the patient, code identifying the pre-
scribing physician, date and pharmacy of the transaction, and 
information regarding reimbursement of cost, if applicable. For 
hospital data we have information of the type of department 
and hospital but no information on the individual consumption 
level.
Before 2012, data from hospitals on certain infusion substanc-
es was obtained directly from the hospital pharmacies. From 
2013 onwards all data from hospitals are reported to and de-
livered by The Register of Medicinal Product Statistics at SSI.
The present report includes data on the consumption of “anti-
infectives for systemic use”, or group J01, of the 2014 update 
of the ATC classification, in primary health care and in hospitals 
as well as consumption of per oral and rectal preparations of 
metronidazole (P01AB01) and oral preparations of vancomycin 
(A07AA09). As recommended by the World Health Organiza-
tion (WHO), consumption of antibacterial agents in primary 
health care is expressed as DIDs, i.e. the number of DDDs per 
1,000 inhabitants per day (DDD/1,000 inhabitant-days). Con-
sumption in primary health care is also reported as the number 
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of packages per 1,000 inhabitants. Consumption of antibacte-
rial agents in hospitals is expressed as DIDs, for comparison 
with primary health care, and DBDs, the number of DDDs per 
100 occupied beds per day (DDD/100 occupied bed-days)
Since antimicrobial consumption expressed as DDD/100 
occupied bed-days does not necessarily reflect changes in 
hospital activity and production, consumption in hospitals is 
also presented as DAD (the number of DDDs per 100 admitted 
patients).
The number of occupied bed-days is calculated as the date of 
discharge minus the date of admission (minimum one day), and 
the number of admissions is counted as one admission when-
ever a patient is admitted to a specific ward (i.e. one patient 
can be registered as admitted multiple times if transferred 
between wards during the same hospital stay). Data on the 
number of occupied bed-days (or patient-days) and number of 
admissions in each hospital were obtained from the National 
Patient Registry at the National Board of Health [www.sst.dk].
9.3 Collection of bacterial isolates
9.3.1 Animals
The sampling for DANMAP has changed markedly since the 
legislation regarding the EU harmonised monitoring of antimi-
crobial resistance in zoonotic and commensal bacteria came 
into force in 2014 [Decision 2013/652/EU]. The legislation re-
quires, in addition to national Salmonella control programmes, 
sampling of broilers and fattening turkeys in even years 
(2014-2020) and sampling of fattening pigs and cattle < 1 
year in odd years (2015-2019). In 2016, most of the sampling 
for DANMAP was allocated to the mandatory sampling of broil-
ers (examined for Campylobacter jejuni, indicator E. coli and 
ESBL/AmpC E. coli) however, additional sampling of fattening 
pigs (examined Salmonella and indicator E. coli) and cattle <1 
year (examined Campylobacter and E. coli) were also carried 
out (Table 9.1).
Meat inspection staff or abattoir personnel at the slaughter 
houses collected caecal samples from healthy pigs, cattle (< 
1 year) and broilers. The samples were collected throughout 
Table 9.1. Legislative and voluntary sampling plans(a) under national control programmes and EU  
harmonised monitoring that contribute isolates to DANMAP 2016 
 DANMAP 2016
Bacteria Origin of isolates Legislative 
sampling 
frequency 
(2013/652/EU)
Number of 
samples in 2016
Salmonella spp. On-farm samples from laying hens, broilers and fattening turkeys (breeder 
and production flocks)
Annually 4290 flocks
Caecal samples from fattening pigs 707 animals
Carcasses of broilers Annually 203 carcasses
Carcasses of fattening pigs and cattle <1 year Annually 15075 carcasses
Imported broiler meat and pork, ready for retail 274 batches
Campylobacter jejuni Caecal samples from broilers Even years 735 animals
Caecal samples from cattle <1 yr 121 animals
Danish and imported broiler meat ready for retail 276 batches
Indicator E. coli Caecal samples from broilers Even years 193 animals
Caecal samples from fattening pigs and cattle <1 yr 150 pigs and 
121 cattle <1yr 
Specific monitoring 
of ESBL/AmpC – 
producing E. coli
Caecal samples from broilers Even years 298 animals
Fresh broiler meat at retail Even years 295 samples
Enterococcus spp. Caecal samples from broilers, fattening pigs or cattle <1 yr 621 broilers
MRSA Samples from animals 227 animals
Samples from fresh meat 259 samples
Note: Only a selected number of the obtained isolates, from each source, were speciated and susceptibility tested. Thus, data in this table should 
not be used for reporting prevalences. 
a) All animal samples originate from different flocks/herds. All food samples originate from different slaughter batches, batches of Danish or 
imported meat ready for retail or packages of fresh meat at retail
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2016, and the sampling was stratified per slaughterhouse by 
allocating the number of samples from domestically produced 
animals collected per slaughterhouse proportionally to the 
annual throughput of the slaughterhouse. For broilers, four 
intact caeca from each flock were pooled into one sample. For 
pigs and cattle, samples contained 30-100 g caecal material 
from a single animal. All samples were processed at the Danish 
Veterinary and Food Administration’s (DVFA) laboratory in 
Ringsted. 
Prior to 2014, DANMAP data also included isolates from the 
national Salmonella surveillance programme in pigs, where se-
rological surveillance at slaughter identified high risk herds for 
on-farm sampling. Salmonella from layers, broilers, turkeys and 
cattle are not included in DANMAP 2016 due to low numbers 
of isolates available from the national surveillance [Annual 
Report on Zoonoses in Denmark, 2016].
9.3.2 Meat
The EU harmonised monitoring requires, in addition to national 
Salmonella control programmes, sampling of broiler meat in 
even years (2014-2020) and sampling of pork and beef in odd 
years (2015-2019). In 2016, broiler meat was examined for 
Salmonella, C. jejuni and ESBL/AmpC E. coli (Table 9.1). 
ESBL/AmpC E. coli isolates originate from samples taken 
throughout the year by the regional DVFA officers. Samples 
consist of packages of chilled or frozen broiler meat collected 
in Danish wholesale and retail outlets according to the 
sampling framework laid down by Decision 2013/652/EU. 
Products with added saltwater or other types of marinade 
were excluded and the packages were selected without 
pre-selecting based on the country of origin. The number of 
establishments and samples selected by each regional DVFA 
control unit was proportional to the number of establishments 
in the region in relation to the total number of establishments 
in the country. One unit of product (minimum of 200 g) 
was collected and all samples were processed at the DVFA 
laboratory. 
The Campylobacter isolates from broiler meat originated from 
the national control programme: Intensified control of Sal-
monella and Campylobacter in fresh meat based on a case-
by-case risk assessment. Sampling of broiler meat ready for 
retail, e.g. located in cold stores, slaughterhouses, cutting and 
processing facilities, but also at catering companies or at bor-
der control posts. The number of batches to be controlled by 
each regional DVFA control unit is proportional to the number 
of establishments in the Region and the country. A 100 gram 
sample is cut from packages of meat, where 10 gram is used 
for analysis. From each batch, 12 packages of meat are tested 
and analysed as single samples. All samples were processed at 
the DVFA laboratory. 
The Salmonella isolates from pork originate from the national 
control programme at the slaughterhouses, where the carcass-
es are swabbed in four designated areas (the jaw, breast, back 
and ham) after min. 12 hours of chilling (covering 10x10cm). 
The numbers of swabs collected depend on the slaughter-
house capacity. All samples were processed at Industry labora-
tories. Isolates from all Salmonella positive samples were send 
to DTU food, where one isolate per sample were serotyped and 
susceptibility tested. 
Salmonella from broiler meat and beef (incl. imported meat) are 
not included in DANMAP 2016 due to low numbers of isolates 
available from the national surveillance [Annual Report on 
Zoonoses in Denmark, 2016].
9.3.3 Humans
S. Typhimurium and C.  jejuni. Antimicrobial susceptibility was 
performed on human faecal isolates submitted to Statens Se-
rum Institut (SSI). Salmonella isolates were submitted from all 
DCM in Denmark and Campylobacter isolates were submitted 
from Departments of Clinical Microbiology (DCM) covering three 
geographical regions: Northern Jutland, Funen and Zealand. Ex-
act figures of the proportion tested and the sampling strategy 
for the different species can be found in Sections 6.1 and 6.2. 
As in previous years, SSI collected information on travel history 
through phone interviews. Patients were asked about the date 
of disease onset and whether they had travelled abroad within 
a seven-day period prior to the onset of disease. Furthermore, 
patients who had been abroad were asked about their destina-
tions. Cases were categorised as “domestically acquired” if the 
patients had not travelled within the week prior to the onset 
of disease.
Staphylococcus aureus. Blood isolates are referred on a volun-
tary basis by all DCM’s to the Staphylococcus reference laborato-
ry at SSI. Detection of Methicillin-resistant S. aureus (MRSA) is a 
notifiable condition in Denmark and therefore all MRSA isolates 
from all sample types are sent to the reference laboratory.
Invasive Streptococcus pneumoniae. Invasive pneumococ-
cal disease is a notifiable disease in Denmark, and therefore all 
invasive isolates nationwide are sent to SSI for identification 
or confirmation as well as susceptibility testing and typing. 
Invasive Streptococcus pyogenes (group A streptococci) 
and group B, C and G streptococci. Isolates are submitted to SSI 
on a voluntary basis. Only isolates from blood and spinal fluid 
are included in the DANMAP report.
E. coli, K. pneumoniae, P. aeruginosa, Acinetobacter spp., 
E. faecium and E. faecalis. Data are provided from all DCM’s 
on all isolates from either blood samples (E. coli, K. pneu-
moniae, P. aeruginosa, Acinetobacter spp., E. faecium and E. 
faecalis) or urine samples (E. coli and K. pneumoniae).
No samples were collected from healthy humans.
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9.4 Microbiological methods
9.4.1 Animals and meat
Salmonella was isolated according to the methods issued 
by the NMKL [NMKL No. 187, 2007] or Annex D, ISO 6579 
[ISO6579:2002/Amd 1:2007]. Serotyping of suspect colonies 
by slide agglutination according to the White- Kauffmann-Le 
Minor Scheme in combination with “The molecular approach” 
developed by CDC [Fitzgerald et al, 2007. J Clin Microbiol. 
45:3323-34; McQuiston et al, 2011. J Clin Microbiol. 49: 
565–573]. Only one isolate per serotype was selected from 
each herd, flock or slaughter batch (food sample).
Campylobacter from broilers, cattle and broiler meat was 
isolated and identified according to the methods issued by the 
NMKL [NMKL No. 119, 2007] with the following exceptions: 
1. Use of direct spread on to selective agar for the broiler and 
cattle samples and 2. Use of pre-enrichment in Bolton broth for 
the cattle samples. Only one C. jejuni isolate per broiler flock, 
cattle herd or per batch of fresh meat was selected.
Indicator E. coli from broilers, pigs and cattle was isolated 
by direct spread of caecal sample material onto violet red bile 
agar and incubated for 24h at 44°C. Presumptive E. coli was 
identified using TBX agar incubated o/n at 44°C. Only one 
indicator E. coli, isolate per broiler flock was selected.
For Isolation of ESBL-, AmpC- and carbapenemase-pro-
ducing E. coli from caecal samples, the EURL-AR laboratory 
protocol was applied (October 2015) [http://www.eurl-ar.
eu/233-protocols.htm]. Only one ESBL-, AmpC- and carbapene-
mase-producing E. coli isolate per broiler flock or meat sample 
was selected.
Enterococcus from broilers was isolate from an adequate 
amount of caecal material suspended in 2 ml BPW. The sus-
pension was streaked onto Slanetz Bartley agar and incubated 
48h at 44°C. Two colonies resembling typical E. faecalis were 
sub-cultivated on blood agar. Species identification was done 
by rtPCR-assay. Only one isolate of E. faecalis was selected 
per broiler flock. 
9.4.2 Humans
Salmonella isolates were serotyped by slide agglutination 
according to the Kauffman-White Scheme.
Campylobacter. Species identification was performed using a 
species-specific PCR assay [Klena et al. 2004. J Clin Microbiol. 
42: 5549–5557].
Staphylococcus aureus. Species confirmation and typing was 
performed by sequencing of the S. aureus specific spa gene 
[Harmsen et al. 2003. J Clin Microbiol. 41: 5442–5448]. Spa 
-negative isolates were confirmed as S. aureus by MALDI-TOF. 
Based on the spa type and known association with MLST 
typing, each isolate was assigned to a clonal complex (CC). 
For MRSA isolates, presence of the mecA or mecC methicillin 
resistance genes was confirmed by PCR [Larsen et al. 2008. 
Clin Microbiol Infect. 14: 611–614; Stegger et al. 2012. Clin 
Microbiol Infect. 18: 395–400]. For all isolates, presence of 
lukF-PV gene (PVL) was demonstrated by PCR [Larsen et al. 
2008. Clin Microbiol Infect. 14: 611–614; Stegger et al. 2012. 
Clin Microbiol Infect. 18: 395–400].
Invasive Streptococcus pneumoniae. Serotype identification 
of invasive S. pneumoniae was performed by latex agglutina-
tion (ImmuLex™ Pneumotest Kit, SSI Diagnostica, Hillerød, 
Denmark) and further with factor specific antisera by the 
Neufeld Quellung test (SSI Diagnostica, Hillerød, Denmark).
Invasive Streptococcus pyogenes (group A streptococci), 
group B, C and G streptococci. Identification of group was 
performed by latex agglutination (Streptococcal Grouping 
Reagent, Oxoid, Roskilde, Denmark).
9.5 Susceptibility testing
Antimicrobial susceptibility testing of Salmonella, Campy-
lobacter, E. coli, Enterococcus and human clinical Staphy-
lococcus aureus was performed as microbroth dilution MIC 
with Sensititre (Trek Diagnostic Systems Ltd.) Inoculation and 
incubation procedures were in accordance with the CLSI guide-
lines [Clinical and Laboratory Standards Institute, USA] and 
the European standard ISO 20776-1:2006. The isolates were 
susceptibility tested in accordance with in Decision 2013/652/
EU.
Relevant quality control strains were used: Staphylococcus au-
reus ATCC 29213, Escherichia coli ATCC 25922, Pseudomonas 
aeruginosa ATCC 27853, Enterococcus faecalis ATCC 29212 
and Campylobacter jejuni ATCC 33560.
Most of the isolates from animals and meat were susceptibil-
ity tested at the DVFA laboratory. Only Salmonella from the 
surveillance of fresh meat were tested at DTU National Food 
Institute. Isolates were stored at -80°C until susceptibility 
testing. Salmonella, Campylobacter and Staphylococcus aureus 
isolates of human origin were tested at SSI. MIC-testing at DTU 
National Food Institute and the DVFA laboratory in Ringsted is 
accredited by DANAK (the national body for accreditation).
Invasive Streptococcus pneumoniae  from humans.  
 Screening for penicillin- and erythromycin-resistant S. pneu-
moniae was performed with 1 μg oxacillin discs and 15 μg 
erythromycin discs (Oxoid, Roskilde, Denmark), respectively, on 
Müller-Hinton agar (Müller-Hinton plate, 5% blood, 20 mg beta-
NAD, SSI Diagnostica, Hillerød, Denmark). Penicillin and erythro-
mycin MICs were determined using STP6F plate, Sensititre (Trek 
Diagnostic Systems Ltd.) as recommended by the manufacturer. 
All breakpoints used were as defined by the EUCAST. Both fully 
and intermediary resistant isolates were defined as resistant.
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Invasive Streptococcus pyogenes (group A), group B, C and G 
streptococci from humans.  Screening for penicillin, erythromycin 
and clindamycin resistance was performed with 1 unit penicil-
lin G discs, 15 μg erythromycin discs and 2 µg clindamycin discs 
(Oxoid, Roskilde, Denmark) on Müller-Hinton agar (Müller-Hinton 
plate, 5% blood, 20 mg beta-NAD, SSI Diagnostica, Hillerød, Den-
mark). Isolates were also tested for inducible clindamycin resis-
tance. For non-susceptible streptococci the MIC was determined 
with E-test (Biomérieux), with either benzylpenicillin, eryth-
romycin or clindamycin on Müller-Hinton agar. The breakpoints 
used were as defined by the EUCAST. Both fully and intermedi-
ary resistant isolates were categorized as resistant.
E. coli, K. pneumoniae, P. aeruginosa, Acinetobacter spp., 
E. faecium and E. faecalis from humans.  Since November 
2015, all Danish DCM used the EUCAST terminology with the  
EUCAST breakpoints and the EUCAST disk diffusion method for 
most species. Interpretation mainly follows EUCAST principles 
but for some DCM local interpretation rules are applied on the 
susceptibility in specific species, primarily from invasive infec-
tions (fx susceptibility to mecillinam in E. coli obtained from 
blood samples). 
Data on antimicrobial resistance from private hospitals and clin-
ics and from psychiatric hospitals were excluded. All sub mitting 
laboratories participate in national and international quality 
assurance collaborations such as the United Kingdom National 
External Quality Assessment Schemes (NEQAS).
9.6 Whole genome sequencing 
Whole genome sequencing (WGS) and in silico bioinformatics 
tools were used to detect the genetic background of the ESBL/
AmpC- and carbapenemase-producing E. coli phenotypes iden-
tified. The strains were sequenced using the Illumina Hiseq 
platform followed by de novo assembly and prediction of anti-
microbial resistance genes, virulence genes, plasmid replicons 
and MLST using the online freely available in silico bioinformat-
ics tool; Bacterial Analysis Pipeline - Batch Upload (version 1.0) 
from Center of Genomic Epidemiology (www.genomicepidemi-
ology.org; https://cge.cbs.dtu.dk//services/all.php) [Thomsen 
et al, 2016; PLoS One 21;11(6) :e0157718]. The sequences 
of isolates negative for all ESBL-, AmpC- and carbapenemase-
encoding genes were investigated for promoter mutations 
compatible with up-regulation of chromosomal ampC expres-
sion by the use of the ResFinder tool (version 3.0). All genome 
sequences were submitted to the European Nucleotide Archive 
(ENA).
9.7 Data handling
9.7.1 Animals and meat
For the samples processed at the DFVA laboratory, sampling 
details and laboratory results were stored in the DVFA Labora-
tory system. Following validation by DVFA, data were electron-
ically transferred to DTU National Food Institute. At the DTU 
National Food Institute, data were harmonised and one isolate 
per epidemiological unit was selected for reporting.
Sampling details and laboratory results from the national Sal-
monella control programmes were stored at DVFA (Salmonella 
database), whereas serotyping and results from the susceptibil-
ity testing were stored in the DTU Laboratory system. Data were 
collated at DTU and validated by DVFA. All data were combined 
in one Oracle database at isolate level (9i Enterprise Edition®). 
The database contained all antimicrobial data reported in DAN-
MAP or to EFSA since 2007 (partial dataset from 2001-2006).
Variables for animal samples include bacterial species, subtype 
where applicable, date of sampling, species of animal and herd 
identifier. For each meat isolate, variables include food type, 
bacterial species, date of sampling, date of examination and 
country of origin whenever possible. MIC values were retained 
as continuous variables in the database, from which binary 
variables were created using the relevant ECOFF from 2016 
for all years. Since 2007, data are interpreted by EUCAST 
epidemiological cut-off values (ECOFFs) with a few exceptions 
described in Table 9.2. 
All MIC-distributions are presented in the web annex at www.
danmap.org. Each of the tables provides information on the 
number of isolates, the applied interpretation of MIC-values 
and the estimated level of resistance and confidence intervals 
calculated as 95% binomial proportions presenting Wilson 
intervals.
All handling, validation and analysis of results were carried out 
using Microsoft Excel and SAS®Software, SAS Enterprise Guide 
6.1.
9.7.2 Human
Salmonella and Campylobacter. Data on Salmonella and 
Campylobacter infections are stored in the Danish Registry 
of Enteric Pathogens (SQL database) maintained by SSI. This 
register includes only one isolate per patient within a window 
of six months and includes data on susceptibility testing of 
gastrointestinal pathogens.
Staphylococcus aureus. For MRSA, data on the characteris-
tics of the isolates and the clinical/epidemiological information 
were obtained from the Danish MRSA register at SSI (manda-
tory reportable). Patients were registered, regardless of coloni-
sation or clinical infection, the first time they were diagnosed 
with MRSA or when a new subtype was demonstrated. Based 
on the reported information, MRSA cases were classified as 
colonization/active screening (i.e. surveillance samples to de-
tect nasal, throat, gut or skin colonization), imported infection 
(i.e. acquired outside Denmark), infection acquired in a Danish 
hospital, defined as diagnosed >48 hours after hospitalisation 
with no sign of infection at admittance (HA-MRSA) or infection 
diagnosed outside hospitals (community onset).
MRSA cases with community onset were further classified 
according to risk factors during the previous 12 months as 
either health-care associated with community onset (HACO) or 
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Table 9.2. Interpretation criteria for MIC-testing by EUCAST epidemiological cut-off values (blue fields) and  
the corresponding EUCAST clinical breakpoints (white fields) DANMAP 2016
Note: EUCAST epidemiological cut-off values (ECOFFs) and EUCAST clinical breakpoints listed unless noted
a) The EUCAST ECOFF (>2) for colistin was applied for S. Typhimurium and other serotypes, except for S. Enteritidis and S. Dublin where ECOFF >8 
was applied according to investigations presented in DANMAP 2011
b) No current EUCAST ECOFF is available, apply complementary interpretative thresholds as suggested by EFSA [EFSA Supporting publication 
2017:EN-1176]
c) Inducible clindamycin resistance is included
Salmonella E. coli E. faecalis C. jejuni S. aureus
Antimicrobial agent ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Ampicillin >8 >8 >8 >8 >4 >8
Azithromycin >16(a) >16(a)
Cefepime >0.125(a) >4 >0.125(a) >4
Cefotaxime >0.5 >2 >0.25 >2
Cefoxitin >8 >8 >4
Ceftaroline >1
Ceftazidime >2 >4 >0.5 >4
Ceftobiprole 9 >1
Chloramphenicol >16 >8 >16 >8 >32
Ciprofloxacin >0.064 >0.064 >0.064 >0.5 >4 >0.5 >0.5 >1
Clindamycin >0.25(c)
Colistin >2(b) >2 >2 >2
Daptomycin >4 >1
Ertapenem >0.064 >1 >0.064 >1
Erythromycin >4 >4 >4 >1
Fusidic acid >0.5
Gentamicin >2 >4 >2 >4 >32 >2 >2
Imipenem >1 >8 >0.5 >8
Kanamycin >8
Linezolid >4 >4 >4
Meropenem >0.125 >8 >0.125 >8
Mupirocin >1
Nalidixic acid >16 >16 >16
Norfloxacin >4
Penicillin >0.125
Rifampicin >0.03
Streptomycin >4
Sulfamethoxazole/
Trimethoprim
>0.5
Sulfonamide 
(Sulfamethoxazole)
>256 >64
Teicoplanin >2 >2
Tetracycline >8 >8 >4 >0.5 >1 >2 >1
Tigecycline >1 >2 >1 >2 >0.25 >0.25
Vancomycin >4 >4 >2
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community-acquired (CA). Health-care associated risk factors 
included prior hospitalizations, stay in long-term care facilities 
and being a health-care worker. Community risk factors includ-
ed known MRSA-positive household members or other close 
contacts. Due to the increasing numbers of cases belonging to 
CC398, this type was treated separately as both epidemiology 
and relevant exposure are different from other CA cases.
Streptococcus pneumoniae, Streptococcus pyogenes 
(group A streptococci), group B, C and G streptococci. 
Data on susceptibility testing of isolates were stored as MICs 
in a Microsoft® Access database linked to a SQL server at SSI. 
Analysis including selection of isolates from blood and spinal 
fluid samples and removal of duplicate isolates was performed 
in Microsoft® Access.
Streptococcus pyogenes (group A streptococci), group B, C 
and G streptococci. Data on susceptibility testing of isolates 
were stored as inhibition zone diameters and if indicated also 
MICs in a Microsoft® Access database linked to a SQL server at 
SSI. 
E. coli, K. pneumoniae,  P. aeruginosa; Acinetobacter spp., 
E. faecium  and E. faecalis. All DCM in Denmark provided 
data on resistance levels in E. coli, K. pneumoniae, invasive P. 
aeruginosa, invasive Acinetobacter spp., invasive E. faecium 
and invasive E. faecalis isolates. Data were extracted from the 
following laboratory information systems:
ADBakt (Autonik AB, Skoldinge, Sweden) for the DCM at Hvi-
dovre, Herlev and Aalborg Hospitals.
MADS (DCM Skejby Hospital, Aarhus, Denmark) for the DCM at 
Rigshospitalet, Slagelse/Region Zealand, Odense, Sønderborg, 
Esbjerg, Vejle, Herning/Viborg, and Aarhus (Skejby) Hospitals. 
Resistance data on the first isolate per patient per year were 
included. Generally, resistance data were excluded if suscep-
tibility to a certain antimicrobial agent was tested on only a 
selected number of isolates.
9.7.3 Statistical tests
Significance tests of differences between proportions of 
resistant isolates were calculated using SAS®Software, SAS 
Enterprise Guide 6.1 using univariable Chi-square, or Fisher’s 
Exact Tests as appropriate.
All changes and differences yielding p<0.05 were commented 
on in the text, whereas the remaining data was visualised in 
figures or tables only.
Some types of resistances were looked for, but not found 
by the DANMAP surveillance system, yielding a prevalence 
of zero. It is not possible for surveys to prove freedom from 
diseases or resistances in populations, but with a defined 
confidence, surveys can identify the maximum possible preva-
lence given that the survey failed to find any positives. This 
maximum prevalence was calculated for the report using 95% 
confidence and assuming a perfect test by a probability for-
mula to substantiate freedom from disease via online epitools.
ausvet.com.au (Cameron and Baldock 1998, Prev. Vet. Med).
Birgitte Borck Høg, Helle Korsgaard, 
Sissel Skovgaard and Ute Wolff Sönksen
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List of abbreviations
AGP  Antimicrobial growth promoter
ATC  Anatomical Therapeutic Chemical Classification System
ATCvet  Anatomical Therapeutic Chemical Classification System for veterinary medicines
BSI   Blood Stream Infection (in humans)
CA  Community-acquired
CC  Clonal complex
CDI  Clostridium difficile infections 
CHR  Central Husbandry Register 
CI  Confidence interval
CNS  Central nervous system
COHA  Community onset hospital-acquired
CPE  Carbapenemase producing Enterobacteriaceae 
CPO  Carbapenemase producing organisms
CPR  Danish Civil Registry, register for social security numbers 
DAD  Defined Daily Doses per 100 admissions
DADD  Defined animal daily dose
DAPD  Defined animal daily dose per 1,000 animals per day 
DBD  Defined Daily Doses per 100 occupied bed-days
DCM  Department of Clinical Microbiology
DDD  Defined Daily Dose
DID  Defined Daily Doses per 1,000 inhabitants per day (DDD/1000 inhabitant days) 
DTU  Technical University of Denmark
DVFA  Danish Veterinary and Food Administration
EARS-Net The European Antimicrobial Resistance Surveillance Network
ECDC  European Centre for Disease Prevention and Control
EFSA  European Food Safety Authority 
ESBL  Extended spectrum beta-lactamase 
GI  Gastrointestinal
GP  General Practitioner
HAI  Hospital-acquired infections
HAIBA  Hospital-acquired infections database 
HLGR  High-level gentamicin resistance 
HOHA  Hospital onset hospital-acquired
MIC  Minimum inhibitory concentration
MRSA  Methicillin-resistant Staphylococcus aureus
N  Number of samples
n  Number of isolates tested for antimicrobial susceptibility 
OIE  World Organisation for Animal Health
RFCA  Regional Veterinary and Food Control Authorities 
SAB   Staphylococcus aureus bacteremia
SEGES  Knowledge Centre for Agriculture
S-I-R   interpretation scale for results from resistance testing noting "susceptible-intermediary-resistant"
SSI  Statens Serum Institut
ST  Serotype/Sequence type
VASC  Veterinary advisory service contracts 
VMP  Veterinary medicinal products
VetStat  Danish Register of Veterinary Medicines 
VRE  Vancomycin resistant enterococci
WGS  Whole-genome sequencing 
WHO  World Health Organization
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Glossary
Anatomical Therapeutic Chemical (ATC) classification. 
International classification system for drug consumption 
studies. The ATC code identifies the therapeutic ingredient(s) 
of each drug for human use according to the organ or system 
on which it acts and its chemical, pharmacological and thera-
peutic properties. Antibacterials for systemic use are known 
as ATC group J01. The ATC classification is maintained by the 
WHO Collaborating Centre for Drug Statistics and Methodology 
(Oslo, Norway) (www.whocc.no/atcddd/indexdatabase/). The 
ATC classification for veterinary medicinal products, ATCvet, 
is based on the same main principles as the ATC classification 
system for medicines for human use and is also maintained by 
the WHO Collaborating Centre for Drug Statistics and Method-
ology (www.whocc.no/ atcvet/database/).
Antibacterial agents. Synthetic (chemotherapeutics) or natural 
(antibiotics) substances that destroy bacteria or suppress 
bacterial growth or reproduction [Source: Dorland’s Illustrated 
Medical Dictionary]. Antimycobacterial agents are not included. 
In the section of human consumption, ‘antibacterial agents’ are 
referred to as ‘antimicrobial agents’ (see below).
Antimicrobial agents. The term ‘antimicrobial agents’ covers 
antibacterial, antiviral, coccidiostatic and antimycotic agents.
In the section on veterinary consumption, the broad term 
‘antimicrobial agents’ is usually used because coccidiostats are 
included. Antiviral substances are not used in veterinary medi-
cine, and antimycotics are only registered for topical veterinary 
use and used mainly in companion animals. Antimycobacterial 
agents are not included. The term ’antibacterial agents’ is only 
used in the veterinary section for precision, to distinguish from 
use of coccidiostats as feed additives (poultry only). In the 
chapter on human consumption, the term ‘antimicrobial agents’ 
refers to all antibacterial agents for systemic use (J01 in the 
ATC system).
Broiler. A type of chicken raised specifically for meat production. 
In Denmark, the average weight after slaughter is 1.51 kg.
CentralHusbandryRegister(CHR).This is a register of all 
Danish farms defined as geographical sites housing produc-
tion animals. It contains information concerning ownership, 
farm size, animal species, age groups, number of animals and 
production type. Each farm has a unique farm identity number 
(CHR-number).
Defined animal daily dose (DADD).DADD is the average main-
tenance dose per day for a drug used for its main indication 
in the appropriate animal species. DADD has been specifically 
defined for use in DANMAP and does not always completely 
match the “prescribed daily dose” or the recommended dosage 
in the Summaries of Product Characteristics (SPC). In contrast 
to the ADD previously used in DANMAP, the DADD has not 
been defined for each antimicrobial agent, administration route 
and animal species but at product level. In DANMAP 2012, the 
DADD replaces the ADD (as defined in VetStat), which had been 
used since DANMAP 2003. For more details, see Chapter 9, 
Materials and Methods. The DADDs used in DANMAP 2015 are 
presented the web annex.
DADD per 1000 animals per day (DAPD).Trends in veterinary 
consumption, both within and across species, are presented 
in DAPD, which allows for comparison between sectors and 
adjustment for changes in live biomass. The estimated live 
biomass is expressed as the number of standard animals with 
an estimated average weight and lifetime. This may also be 
referred to as the ‘standard-animals-at-risk’ and takes into 
account species differences in body-mass and life-span. DAPD 
is a statistical measure, providing an estimate of the propor-
tion of animals (in thousands) treated daily with a particular 
antimicrobial agent. For example, 10 DAPDs indicate that an 
estimated 1% of the population, on average, receives a certain 
treatment on a given day (Section 4.3 and Chapter 9, Materials 
and Methods).
Defined Daily Dose (DDD).This is the assumed average main-
tenance dose per day for a drug used for its main indication in 
adults. It should be emphasised that the Defined Daily Dose 
is a unit of measurement and does not necessarily reflect 
the recommended or prescribed daily dose. DDDs provide a 
fixed unit of measurement independent of price and formula-
tion, enabling the assessment of trends in drug consumption 
and to perform comparisons between population groups. The 
DDDs are defined and revised yearly by the WHO Collaborating 
Centre for Drug Statistics and Methodology (www.whocc.no/
atcddd/ index database).
DDD per 1000 inhabitants per day (DID). Consumption in both 
primary health care, hospital care and the overall total con-
sumption is presented in DID, allowing for comparison between 
sectors and for illustration of the consumption in hospital care 
without taking account of hospital activity (discharges). Data 
presented in DID provide a rough estimate of the proportion 
of the population within a defined area treated daily with 
certain drugs. For example, 10 DIDs indicates that 1% of the 
population on average gets a certain treatment daily. In figure 
presented as DDD/1000 inhabitant-days.
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ESBL. In the DANMAP report, ‘ESBL’ describes the clinically 
important acquired beta-lactamases with activity against 
extended-spectrum cephalosporins; including the classical 
class A ESBLs (CTX-M, SHV, TEM), the plasmid-mediated AmpC 
and OXA-ESBLs  [Giske et al. 2009. J. Antimicrob. Chemother. 
63: 1-4].
Finishers. Pigs from 30-100 kg live weight from after the 
weaner stage to time of slaughter.
Fully  sensitive. An isolate will be referred to as fully sensitive 
if susceptible to all antimicrobial agents included in the test 
panel for the specific bacteria.
Intramammaries. Antimicrobial agents for local application in 
the mammary gland (udder) to treat mastitis.
Layer. A hen raised to produce eggs for consumption.
Minimum inhibitory concentration (MIC). This is the lowest con-
centration of antimicrobial agent in a given culture medium, 
e.g. broth or agar, below which growth of the bacteria is not 
inhibited.
Multi-resistant. A Salmonella, Campylobacter, Enterococcus 
or E. coli isolate is assumed multi-resistant if it is resistant 
to three or more of the antimicrobial classes. The number of 
antimicrobial classes and antimicrobial agent included therein 
depend on the test panel for each bacterium.
Pets or pet animals. Dogs, cats, birds, mice, Guinea pigs and 
more exotic species kept at home for pleasure, rather than one 
kept for work or food. Horses are not included as pet animals. 
The live biomasses of Danish pets used for estimating veteri-
nary consumption only include dogs and cat.
Piglet. The new-born pig is called a piglet from birth till they 
are permanently separated from the sow at 3-4 weeks of age. 
The weight of the piglet at weaning is approximately 7 kg.
Poultry. The major production species are fowl Gallus gallus 
(broilers, layers, including breeding and rearing) and turkey. 
Regarding antimicrobial consumption, ‘poultry’ also includes 
domesticated ducks, geese, game birds and pigeons.
Sow. Any breeding female pig on the farm.
Weaner.  Any pig of 7–30 kg live weight after it has been 
weaned
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